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Abstract
Background: The last two decades have seen a significant decrease in mortality for
children <5 years of age in low and middle‐income countries (LMICs); however,
neonatal (age, 0–28 days) mortality has not decreased at the same rate. We assessed
three neonatal nutritional interventions that have the potential of reducing mor-
bidity and mortality during infancy in LMICs.
Objectives: To determine the efficacy and effectiveness of synthetic vitamin A,
dextrose oral gel, and probiotic supplementation during the neonatal period.
Search Methods: We conducted electronic searches for relevant studies on the
following databases: PubMed, CINAHL, LILACS, SCOPUS, and CENTRAL, Cochrane
Central Register for Controlled Trials, up to November 27, 2019.
Selection Criteria: We aimed to include randomized and quasi‐experimental studies.
The target population was neonates in LMICs. The interventions included synthetic
vitamin A supplementation, oral dextrose gel supplementation, and probiotic sup-
plementation during the neonatal period. We included studies from the community
and hospital settings irrespective of the gestational age or birth weight of the
neonate.
Data Collection and Analysis: Two authors screened the titles and extracted the
data from selected studies. The risk of bias (ROB) in the included studies was as-
sessed according to the Cochrane Handbook of Systematic Reviews. The primary
outcome was all‐cause mortality. The secondary outcomes were neonatal sepsis,
necrotizing enterocolitis (NEC), prevention and treatment of neonatal hypoglycae-
mia, adverse events, and neurodevelopmental outcomes. Data were meta‐analyzed
by random effect models to obtain relative risk (RR) and 95% confidence interval
(CI) for dichotomous outcomes and mean difference with 95% CI for continuous
outcomes. The overall rating of evidence was determined by the Grading of Re-
commendations Assessment, Development, and Evaluation (GRADE) approach.
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Main Results: Sixteen randomized studies (total participants 169,366) assessed the
effect of vitamin A supplementation during the neonatal period. All studies were
conducted in low‐ and middle‐income (LMIC) countries. Thirteen studies were
conducted in the community setting and three studies were conducted in the hos-
pital setting, specifically in neonatal intensive care units. Studies were conducted in
10 different countries including India (four studies), Guinea‐Bissau (three studies),
Bangladesh (two studies), and one study each in China, Ghana, Indonesia, Nepal,
Pakistan, Tanzania, and Zimbabwe. The overall ROB was low in most of the included
studies for neonatal vitamin A supplementation. The pooled results from the com-
munity based randomized studies showed that there was no significant difference in
all‐cause mortality in the vitamin A (intervention) group compared to controls at
1 month (RR, 0.99; 95% CI, 0.90–1.08; six studies with 126,548 participants,
statistical heterogeneity I2 0%, funnel plot symmetrical, grade rating high), 6 months
(RR, 0.98; 95% CI, 0.89–1.07; 12 studies with 154,940 participants, statistical het-
erogeneity I2 43%, funnel plot symmetrical, GRADE quality high) and 12 months of
age (RR, 1.04; 95% CI, 0.94–1.14; eight studies with 118,376 participants, statistical
heterogeneity I2 46%, funnel plot symmetrical, GRADE quality high). Neonatal vi-
tamin A supplementation increased the incidence of bulging fontanelle by 53%
compared to control (RR, 1.53; 95% CI, 1.12–2.09; six studies with 100,256 parti-
cipants, statistical heterogeneity I2 65%, funnel plot symmetrical, GRADE quality
high). We did not identify any experimental study that addressed the use of dextrose
gel for the prevention and/or treatment of neonatal hypoglycaemia in LMIC. Thirty‐
three studies assessed the effect of probiotic supplementation during the neonatal
period (total participants 11,595; probiotics: 5854 and controls: 5741). All of the
included studies were conducted in LMIC and were randomized. Most of the studies
were done in the hospital setting and included participants who were preterm
(born < 37 weeks gestation) and/or low birth weight (<2500 g birth weight). Studies
were conducted in 13 different countries with 10 studies conducted in India, six
studies in Turkey, three studies each in China and Iran, two each in Mexico and
South Africa, and one each in Bangladesh, Brazil, Colombia, Indonesia, Nepal, Pa-
kistan, and Thailand. Three studies were at high ROB due to lack of appropriate
randomization sequence or allocation concealment. Combined data from 25 studies
showed that probiotic supplementation reduced all‐cause mortality by 20% com-
pared to controls (RR, 0.80; 95% CI, 0.66–0.96; total number of participants 10,998,
number needed to treat 100, statistical heterogeneity I2 0%, funnel plot symmetrical,
GRADE quality high). Twenty‐nine studies reported the effect of probiotics on the
incidence of NEC, and the combined results showed a relative reduction of 54% in
the intervention group compared to controls (RR, 0.46; 95% CI, 0.35–0.59; total
number of participants 5574, number needed to treat 17, statistical heterogeneity I2
24%, funnel plot symmetrical, GRADE quality high). Twenty‐one studies assessed
the effect of probiotic supplementation during the neonatal period on neonatal
sepsis, and the combined results showed a relative reduction of 22% in the inter-
vention group compared to controls (RR, 0.78; 95% CI, 0.70–0.86; total number of
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participants 9105, number needed to treat 14, statistical heterogeneity I2 23%,
funnel plot symmetrical, GRADE quality high).
Authors' Conclusions: Vitamin A supplementation during the neonatal period
does not reduce all‐cause neonatal or infant mortality in LMICs in the community
setting. However, neonatal vitamin A supplementation increases the risk of
Bulging Fontanelle. No experimental or quasi‐experimental studies were avail-
able from LMICs to assess the effect of dextrose gel supplementation for the
prevention or treatment of neonatal hypoglycaemia. Probiotic supplementation
during the neonatal period seems to reduce all‐cause mortality, NEC, and sepsis
in babies born with low birth weight and/or preterm in the hospital setting. There
was clinical heterogeneity in the use of probiotics, and we could not recommend
any single strain of probiotics for wider use based on these results. There was a
lack of studies on probiotic supplementation in the community setting. More
research is needed to assess the effect of probiotics administered to neonates
in‐home/community setting in LMICs.
1 | PLAIN LANGUAGE SUMMARY
1.1 | Neonatal probiotic supplementation can
improve infant illness and reduce death, but vitamin
A does not, and may have adverse effects
Nutritional support during the 1st month of life is vital for the short‐ and
long‐term survival of the newborn. Neonatal nutrition interventions have
the potential to decrease death and illness in young infants in LMICs.
1.1.1 | What is this review about?
This review assesses the efficacy of synthetic vitamin A, dextrose, and
probiotic supplementation during the neonatal period. These interven-
tions were assessed separately and not in combination with each other.
What is the aim of this review?
This Campbell systematic review assesses the
efficacy of three neonatal nutritional interven-
tions that have the potential of reducing mor-
bidity and mortality during infancy in LMICs:
synthetic vitamin A, dextrose, and probiotic
supplementation.
1.1.2 | What studies are included?
Sixteen studies that assessed the effect of vitamin A supplementation
during the neonatal period were included. Thirteen of these studies
were conducted in the community setting and three studies were
conducted in the hospital setting. All the included studies on neonatal
vitamin A supplementation were conducted in LMICs. Most of the
studies had a low ROB.
No experimental studies were found that evaluated the use of
dextrose for the prevention or treatment of low blood sugar during
the neonatal period.
Thirty‐three studies assessed the use of probiotics during the 1st
month of life. All included studies on probiotic supplementation were
randomized and conducted in LMICs. Most of the included studies
had a low ROB. The probiotics studies mainly included babies born
early and/or with low birth weight, and these studies were mostly
conducted in hospital settings.
1.1.3 | Key results
Combined results from thirteen vitamin A studies conducted in the
community settings showed that there was no significant effect of
vitamin A supplementation for reduction of death in young infants at
1, 6, or 12 months of age. Neonatal vitamin A supplementation in-
creases the risk of bulging fontanelle by 53%. The pooled data from
probiotics studies showed that this intervention reduced the risk of
death by 20% compared to controls. Further analysis showed that
compared to controls, probiotic supplementation reduced the risk of
a severe form of gastrointestinal illness in neonates called NEC by
54%. Probiotic supplementation also reduced the risk of blood in-
fection called sepsis by 22% compared to controls. The quality grade
ratings for these outcomes were “high.”
1.1.4 | What are the main findings of the review?
Combined results from thirteen vitamin A studies conducted in the
community settings showed that there was no significant effect of
vitamin A supplementation for reduction of death in young infants at
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1, 6, or 12 months of age. However, neonatal vitamin A supple-
mentation increased the incidence of bulging fontanelle by 53%.
The pooled data from probiotics studies showed that this interven-
tion reduced the risk of death by 20% compared to controls. Further
analysis showed that compared to controls, probiotic supplementation
reduced the risk of a severe form of gastrointestinal illness in neonates
called NEC by 54%. Probiotic supplementation also reduced the risk of
blood infection called sepsis by 22% compared to controls. The quality
grade ratings for these outcomes were “high.”
1.1.5 | What do the findings of this review mean?
Vitamin A supplementation during the 1st month of life does not
reduce the risk of death during the 1st year of life in LMICs. How-
ever, neonatal vitamin A supplementation increases the risk of bul-
ging fontanelle, which may cause damage to the brain.
We did not find any experimental studies from LMICs that as-
sessed the use of dextrose gel supplementation during the 1st month
of life for the prevention or treatment of low blood sugar.
Probiotic supplementation during the 1st month of life to babies
born preterm and/or low birthweight can reduce the risk of death,
blood infection and bowel sickness (NEC).
There was clinical heterogeneity in the use of probiotics and we
could not recommend any single strain or combination of probiotics
for wider use based of these results.
There is a lack of studies on probiotic supplementation in the 1st
month of life in community settings. More research is needed to
assess the effect of probiotics administered to neonates in home/
community settings in LMICs.
1.1.6 | How up‐to‐date is this review?
The review authors searched for studies published up to
November 2019.
2 | BACKGROUND
The decline in rates of neonatal (age, 0–28 days) mortality has been
slower than the decline in child mortality between 1990 and 2016
(Alkema et al., 2014; Bhutta et al., 2015). Neonatal mortality ac-
counted for 46% of child mortality in 2016 compared to 40% of all
under‐five mortality rates in 1990 (WHO, 2017a). Globally, the
percentage of neonatal mortality is the highest in South Asia and
Sub‐Saharan Africa (Alkema et al., 2014). Optimal nutritional support
during the neonatal period is vital to the short and long term survival
of the newborn (Bhutta et al., 2013; WHO, 2017b). Poor nutritional
status of neonates is a major cause of illness and can lead to poor
growth, increased risk of infection, bleeding, and neonatal death
(Bhutta et al., 2013; WHO, 2017b). The risk of morbidity and mor-
tality during the neonatal period is higher in LMICs where many
births happen at home and the prevalence of maternal malnutrition
and incidence of low birth weight (birth weight <2500 g) and preterm
birth (gestational age <37 weeks) is high (Bhutta et al., 2013; Lee
et al., 2017; WHO, 2017b). This review focused on three nutritional
interventions during neonatal periods that have the potential to re-
duce illness and death during infancy in LMIC.
2.1 | Description of the condition
The approach to nutritional management of newborn depends on
maternal nutritional status, comorbidities during pregnancy (such as
gestational diabetes), pregnancy duration (term vs. preterm birth),
events at birth (such as birth asphyxia), birth weight (low birth weight
vs. normal birth weight) and available resources for postpartum
care of the mother and the baby (such as skilled birth attendant,
home vs. facility birth, availability of neonatal intensive care) (Bhutta
et al., 2013; WHO, 2015, 2017a, 2017b). The most important nu-
tritional intervention after birth is breastfeeding, which is covered in
a separate Campbell review of this series. There are a number of
other nutritional interventions that have been proposed in addition
to breastfeeding. It is beyond the scope of this review to compre-
hensively evaluate all the possible nutritional interventions during
the neonatal period. We limited our review to the following three
interventions: neonatal synthetic vitamin A supplementation, oral
dextrose gel supplementation, and probiotic supplementation during
the neonatal period in LMIC. Below in this section and in the rest
of the introduction, we describe the rationale and importance of
reviewing these interventions.
2.1.1 | Neonatal vitamin A deficiency (VAD)
Globally, about 190 million children and 19.1 million pregnant wo-
men are vitamin A deficient based on serum retinol levels (i.e., serum
retinol <0.70 μmol/L) (WHO, 2009a). VAD is most prevalent in South
Asia and Africa (Stevens et al., 2015). VAD is associated with
increased risk of blindness, infections, and mortality (Imdad
et al., 2017). Most of the newborns are vitamin A deficient and rely
on supplementation from maternal breast milk (Haider et al., 2017).
High prevalence of maternal VAD in LMICs increases the risk of
neonatal VAD. There has been interest in vitamin A supplementation
during neonatal period to assess if it reduces risk of illness and death
(Haider et al., 2017; WHO, 2009b), as it has been shown to reduce
morbidity and mortality in children 6–59 months of age (Imdad
et al., 2017).
2.1.2 | Hypoglycemia during the neonatal period
Hypoglycemia (low blood sugar) is common during the immediate
neonatal period. The definition of neonatal hypoglycaemia varies. The
American Academy of Pediatrics defines neonatal hypoglycaemia as
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blood glucose below 47mg/dl (2.61 mmol/L); however, other socie-
ties such as the Pediatric Endocrine Society define neonatal
hypoglycaemia as blood glucose <50mg/dl (2.77mmol/L; Thompson‐
Branch & Havranek, 2017; Thornton et al., 2015). Recurrent, severe,
and/or persistent hypoglycaemia can lead to complications such as
death; there is limited evidence to show that blood sugars below a
certain level leads to long‐term brain damage (Kaiser et al., 2015;
McKinlay et al., 2017; Thornton et al., 2015). About 10–15% of
otherwise healthy newborns have low blood sugar, and the rate is
much higher among infants with additional risk factors such as large
for gestational age, small for gestational age, low birth weight, pre-
term birth, infant of diabetic mother, and newborns with perinatal
asphyxia (Thompson‐Branch & Havranek, 2017). Additional risk fac-
tors for neonatal hypoglycaemia include neonatal sepsis, prolonged
labor, and maternal medication use such as use of β‐agonists and
β‐blockers (Thompson‐Branch & Havranek, 2017). The recommended
initial intervention to treat neonatal hypoglycaemia is to offer feed-
ing in the form of breastfeeding followed by formula feeding if
breastfeeding is unsuccessful. Persistent hypoglycaemia may require
IV dextrose supplementation and admission to a neonatal intensive
care unit (Thompson‐Branch & Havranek, 2017; Thornton
et al., 2015). In LMIC, where a significant proportion of births happen
at home and incidence of low birth weight and preterm birth is high,
prevention and treatment of hypoglycaemia encounters additional
challenges (Singhal et al., 1991, 1992; WHO, 2017b; Williams, 1997).
The instruments to test blood sugar might not be available in low‐
resource settings; In addition, formula, IV dextrose, and intensive
care units might not be available to treat persistent and/or severe
hypoglycaemia. Recent studies have tested simple interventions such
as oral dextrose gel to treat neonatal hypoglycaemia and to prevent
hypoglycaemia in high‐risk newborns (Hegarty et al., 2016; Weston
et al., 2016).
2.1.3 | Neonatal sepsis and NEC
Neonatal sepsis and NEC are neonatal morbidities that can be fatal
(Oza et al., 2015; WHO, 2017b). Neonatal sepsis is the presence of an
infection leading to systemic illness. Bacterial sepsis is common in
LMIC and is a significant risk factor of morbidity and mortality
in these countries (WHO, 2017a). NEC is a condition that occurs in
newborns and can lead to intestinal injury and death. The extent of
injury may vary from mucosal injury to full thickness intestinal wall
injury. NEC happens most commonly in preterm babies and especially
in extremely preterm babies (<28 weeks gestational age; AlFaleh &
Anabrees, 2014; Patel & Denning, 2015). Multiple factors lead to the
development of NEC in preterm infants including altered bacterial
gut flora affecting the protective intestinal barrier, decreased in-
testinal motility, and the increased susceptibility of preterm infants
to inflammation and infections (Patel & Denning, 2015). Recent
studies have shown that an imbalance between commensal bacteria
and pathogenic bacteria (intestinal dysbiosis) makes babies vulner-
able to pathogenic bacterial growth in the intestine which then
causes inflammation that may contribute to neonatal sepsis and/or
NEC (Arrieta et al., 2014; Deshmukh et al., 2014; Gewolb et al., 1999;
Panigrahi et al., 2017). There is an increasing interest in correction of
intestinal dysbiosis by probiotics to prevent NEC and neonatal sepsis.
Data from early studies on probiotic use in neonates from LMIC is
encouraging (AlFaleh & Anabrees, 2014; Rao et al., 2016).
2.2 | Description of the intervention
2.2.1 | Neonatal vitamin A supplementation
Vitamin A is a term used for a subclass of the family of fat soluble
compounds named retinoic acids. Vitamin A is found in nature in two
forms, provitamin A carotenoids and preformed vitamin A, which is
essential to human bodily function. Plant‐based foods are the main
source of provitamin A carotenoids, of which β‐carotene is the most
commonly known. Animal‐based foods are the main source of pre-
formed vitamin A (Bates, 1995; Haider & Bhutta, 2011). Vitamin A
from animal sources (retinol, retinal, retinoic acid, and retinyl esters)
is the most active form, and synthetic vitamin A retinol has been used
in most intervention trials in the past (Haider & Bhutta, 2011; Imdad
et al., 2017). Plant‐based foods may not be an adequate source of
vitamin A, as the gastrointestinal conversion ratio from carotenoid‐
to‐retinol varies from 6:1 to 26:1 (US Institute of Medicine, Food and
Nutrition Board). VAD may, therefore, exist in areas even when there
is high consumption of plant‐based foods such as in South Asia and
Africa (Imdad et al., 2017; Stevens et al., 2015).
2.2.2 | Oral dextrose gel supplementation during
neonatal period
Dextrose gel is a thickened aqueous solution that contains the con-
centrated simple carbohydrate dextrose. It can be administered by
direct application to oral, buccal, or sublingual mucosa and can in-
crease blood sugars rapidly by absorption through the highly vas-
cularized and thin mucus membranes of the oral mucosa (Hegarty
et al., 2016). Detxrose gel is a low cost nonproprietary intervention,
and the gel can be prepared in hospital pharmacies. The typical in-
gredients include water, glucose, a gelling agent, and preservatives
(Hegarty et al., 2016). The decision to use dextrose gel in a neonate
should be taken on individual basis and should be avoided in neo-
nates with compromised neurological or respiratory status (Hegarty
et al., 2016; Weston et al., 2016).
2.2.3 | Probiotic supplementation during neonatal
period
Prebiotics are supplements that promote the growth of commensal
bacteria (AlFaleh & Anabrees, 2014; Panigrahi et al., 2017). Probio-
tics contain live bacteria that enrich pools of commensal bacteria
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(AlFaleh & Anabrees, 2014; Millar et al., 2003; Panigrahi et al., 2017).
Synbiotics are a combination of prebiotics and probiotics and
might have synergistic effect (Johnson‐Henry et al., 2016, Nandhini
et al., 2016; Panigrahi et al., 2017). These supplements are meant to
optimise gut health and their hypothesized mechanisms of actions in-
clude enhanced gut barrier function, inhibition of gut colonization with
pathogenic bacteria, improvement in colonization with healthy com-
mensal bacteria that protect the infant from enteropathogenic infection
through production of acetate, enhanced innate immunity, and in-
creased maturation of the enteric nervous system (Rao et al., 2016).
Recent data have shown that probiotic supplements can prevent the
incidence of NEC in preterm babies (AlFaleh & Anabrees, 2014; Millar
et al., 2003; Patel & Denning, 2015; van den Akker et al., 2018). There is
also promising data on use of probiotocs/synbiotics for prevention
of neonatal sepsis (Rao et al., 2016; Panigrahi et al., 2017). The
most commonly used strains of probiotics include Lactobacillus and
Bifidobacterium (Rao et al., 2016).
2.3 | How the intervention might work
2.3.1 | Neonatal vitamin A supplementation
Vitamin A has an effect on cell differentiation and helps maintain
normal functioning of epithelial cells (Bates, 1995; Bhutta
et al., 2013; Haider & Bhutta, 2011). It is considered anti‐infective
because it helps to maintain the protective epithelial barrier of the
skin and mucosa, which protects the body from infections. Vitamin A
helps in the regeneration of the epithelium and therefore maintains
the integrity of the body's first line of defence. These mechanisms
may help prevent infections in newborns (McCullough et al., 1999;
Wolbach, 1933). Synthetic vitamin A supplementation has been
shown to reduce morbidity and mortality in children 6–59 months of
age (Imdad et al., 2017). The potential side effects of synthetic vi-
tamin A supplementation include vomiting and bulging fontanelle
(Imdad et al., 2016, 2017; Haider & Bhutta, 2011; Haider
et al., 2017). Excess vitamin A supplementation can cause toxicity
that presents in the form of a bulging fontanelle in children under
1 year, headaches, vomiting, diarrhea, loss of appetite, and irritability
(Haider et al., 2017; Imdad et al., 2017).
2.3.2 | Oral dextrose gel supplementation during
neonatal period
The absorption of dextrose gel through the oral mucosa leads to
entry of glucose into lingual veins and into the internal jugular vein.
This pathway provides almost immediate delivery of glucose to the
systemic circulation and bypasses first pass liver metabolism through
the portal circulation. If proven effective in preventing and treating
hypoglycaemia, dextrose gel can avoid the need of intravenous glu-
cose and reduce separation of baby from mother (Hegarty
et al., 2016; Weston et al., 2016). The intervention is simple enough
that it does not require special skills (such as IV placement) and can
be administered by community, lay health workers, or the caregiver
herself. Potential adverse effects include vomiting, choking, gagging,
respiratory distress, and delay of treatment for severe hypoglycae-
mia (Hegarty et al., 2016; Weston et al., 2016).
2.4 | Probiotics supplementation during neonatal
period
Newborn, and especially preterm, babies have immature intestines
free of normal commensal bacteria that would normally protect them
from developing NEC and sepsis by inhibiting the growth of patho-
genic bacteria in the intestines (AlFaleh & Anabrees, 2014; Patel &
Denning, 2015; Rao et al., 2016). Probiotics are used to proactively
colonize the intestines with beneficial bacteria such as Lactobacillus
species (Millar et al., 2003; Patel & Denning, 2015). Probiotics
therefore reduce the growth of pathogenic bacteria which would
otherwise increase the risk of NEC and sepsis. Also probiotics pro-
mote gut immunity by increasing IgA levels and contributing to im-
proved mucosal barrier function (Patel & Denning, 2015). These
protective mechanisms reduce intestinal permeability by producing a
protective mucosal barrier against bacteria and increase the pro-
duction of anti‐inflammatory cytokines (Deshpande et al., 2017;
Millar et al., 2003). Probiotics are especially protective in preterm
babies with immature intestinal microbiomes and neonates on anti-
biotics; antibiotics may reduce bacterial diversity in the intestine and
thus also dispose to colonization by pathogenic bacteria causing NEC.
Prebiotics and probiotics can be given together in the form of a
synbiotic to improve the gut flora and can potentially reduce all‐
cause neonatal mortality (Johnson‐Henry et al., 2016; Panigrahi
et al., 2017). Probiotics are considered safe; however, there are
concerns regarding probiotic supplementation in extremely pre-
mature or immunocompromised neonates. A few cases of neonatal
sepsis have been reported that were thought to be caused by
probiotics (Dani et al., 2016).
2.5 | Why it is important to do this review
2.5.1 | Neonatal vitamin A supplementation
Randomized trials on neonatal vitamin A supplementation have
produced conflicting results with some studies (mostly from South
Asia) showing a mortality benefit while no major benefit in other
studies (mostly from Africa) (Haider et al., 2017) and some studies
showing even an increased risk of infant mortality in certain popu-
lations (Smith et al., 2016).The exact reason for this difference in
results is not clear. Previous reviews (Haider et al., 2017; Gogia &
Sachdev, 2009) and a WHO technical consultation (WHO, 2009b)
have hypothesized on what factors may explain these varied results.
Our group has previously published a Cochrane review on the evidence
on neonatal vitamin A supplementation (Haider & Bhutta, 2011), and
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we wanted to update the previous review. The previous review in-
cluded studies conducted in the community setting. In this review, we
considered studies conducted in both the community and the hospital
setting in LMIC. We also included neurodevelopment outcomes for this
review that were not covered in the previous Cochrane review.
2.5.2 | Oral dextrose gel supplementation during
neonatal period
Oral dextrose gel has been studied in the prevention and
treatment of neonatal hypoglycaemia in high‐income countries
(Hegarty et al., 2017; Weston et al., 2016); however, it was not
clear if similar studies were available from LMICs. Our objective
was to consider both randomized and nonrandomized observa-
tional studies with a control arm. We hypothesized that the use of
dextrose may be more beneficial in LMIC than in high‐income
countries, as the incidence of neonatal hypoglycaemia might be
higher in these countries due to an increased rate of preterm and
low birth weight birth.
2.5.3 | Probiotics supplementation during neonatal
period
The effect of probiotic supplementation for the prevention of NEC and
neonatal sepsis has been assessed in previous reviews (AlFaleh &
Anabrees, 2014; Rao et al., 2016; van den Akker et al., 2018). Most of
these reviews included studies from both high‐ and LMICs. Deshpande
et al. (2017) reviewed studies from LMIC where neonates were sup-
plemented with probiotics. More studies (Amini et al., 2017;
Chowdhury et al., 2016; Guney‐Varal et al., 2017; Hernández‐Enríquez
et al., 2016; Hussain et al., 2016) have been published since the
publication of Deshpande et al.'s (2017) review. Overall, our objective
was to assess the current evidence for the effect of probiotic
supplementation during the neonatal period in the hospital and
community setting in LMIC.
3 | OBJECTIVES
3.1 | Primary objectives
To determine the efficacy of the following interventions on neonatal
morbidity and mortality:
1. Synthetic vitamin A supplementation,
2. Oral dextrose gel supplementation, and
3. Oral probiotic supplementation.
A detailed description of background and methods for this
review was published in the form of a protocol as Imdad
et al. (2019).
4 | METHODS
4.1 | Criteria for considering studies for this review
4.1.1 | Types of studies
We included the following study designs:
• Randomized controlled trials (RCTs), where participants were
randomly assigned either individually or in clusters to intervention
and comparison groups. Cross‐over designs were also eligible for
inclusion.
• Quasi‐experimental designs, which include:
a. Natural experiments: studies where nonrandom assignment was
determined by factors that were out of the control of the in-
vestigator. One common type includes allocation based on exo-
genous geographical variation.
b. Controlled before‐after studies (CBA), in which measures were
taken of an experimental group and a comparable control group
both before and after the intervention. We also require that ap-
propriate methods were used to control for confounding, such as
statistical matching (e.g., propensity score matching or covariate
matching) or regression adjustment (e.g., difference‐in‐differences,
instrumental variables).
c. Regression discontinuity designs; here, allocation to intervention/
control was based upon a cut‐off score.
d. Interrupted time series studies, in which outcomes were mea-
sured in the intervention group at at least three time points be-
fore the intervention and after the intervention.
4.1.2 | Types of participants
Participants for this review included neonates (aged 0–28 days) from
LMICs. We included neonates regardless of their health status. This
includes low birth weight and preterm babies. However, studies that
focused on neonates with congenital anomalies were excluded. We
considered studies that included older age population groups in ad-
dition to neonates only if we could disaggregate relevant data for the
neonatal population. For example, a study might include infants up to
6 months of age. We included such a study if the disaggregated data
were available for neonates (0–28 days). Even though we planned to
assess later childhood outcomes, we did not plan to include studies
that recruited participants after the neonatal period.
4.1.3 | Types of interventions
The following interventions were included in the review:
1. Neonatal vitamin A supplementation compared to no supple-
mentation or placebo: we considered only oral synthetic vitamin A
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supplementation. There was no restriction on the dosage and
frequency of the medicine. The comparison group could include a
placebo or standard of care.
2. Oral dextrose gel supplementation during the neonatal period
compared to no supplementation: we placed no limits on the dose
or frequency of the dextrose supplementation. We only con-
sidered dextrose gel as the intervention and excluded dextrose
given in other forms such as intravenous, nasogastric tube, or
mixed with infant formula. The reason to exclude forms other
than dextrose gel was that administration of dextrose in those
forms may require special circumstances (like trained staff to
place an IV) or special delivery vehicles, such as formula, that may
not be available in LMIC. The comparison group included placebo
or standard of care.
3. Neonatal oral probiotics/synbiotics compared to no probiotic sup-
plementation: probiotics are live microbial organisms that are given
to promote the growth of commensal gut bacteria and prevent the
growth of pathogenic bacteria. Prebiotics are dietary supplements
that promote the growth of commensal bacteria. Synbiotics are a
combination of prebiotics and probiotics (Millar et al., 2003; Patel
& Denning, 2015). We placed no limits on the dose or frequency of
probiotics. We included studies that used probiotics and synbiotics
supplementation and excluded studies that used only prebiotics.
Comparison groups included placebo or standard of care.
Each of the above interventions (i.e., vitamin A, dextrose, or
probiotics) was summarized separately, and the interventions were
not compared to each other directly or indirectly.
4.1.4 | Types of outcome measures
Primary outcomes
The primary outcomes were:
1. All‐cause neonatal mortality (death between 0 and 28 days of life)
2. All cause infant mortality at 6 months (death between 0 days and
6 months of life)
3. All‐cause infant mortality at 12 months (death between 0 days
and 12 months life).
We anticipated that studies might not report the outcomes in the
follow‐up period mentioned above for the primary outcomes. If a
study did not report mortality outcomes at day 28, 6 months, or
12 months, we contacted authors for data for the same. If segregated
data were not available from authors, we included mortality data as
follows: mortality in the first 6 weeks of life was included as neonatal
mortality at day 28; between 3 and 6 months was included as
6 months, and between 9 and 12 months was included as 12 months.
If the follow up was not clear, we included the mortality data at the
longest follow‐up.
Secondary outcomes
The secondary outcomes included:
1. Sepsis‐specific mortality measured between 0 and 28 days, 0 days
and 6 months, and 0 days and 12 months of life
2. Neonatal sepsis (as defined by authors) in the first 6 weeks of life
3. NEC as defined by authors
4. VAD
5. Prevention of Hypoglycemia (as defined by authors) during the
neonatal period
6. Treatment of Hypoglycemia (recurrence of hypoglycaemia after
the episode treated)
7. Any adverse reactions during the intervention period
8. Serious adverse events
9. Neurodevelopmental outcomes at 12 and 24 months and at the
longest follow‐up.
The term neurodevelopment is a composite term that refers to
cognitive, neurologic, and/or sensory outcomes. The term neurode-
velopment may include intellectual disability as measured on the
Mental Developmental Index of the Bayley Scales of Infant Devel-
opment; gross motor delay measured on Gross Motor Function
Classification System, and hearing and vision loss requiring amplifi-
cation devices.
In order to be eligible for inclusion in the review, a study should
have reported at least one of the primary or secondary outcomes.
This was assessed at the full‐text review stage.
Duration of follow‐up. We included all participants in eligible stu-
dies that had outcomes of interest measured. There were no re-
strictions based on the duration of exposure, duration of follow‐
up, or timing of the outcome measurement. If the duration of
treatment exceeded the neonatal period (i.e., 28 days), we con-
sidered another 2 weeks maximum but did not include studies in
which the treatment went beyond 6 weeks of supplementation.
We included mortality outcomes measured at 28 days, 6 months,
12 months of life, and at the longest follow‐up as reported by
authors.
Type of settings. We included studies conducted in LMIC. Low‐income
countries were defined as those with a gross national income (GNI)
per capita of USD 1005 or less in 2016, and middle‐income econo-
mies were those with a GNI per capita between USD 1006 and 3955
in 2016 (World Bank, 2017).
4.2 | Search methods for identification of studies
The identification of studies included various methods, such as
electronic and other sources. We did not exclude any based on the
outcome at the screening stages.
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4.2.1 | Electronic searches
The electronic search for relevant studies was done in the following
databases: PubMed, CINAHL, LILACS, SCOPUS, and CENTRAL
(Cochrane Central Register for Controlled Trials).
Appendix 1 gives the search strategy for PubMed, CINAHL, LI-
LACS, SCOPUS, and CENTRAL. It includes keywords and MeSH terms
as appropriate. This approach includes a search strategy for the popu-
lation (neonates) and interventions of interest. We planned to run
searches for each intervention separately. We first ran the search for
the population, which is the same for each intervention. Then we ran
the search for each intervention. We then combined both searches by
using “AND” and kept the searches in a separate EndNote file.
An example of a search strategy for vitamin A for PubMed was as
follows:
(((((“Vitamin A”[Mesh]) OR (Vitamin A[tiab] OR Aquasol A[tiab]
OR Retinol[tiab] OR All Trans Retinol[tiab] OR All‐Trans‐Retinol[tiab]
OR Vitamin A1[tiab] OR Vitamin A 1[tiab] OR 11‐cis‐Retinol[tiab] OR
11 cis Retinol[tiab] OR Tretinoin[tiab])AND Supplement*[tiab]))AND
((“Infant”[Mesh] OR “Premature Birth”[Mesh]) OR (Neonat*[tiab] OR
neo nat*[tiab]) OR (newborn* OR new Born*[tiab] OR newly born*
[tiab]) OR (preterm[tiab] OR preterms[tiab] OR pre term[tiab] OR pre
terms[tiab]) OR (premature*[tiab] AND (birth*[tiab] OR born[tiab]
OR deliver*[tiab])) OR (low[tiab] AND (birthweight*[tiab] OR birth
weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR elbw[tiab]) OR infant*
[tiab] OR (baby[tiab] OR babies[tiab])))) NOT (“Animals”[Mesh] NOT
(“Animals”[Mesh] AND “Humans”[Mesh]))
We applied restriction of “humans” to searches. We did not apply
any restrictions on searches based on outcomes, study design, or
language. There was no restriction on date of publication.
The searches were conducted for vitamin A on December 10,
2018 (updated on November 13, 2019); probiotics on February 8,
2019 (updated on November 27, 2019); and dextrose on April 25,
2019 (updated on November 26, 2019).
4.2.2 | Searching other resources
Other resources included the search for ongoing trials at www.
clinicaltrials.gov and WHO's ICTRP trials database. We also searched
websites of international agencies such as WHO (including WHO's
Reproductive Health Library), UNICEF, Global Alliance for Improved
Nutrition (GAIN), International Food Policy Research Institute, In-
ternational Initiative for Impact Evaluation (3ie), Nutrition Interna-
tional (NI), World Bank, USAID and USAID affiliates (e.g., FANTA,
SPRING), and the World Food Programme.
Grey literature search sources included NI, GAIN, International
Food Policy and Research Institute (IFPRI), and the WHO library
database (WHOLIS).
We searched the reference lists of all included studies. We did
citation searches of included studies in Google Scholar and Web of
Science. We also searched the reference sections of previously
published systematic reviews and the latest published studies. We
contacted the experts and authors of the newest published studies to
ask about any additional studies. Duplicates were removed.
4.3 | Data collection and analysis
4.3.1 | Selection of studies
Two authors independently screened titles/abstracts using pre-
specified inclusion/exclusion criteria. A full text was reviewed for the
studies selected in the initial screening, and the same inclusion/ex-
clusion criteria were applied. If there was a conflict about the in-
clusion of a study between the two reviewers, a third reviewer (ZAB)
was consulted. We used a web‐based software “Covidence”
(Covidence, 2019) to do both title/abstract and full‐text screening.
This software allows simultaneous independent screening of studies,
and inter‐reviewer reliability can be assessed by checking the num-
ber of conflicts in the resolved conflict page following each stage of
screening.
Description of methods used in primary research
We expected that the majority of the included studies would be
randomized or cluster‐randomized. We extracted the information
on study design explicitly and made a careful differentiation be-
tween experimental and observational studies. We aimed to
analyze randomized and nonrandomized studies separately.
Criteria for determination of independent findings
We anticipated that authors might report the results of a study in
multiple publications. We coded such trials as a single study to avoid
double counting of the data and included all the relevant outcomes
decided a priori for this review. If a pilot study was done before the
larger study, we included the two studies separately unless the data
from the pilot study was included in the main trial. When a clinical
trial registration number was available for a study, we searched that
number on PubMed to locate all the published studies linked to that
trial number.
4.3.2 | Data extraction and management
Details of study coding categories
The data from included studies were abstracted into a standardized
data abstraction form by two authors. We extracted data in dupli-
cates, and any discrepancies were resolved by discussion firs. A third
reviewer (ZAB) was consulted if the conflict existed after the initial
discussion.
The data extraction sheet had the following information.
• General study information: authors, publication year, study design
• Study setting: World Bank region, country, World Bank income
level, city/town, urban/urban slum/rural/mixed setting, duration of
data collection, date of data collection
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• Study population: sample size recruited, sample size analysed, fe-
male (%), description of participants (i.e., inclusion/exclusion cri-
teria applied to recruitment)
• Intervention characteristics: type of intervention, duration of in-
tervention, unit of randomization (where applicable), dose, fre-
quency of provision, duration of follow up, attrition rate
• Quality assessment
Each quantitative outcome sheet contained the following:
• Subgroup (if applicable)




a. Outcome measure treatment group





4.3.3 | Assessment of ROB in included studies
We used the Cochrane ROB tool (Higgins & Green, 2011) for ran-
domized studies. The Cochrane ROB tool includes the following
items:
• Selection bias: random sequence generation and allocation
concealment
• Performance bias: blinding of participants and personnel
• Detection bias: blinding of outcome assessment
• Attrition bias: incomplete outcome data
• Reporting bias: selective reporting
• Other sources of bias
Two authors independently performed the ROB assessments for
each study. A third reviewer was involved to resolve any disagree-
ments (ZAB). An overall score was not provided.
4.3.4 | Measures of treatment effect
We performed a meta‐analysis for the synthesis of quantitative data
when the included studies had comparable participants, interven-
tions, and outcomes. We did not assess the effect on outcome across
the interventions, such as is done in network meta‐analysis. Each
intervention was analysed separately. We analysed continuous and
dichotomous data separately. For dichotomous outcomes, results
were presented as summary risk ratios with 95% CI. We combined
risk ratios (events per child) and rate ratios (events per child year) for
incidence data because of their similar interpretation and scale.
For continuous outcomes, we presented the summary results as the
mean difference with 95% CI when data were available on the
same scale across the studies. We used the standardized mean dif-
ference with 95% CI when data were presented in different scales
across the studies.
To avoid reviewer bias, we planned to predetermine the pre-
ference for specific data for certain outcomes. For example, for
mortality outcomes, we gave preference to denominators in the
following order: number with the definite outcome known, number
randomized, and child‐years. For morbidity data such as neonatal
sepsis where both survivors and nonsurvivors might have con-
tributed data, we gave preference to child years, number with the
definite outcome known, and number randomized. For randomized
trials, we gave preference to data that required the least manipula-
tion by authors or inference by reviewers. We extracted the raw
values (e.g., means and SDs) and built the intention‐to‐treat (ITT)
analysis where applicable.
We anticipated that cause‐specific morbidity or mortality data
might not be readily available, as febrile illness due to respiratory,
urinary, or central nervous system infection during the neonatal
period are often categorized under a broader term of neonatal sepsis
(WHO, 2017b).
4.3.5 | Unit of analysis issues
As we planned to include multiple interventions, all interventions and
outcomes within those interventions, were meta‐analyzed separately.
For randomized trials, we meta‐analyzed individual and cluster‐
randomized trials in the same analysis. We assessed analyses in the
cluster‐randomized trials to ensure that clustering was appropriately
accounted for within the analysis of the primary study, such that
study precision was not over or under‐estimated within our analysis.
If the authors adjusted for cluster randomization, no further adjust-
ment was made. In case a cluster‐randomized study was not adjusted
by primary authors, we adjusted effect estimates by using the mean
cluster size (M) and the intra‐cluster correlation coefficient (ICC) to
calculate the design effect as follows: design effect = 1 + (M − 1) ICC.
We then used the design effect to adjust the study data such that a
trial was reduced to its effective sample size or standard error of the
summary estimate was inflated. We used the ICC given in the pub-
lished studies. If the ICC was not available from the published study,
we contacted the authors for the same. If the ICC was not available
from the authors, we used ICC from the similar studies done in the
similar region and on a similar population or took it from the
previously published reviews (Haider et al., 2017).
Multiple‐arm trials
We included studies with multiple intervention arms, but we only
included the arms that were eligible for the review. We selected one
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pair (with appropriate intervention and control group) that satisfied
the inclusion criteria of the review and excluded the rest. In case
there were more than two groups eligible for inclusion, we combined
these groups into a single pair‐wise comparison. In multiple‐arm trials
using two different doses of the same intervention, we combined the
two groups to avoid double counting the participants in the control
group.
4.3.6 | Dealing with missing data
Any missing data were noted including loss to follow‐up and drop-
outs. The reasons for the missing data were taken from the studies,
and if it was not mentioned in the studies, the authors were con-
tacted for the same. If the authors reported the adjusted values for
missing data, we used the adjusted values.
4.3.7 | Assessment of heterogeneity
Statistical heterogeneity was assessed using τ2, I2, and significance of
the χ2 test. We also assessed statistical heterogeneity by visually
inspecting the forest plots.
4.3.8 | Assessment of reporting biases
A funnel plot and its symmetry were used to assess publication bias if
the number of included studies for intervention was more than 10. If
the funnel plot was suggestive of publication bias, we further in-
vestigated the publication bias with the use of Egger's test (Higgins &
Green, 2011).
4.3.9 | Data synthesis
Synthesis procedures and statistical analysis
We used the software Review Manager 5.3 (Review Manager, 2019)
to conduct the statistical analysis. For randomized trials, we followed
the ITT analysis. If ITT was not available, and the author reported the
analyses as specified in the protocol, we reconstructed the data to
create an ITT analysis.
We used a random‐effect model to account for expected het-
erogeneity in the intervention, comparisons, or setting within studies
included in a given synthesis. We used the generic inverse variance
method of meta‐analysis for fixed effect models and random effect
models. This method of meta‐analysis gives weight to studies based
on their variance in a way that a study with low variance gets a high
weight and vice versa.
We interpreted the results of the meta‐analysis based on
p value at the 95% confidence level (a value <0.05 was considered
statistically significant) and reported both significant and non-
significant results. For subgroup analysis, we used an interaction
test to determine if there was a relevant difference in effect across
subgroups.
We assessed the quality of overall evidence using the GRADE
approach. This method of quality assessment considers study type,
within‐study ROB (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates, and risk of publication
bias (Guyatt et al., 2011). We rated the quality of the body of evi-
dence for each key outcome as “high,” “moderate,” “low,” or
“very low.”
4.3.10 | Subgroup analysis and investigation of
heterogeneity
Neonatal vitamin A supplementation
Although we had planned a number of subgroup analyses for neo-
natal vitamin A supplementation; however, a recent IPD analysis
(West et al., 2019) covered both individual and study level subgroup
analyses, so we did not perform any subgroup analysis for vitamin A
supplementation at this stage
Neonatal probiotic supplementation
1. Gestational age: term and preterm
2. Strains used in probiotics: single strain versus multiple strain and
of type of strain used in each probiotic
3. Strains used in probiotics: contains Lactobacillus versus Bifido-
bacterium versus both
4. Settings: community‐based versus hospital setting
5. Type of feedings: breastmilk versus formula milk versus mixed.
Oral dextrose gel supplementation
1. Gestational age: term and postterm versus late preterm (35–36
weeks) versus moderately preterm (30–34 weeks) versus ex-
tremely preterm (<30 weeks)
2. Dose: equal or <200mg/kg versus >200mg/kg
3. Frequency: one versus more than one dose
4. Time of administration: ≤1 h of age versus after 1 h of age versus
after 2 h of age.
4.3.11 | Sensitivity analysis
1. High quality studies versus low quality studies. The quality of
study was subjectively based on the ROB assessment. Even
though we considered all the domains included in the Cochrane
ROB tool, we gave higher importance to sequence generation and
allocation concealment, as most of the outcomes for this review
were objective, and it was less likely that the results of the in-
cluded studies would have been biased by a lack of blinding.
2. Random versus fixed effect models. We chose this sensitivity
analysis to assess if the summary estimates will change
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significantly based on use of random versus fixed effect model.
There is no exact criterion to choose between the two models,
and we wanted to make sure that estimates were not significantly
different between the two models.
Treatment of qualitative research
We did not plan to include qualitative research.
4.3.12 | Summary of findings and assessment of the
certainty of the evidence
Summary of findings' tables
We constructed “Summary of findings” tables for all of the primary
outcomes using the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) criteria (GRADEpro GDT 2015).
These covered consideration of within‐study ROB (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias. We rated the certainty of
evidence for each key outcome as “high,” “moderate,” “low,” or “very
low.” The GRADE evidence is described in Table 1. Nonrandomised
studies were initially rated as “low” quality. If there were no serious
methodological flaws, we upgraded the evidence for studies with a
large magnitude of effect; presence of a dose response relationship;
and effect of plausible residual confounding.
We used GRADE and prepared the summary of findings tables
for the following primary outcomes:
• Stillbirth defined as baby born with no signs of life at or after 28
weeks' gestation
• Perinatal mortality (stillbirth and deaths ≤7 days)
• Neonatal mortality (death < 28 days)
• Infant mortality (deaths between 0 and 12 months)
• Under‐five mortality (deaths between 0 and 59 months)
• Miscarriage
• Mean maternal body mass index
5 | RESULTS
5.1 | Description of studies
5.1.1 | Results of the search
Figure 1 shows the PRISMA flow diagram for our literature search.
Vitamin A supplementation during neonatal period
Sixteen studies reported in 45 publications assessed the effect of neo-
natal vitamin A supplementation (Ahmad et al., 2019; Basu et al., 2019;
Benn et al., 2008, 2010, 2014; Edmond et al., 2015; Giridhar et al., 2019;
Humphrey et al., 1996; Klemm et al., 2008; Malaba et al., 2005; Masanja
et al., 2015; Mazumder et al., 2015; Rahmathullah et al., 2003; Soofi
et al., 2017; Sun et al., 2019; West et al., 1995). These studies included a
total of about 16,366 participants. All the studies were RCTs and
published in a peer‐reviewed journal.
Dextrose gel supplementation during neonatal period
We did not identify any studies that assessed the use of dextrose gel
supplementation during neonatal period for prevention or treatment
of hypoglycaemia in LMIC.
Probiotic supplementation during neonatal period
Thirty‐three studies reported in 37 publications evaluated the effect
of probiotic supplementation during the neonatal period and in-
cluded a total of 11,595 participants (probiotics, 5854 and controls,
5741; Amini et al., 2017; Braga et al., 2011; Chowdhury et al., 2016;
Cooper et al., 2017; Cui et al., 2019; Dashti et al., 2014; Demirel
et al., 2013; Dilli et al., 2015; Dongol Singh et al., 2017; Dutta
et al., 2015; Fernández‐Carrocera et al., 2013; Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Hussain et al., 2016;
Kaban et al., 2019, Mazumder et al., 2015; Nandhini et al., 2016;
Guney‐Varal et al., 2017; Oncel et al., 2014; Panigrahi et al., 2017;
Rojas et al., 2012; Roy et al., 2014; Samanta et al., 2009; Shashidhar
et al., 2017; Sinha et al., 2015; Sari et al., 2011; Serce et al., 2013;
Shadkam et al., 2015; Saengtawesin et al., 2014; Tewari et al., 2015;
Xu et al., 2016).
Three of the studies were available in the form of abstracts
(Hariharan et al., 2016; Huaxian, 2013; Rehman et al., 2018). The rest
of the studies were published in a peer‐reviewed journal.
5.1.2 | Included studies
The characteristics of included studies are available in the table
Characteristics of included studies.
Vitamin A supplementation during neonatal period
Type of studies. All the included studies were RCTs. Thirteen studies
were individually randomized (Ahmad et al., 2019; Basu et al., 2019;
Benn et al., 2008, 2010, 2014; Edmond et al., 2015; Giridhar
et al., 2019; Humphrey et al., 1996; Malaba et al., 2005; Masanja
et al., 2015; Mazumder et al., 2015; Rahmathullah et al., 2003), and
three studies were cluster‐randomized (Klemm et al., 2008; Soofi
et al., 2017; Sun et al., 2019; West et al., 1995). Three trials had
multiple arms of interventions (Benn et al., 2010, 2014; Malaba
et al., 2005).
Country. Studies were conducted in 10 different countries with four
studies conducted in India (Basu et al., 2019; Giridhar et al., 2019;
Mazumder et al., 2015; Rahmathullah et al., 2003), three studies in
Guinea‐Bissau (Benn et al., 2008, 2010, 2014), two studies in Ban-
gladesh (Ahmad et al., 2019; Klemm et al., 2008), and one each in
China (Sun et al., 2019), Ghana (Edmond et al., 2015), Indonesia
(Humphrey et al., 1996), Nepal (West et al., 1995), Pakistan (Soofi
et al., 2017), Tanzania (Masanja et al., 2015), and Zimbabwe (Malaba
et al., 2005).
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TABLE 1 Effect of probiotic supplementation during neonatal period: Subgroup analysis





All‐cause mortality: subgroup analysis: settings
Hospital based 22 0.78 [0.65, 0.94] p = .31
Community based 3 1.25 [0.51, 3.05] I2 = 0%
All‐cause mortality: subgroup analysis: type of probiotics
Preparation contain a single strain of probiotics 9 0.80 [0.61, 1.05] p = .95
Preparation contained multiple strains of probiotics 12 0.80 [0.58, 1.09] I2 = 0%
Preparation contained synbiotics
(prebiotics + probiotics)
5 0.69 [0.29, 1.61]
All‐cause mortality: subgroup analysis: type of participants
Study include preterm/low birth weight babies 24 0.79 [0.65, 0.95] p = .47
Study included term infants only 1 1.38 [0.31, 6.08] I2 = 0%
All‐cause mortality: subgroup analysis: type of feedings
Baby received breastmilk only 14 0.81 [0.62, 1.05] p = .44
Baby received formula milk only 1 1.38 [0.31, 6.08]
Baby received both both breastmilk and formula milk 8 0.69 [0.48, 0.99] I2 = 0%
Type of feeding was unclear 3 1.33 [0.63, 2.81]
All‐cause mortality: subgroup analysis: probiotics preparation
Preparation contained Lactobacillus 10 0.82 [0.63, 1.05] p = .47
Preparation contained Bifidobacterium 1 0.43 [0.17, 1.09]
Preparation contained both Lactobacillus and
Bifidobacterium
13 0.71 [0.47, 1.08] I2 = 0%
Preparation contained Saccharomyces boulardii only 2 1.12 [0.46, 2.71]
Necrotizing enterocolitis: subgroup analysis: probiotic preparation
Preparation contained Lactobacillus 13 0.39 [0.25, 0.61] p = .05
Preparation contained Bifidobacterium 1 0.20 [0.09, 0.47]
Preparation contained both Lactobacillus and
Bifidobacterium
14 0.49 [0.36, 0.68] I2 = 60.5%
Preparation contained S. boulardii only 2 0.94 [0.45, 1.95]
Necrotizing enterocolitis: subgroup analysis: type of feeding
Baby received breastmilk only 13 0.43 [0.31, 0.59] p = .74
Baby received formula only 1 0.21 [0.03, 1.76]
Baby received both breastmilk and formula milk 9 0.55 [0.33, 0.92] I2 = 0%
Type of feeding was unclear 7 0.41 [0.17, 1.00]
Necrotizing enterocolitis: subgroup analysis: type of probiotics
Preparation contained a single strain of probiotics 12 0.48 [0.30, 0.76] p= .50
Preparation contained multiple strains of probiotics 15 0.48 [0.35, 0.67] I2 = 0%
Preparation contained synbiotics
(prebiotics + probiotics)
3 0.28 [0.12, 0.67]
Neonatal sepsis: subgroup analysis: probiotic preparation
Preparation contained Lactobacillus 11 0.74 [0.62, 0.87] p = .79
Preparation contained Bifidobacterium 1 0.81 [0.60, 1.09]
Preparation contained both Bifidobacterium and
Lactobacillus
6 0.83 [0.68, 1.02] I2 = 0%
Preparation contained S. boulardii only 3 0.73 [0.57, 0.94]
Neonatal sepsis: subgroup analysis: type of feeding
Baby received breastmilk only 8 0.71 [0.61, 0.83] p = .04
Baby received formula milk only 2 0.59 [0.22, 1.56]
Baby received both formula and breastmilk only 6 0.77 [0.65, 0.90] I2 = 65%
Type of feeding was unclear 4 0.95 [0.82, 1.09]
Neonatal sepsis: type of probiotics
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Settings. Thirteen studies were conducted in the community
setting, while three studies were conducted in the hospital setting
(Basu et al., 2019; Giridhar et al., 2019; Sun et al., 2019).
Participants. Most of the studies included live born infants who were
otherwise healthy. One study included only low birth weight babies
(Benn et al., 2010), two studies included newborns with very low
birth weight (Basu et al., 2019; Giridhar et al., 2019), and one study
included extremely premature babies (Sun et al., 2019). The sample
size of each study ranged from 120 (Giridhar et al., 2019) to 44,948
(Mazumder et al., 2015).
Dose. Most of the included studies for the use of neonatal vitamin A
supplementation used a dose of 50,000 IU. Rahmathullah et al.
(2003) gave 24,000 IU daily, and Benn et al. (2010) used 25,000 IU.
Benn et al. (2014) compared doses of 50,000 IU versus 25,000 IU.
Basu et al. (2019) used a daily dose of 1,500 IU.
Comparison. In all the included studies for neonatal vitamin A
supplementation a placebo was given to the control group.
Probiotic supplementation during neonatal period
Type of studies. All the studies that evaluated the effect of pro-
biotic supplementation during the neonatal period were individual
RCTs. Two studies had multiple intervention groups (Dilli
et al., 2015; Dutta et al., 2015). One of these studies compared
different combinations of probiotics with prebiotics (Dilli
et al., 2015), and the other study compared different doses of
probiotics (Dutta et al., 2015). For the study by Dilli et al. (2015),
we included the data in a way that the only difference between
the two groups was probiotics. For the study by Dutta et al.
(2015), we combined all the groups that compared different doses
and compared them with the placebo to avoid double‐counting of
the placebo group data.
One study included neonates with and without exposure to hu-
man immunodeficiency virus (HIV; based on maternal history of HIV).
We included the data for these groups separately in the meta‐
analysis (Niekerk et al., 2015 (HIV exposed); Niekerk et al., 2015
(HIV nonexposed).
Country. Studies were conducted in 13 different countries with 10 stu-
dies conducted in India (Dutta et al., 2015; Hariharan et al., 2016;
Mazumder et al., 2015; Nandhini et al., 2016; Panigrahi et al., 2017;
Roy et al., 2014; Samanta et al., 2009; Shashidhar et al., 2017; Sinha
et al., 2015; Tewari et al., 2015), six studies in Turkey (Demirel
et al., 2013; Dilli et al., 2015; Guney‐Varal et al., 2017; Oncel et al., 2014;
Sari et al., 2011; Serce et al., 2013), three studies each in China (Cui
et al., 2019; Huaxian, 2013; Xu et al., 2016) and Iran (Amini et al., 2017;
Dashti et al., 2014; Shadkam et al., 2015), two each in Mexico
(Fernández‐Carrocera et al., 2013; Hernández‐Enríquez et al., 2016) and
South Africa (Cooper et al., 2017; Niekerk et al., 2015 (HIV exposed)),
and one each in Bangladesh (Chowdhury et al., 2016), Brazil (Braga
et al., 2011), Colombia (Rojas et al., 2012), Indonesia (Kaban et al., 2019),
Nepal (Dongol Singh et al., 2017), Pakistan (Hussain et al., 2016), and
Thailand (Saengtawesin et al., 2014).
Settings. All the studies were conducted in the hospital setting except for
three studies where participants were followed in the community setting
(Cooper et al., 2017; Dongol Singh et al., 2017; Panigrahi et al., 2017).
Participants. Only one study (Cooper et al., 2017) included neonates
that were full term. The rest of the studies included participants that
were either low birth weight, preterm, or both. The participants were
recruited from neonatal intensive care units except in three studies
(Cooper et al., 2017; Dongol Singh et al., 2017; Panigrahi et al., 2017),
where participants were recruited from the community.
The intervention. Thirteen studies used a single strain of probiotics (Cui
et al., 2019; Demirel et al., 2013; Dongol Singh et al., 2017; Hernández‐
Enríquez et al., 2016; Hussain et al., 2016; Kaban et al., 2019; Oncel
et al., 2014; Rojas et al., 2012; Roy et al., 2014; Serce et al., 2013;
Shadkam et al., 2015; Tewari et al., 2015; Xu et al., 2016), and 13 studies
used a preparation that contained multiple strains of probiotics (Amini
et al., 2017; Braga et al., 2011; Chowdhury et al., 2016; Dashti
et al., 2014; Dutta et al., 2015; Fernández‐Carrocera et al., 2013;
TABLE 1 (Continued)





Preparation contained single strain of probiotics 8 0.84 [0.74, 0.96] p = .21
Preparation contained multiple strains of probiotics 9 0.81 [0.68, 0.97] I2 = 35%
Preparation contained synbiotics
(prebiotics + probiotics)
4 0.67 [0.54, 0.83]
Neonatal sepsis: subgroup analysis: settings
Hospital based 19 0.83 [0.76, 0.91] p = .19
Community based 2 0.67 [0.49, 0.91] I2 = 42%
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Hariharan et al., 2016; Niekerk et al., 2015 (HIV exposed); Roy
et al., 2014; Saengtawesin et al., 2014; Samanta et al., 2009; Shadkam
et al., 2015; Sinha et al., 2015). Five studies used a preparation that had a
probiotic + prebiotic (synbiotic) (Cooper et al., 2017; Dilli et al., 2015;
Guney‐Varal et al., 2017; Nandhini et al., 2016; Panigrahi et al., 2017);
among these five studies, three studies (Cooper et al., 2017; Dilli
et al., 2015; Panigrahi et al., 2017) used a probiotic preparation that had a
single strain of bacteria, and the other two studies used a preparation
that had multiple strains of bacteria (Guney‐Varal et al., 2017; Nandhini
et al., 2016). One study did not report the strain of probiotic supple-
mentation (Huaxian, 2013).
Ten studies used a probiotic preparation that contained Lactoba-
cillus (Cooper et al., 2017; Cui et al., 2019; Dongol Singh et al., 2017;
Hernández‐Enríquez et al., 2016; Kaban et al., 2019; Oncel et al., 2014;
Panigrahi et al., 2017; Rojas et al., 2012; Roy et al., 2014; Shadkam
et al., 2015), and two studies used a preparation that contained Bifi-
dobacterium (Dilli et al., 2015; Hussain et al., 2016). Fourteen studies
used a preparation that had both Lactobacillus and Bifidobacterium
(Amini et al., 2017; Braga et al., 2011; Chowdhury et al., 2016; Dashti
et al., 2014; Fernández‐Carrocera et al., 2013; Guney‐Varal et al., 2017;
Hariharan et al., 2016; Nandhini et al., 2016; Niekerk et al., 2015 (HIV
exposed); Roy et al., 2014; Saengtawesin et al., 2014; Samanta
et al., 2009; Shashidhar et al., 2017; Sinha et al., 2015). Three studies
used Saccharomyces boulardii (Demirel et al., 2013; Serce et al., 2013; Xu
et al., 2016), and one study used Bacillus clausii (Tewari et al., 2015).
The probiotics were mostly given with breastmilk or formula
feedings and started when the baby was able to tolerate minimal
enteral feeds. The duration and dose of probiotic supplementation
varied among the studies.
Comparison. Sixteen studies used a placebo (Cui et al., 2019; Dashti
et al., 2014; Demirel et al., 2013; Dilli et al., 2015; Dongol
Singh et al., 2017; Dutta et al., 2015; Kaban et al., 2019; Niekerk
et al., 2015 (HIV exposed); Oncel et al., 2014; Panigrahi
et al., 2017; Rojas et al., 2012; Roy et al., 2014; Serce et al., 2013;
Shadkam et al., 2015; Sinha et al., 2015; Tewari et al., 2015); the
rest of the studies used a control group receiving standard of
care only.
Outcomes. All the studies reported data for at least one outcome that
could be included in the meta‐analysis. Twenty five studies reported
data for all‐cause mortality, 29 studies reported data for NEC, and 21
studies reported data for the incidence of neonatal sepsis. See
Section 5.3 for more details.
5.1.3 | Excluded studies
Overall, 138 studies were excluded. See the Characteristics of ex-
cluded studies for reasons for exclusion of studies.
F IGURE 1 PRISMA flow diagram
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Among excluded studies, 86 studies were excluded
because of the wrong settings, and most of these studies were
conducted in high‐income countries. Fifteen studies were
excluded because no relevant clinical outcomes were available
from the abstract or full text of the studies. Fourteen studies
were excluded for the wrong population, and 10 studies
were excluded because of the wrong study design. Nine studies
had a wrong intervention, and four studies had a wrong
comparator.
5.2 | ROB in included studies
5.2.1 | Vitamin A supplementation during the
neonatal period
Figure 2 shows the ROB in the 16 included studies that addressed
vitamin A supplementation during the neonatal period.
5.2.2 | Probiotic supplementation during the
neonatal period
Figure 3 show the ROB in the 33 included studies that addressed
probiotic supplementation during the neonatal period.
5.2.3 | Allocation (selection bias)
Vitamin A supplementation during the neonatal period
All the studies for vitamin A supplementation were at low ROB for
sequence generation and allocation concealment.
Probiotic supplementation during the neonatal period
Two studies were judged to be at high ROB due to inad-
equate randomization (Guney‐Varal et al., 2017; Kaban et al.,
2019), and four studies did not provide enough information
to allow a judgment about methods of randomization; these
were labelled as having an unclear ROB (Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Rehman
et al., 2018). The rest of the studies had a low ROB for sequence
generation.
Two studies were considered at high ROB due to inability to
conceal the allocation (Dongol Singh et al., 2017; Guney‐Varal
et al., 2017). Ten studies had an unclear ROB, as these studies did not
provide enough information to assess methods of allocation con-
cealment (Amini et al., 2017; Cui et al., 2019; Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Hussain et al., 2016;
Kaban et al., 2019, Rehman et al., 2018; Samanta et al., 2009;
Shadkam et al., 2015). The rest of the studies had a low ROB for
allocation concealment.
5.2.4 | Blinding (performance bias and
detection bias)
Vitamin A supplementation during neonatal period
None of the included studies for neonatal vitamin A supplementation
was at increased ROB for blinding.
F IGURE 2 Risk of bias: neonatal vitamin A supplementation
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Probiotic supplementation during neonatal period
Ten studies had an unclear ROB due to blinding of the partici-
pants (Amini et al., 2017; Guney‐Varal et al., 2017; Hariharan
et al., 2016; Hernández‐Enríquez et al., 2016; Huaxian, 2013;
Hussain et al., 2016; Kaban et al., 2019; Nandhini et al., 2016;
Rehman et al., 2018; Samanta et al., 2009). The rest of the studies
had a low ROB due to the inability to do blinding of the
participants.
Thirteen studies had an unclear ROB for blinding of the outcome
assessors (Amini et al., 2017; Cui et al., 2019; Dongol Singh
et al., 2017; Guney‐Varal et al., 2017; Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Hussain et al., 2016;
Kaban et al., 2019; Nandhini et al., 2016; Rehman et al., 2018; Serce
et al., 2013; Samanta et al., 2009). The rest of the studies had a
low ROB.
5.2.5 | Incomplete outcome data (attrition bias)
Vitamin A supplementation during the neonatal period
All studies were at low risk for attrition bias except two
studies that had an unclear ROB (Benn et al., 2010; Malaba
et al., 2005).
Probiotic supplementation during the neonatal period
Most of the studies had a minimal loss to follow‐up. One study
was at high ROB where more than 20% of the participants
were lost to follow‐up (Xu et al., 2016). Four studies had
an unclear ROB, as there was not enough information to make
an assessment in these studies (Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Rehman
et al., 2018).
5.2.6 | Selective reporting (reporting bias)
Vitamin A supplementation during neonatal period
All studies were considered to have low ROB for selective outcome
reporting.
Probiotic supplementation during neonatal period
Most of the studies reported all relevant outcomes, and we did not
consider any particular study at high ROB. Three studies had unclear
ROB for selective outcome reporting (Hernández‐Enríquez
et al., 2016; Kaban et al., 2019; Rehman et al., 2018).
5.2.7 | Other potential sources of bias
Vitamin A supplementation during neonatal period
No study was considered at high ROB due to other reasons.
F IGURE 3 Risk of bias: probiotic supplementation during
neonatal period
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Probiotic supplementation during neonatal period
No other major source of ROB was noted. Five studies had unclear
ROB due to limited available information (Hariharan et al., 2016;
Hernández‐Enríquez et al., 2016; Huaxian, 2013; Kaban et al., 2019;
Rehman et al., 2018).
5.3 | Effects of interventions
5.3.1 | VItamin A supplementation during neonatal
period
All‐cause mortality during the neonatal period
Five studies from community settings reported the effect of vitamin
A supplementation on all‐cause neonatal mortality. These combined
results showed no significant difference between the intervention
and the control group (RR, 0.99; 95% CI, 0.90–1.08; six studies,
126,548 participants, heterogeneity: τ2 = 0.00; χ2 = 3.64, (p = 0.46);
I2 = 0%). The grade rating for this outcome was “high.” Summary of
findings Table 2.
Sensitivity analysis: Fixed effect model. Use of a fixed effect model did
not change the summary estimate for neonatal mortality (RR, 0.99;
95% CI, 0.90–1.08).
All‐cause mortality at 6 months
Twelve studies from community settings reported the data for the
effect of neonatal vitamin A supplementation on all‐cause mortality
at 6 months. The combined results showed no difference between
the intervention and control group (RR, 0.98; 95% CI, 0.89–1.07; 12
studies, 154,940 participants; heterogeneity: τ2 = 0.01; χ2 = 19.14,
(p = 0.06); I2 = 43%). The Grade rating for this outcome was “high.”
Summary of findings Table 2. A funnel plot for publication bias was
symmetrical.
Sensitivity analysis: Fixed effect model. Use of a fixed effect model led
to minimal change in the summary estimate (RR, 0.97; 95% CI,
0.91–1.03).
All‐cause mortality at 12 months
Eight studies from community settings reporting on the impact of
neonatal vitamin A supplementation reported data for all‐cause
mortality at 12 months (RR, 1.04; 95% CI, 0.94–1.14; eight studies,
118,376 participants; Heterogeneity: τ2 = 0.01; χ2 = 12.99, df = 7
(p = 0.07); I2 = 46%]. We rated this evidence as high certainty
Summary of findings Table 2.
Sensitivity analysis: Fixed effect model. Use of a fixed effect model did
not change the summary estimate significantly (RR, 1.02; 95% CI;
0.96–1.08).
Three studies from hospital settings also reported data on mor-
tality. The time to event for mortality was not clear in these studies. We
did not pool data from the hospital‐based studies with other studies, as
the community‐based studies had participants that were very different
from hospital‐based studies. We briefly describe the results of these
studies below.
A study by Basu et al. (2019) reported the primary outcome; this
was a composite incidence of all‐cause mortality and oxygen re-
quirement for 28 days. The results showed a reduction in mortality in
the vitamin A group compared to the control group (RR, 0.44; 95% CI,
0.23–0.84).
No difference in mortality was reported by Sun et al. (2019) in
the Vitamin A group versus placebo (RR, 0.49; 95% CI, 0.45–5.32).
Similarly, no difference was noted in all‐cause mortality by Gir-
idhar et al. (2019) (RR, 2; 95% CI, 0.63–6.30).
Adverse outcomes: Bulging fontanelle
Six studies reported on the effect of neonatal vitamin A supple-
mentation on incidence of bulging fontanelle. The combined re-
sults showed a 53% increased risk of bulging fontanelle in the
intervention group compared to control (RR, 1.53; 95% CI,
1.12–2.09; heterogeneity: τ2 = 0.08; χ2 = 14.20, (p = 0.01);
I2 = 65%). We have high certainty in this evidence. Summary of
findings Table 2.
Adverse outcomes: Vomiting
The combined results from six studies showed that neonatal
vitamin A supplementation did not increase the risk of vomiting
(RR, 1.00; 95% CI, 0.93–1.07; heterogeneity: τ2 = 0.00; χ2 = 3.90,
(p = 0.42); I2 = 0%).
Vitamin A deficiency
One study from the community setting (Benn et al., 2008) reported
VAD at 6 weeks and 4 months post neonatal supplementation. No
significant difference was noted between the two groups at 6 weeks
(RR, 0.94; 95% CI, 0.75–1.19) or 4 months (RR, 1.02; 95% CI,
0.64–1.62).
Another study from the hospital setting (Giridhar et al., 2019)
showed a significant decrease in VAD in the intervention group
compared to control (RR, 0.09; 95% CI, 0.024–0.38).
Neurodevelopment outcomes
Two studies reported long‐term neurodevelopmental outcomes after
use of vitamin A supplementation during the neonatal period. As the
outcomes measured and duration of follow up were different, we did
not pool the studies.
Humphrey et al. (1996) reported on neurodevelopmental out-
comes at 3 year follow‐up after neonatal vitamin A supplementation
by using Bayley Scales of Infant Development. The study authors
analysed the data for children with (n = 91) and without (n = 432)
bulging fontanelle who received vitamin A versus placebo. The re-
sults showed that neonatal vitamin A supplementation did not have
any adverse effect on development in the presence or absence of
bulging fontanelle. Neonatal vitamin A supplementation had a posi-
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tive effect on all developmental scores. The reported developmental
scores addressed developmental areas such as orientation‐
engagement, emotional regulation, and motor quality.
Klemm et al. (2008) reported data on neurodevelopmental outcomes
8 years after vitamin A supplementation. The authors followed a cohort
of participants (n=1613) who either directly received neonatal vitamin A
or whose mother received vitamin A during pregnancy. The results
showed no significant difference in intelligence, memory, and motor
function; however, when the neonates and their mothers were supple-
mented with vitamin A versus placebo, it increased their
performance in reading, spelling, and math computation.
5.3.2 | Probiotic supplementation during the
neonatal period
Data were available for the effect of probiotic supplementation for
all‐cause mortality, NEC, sepsis, and sepsis‐specific mortality.
All‐cause mortality at longest follow‐up
Twenty‐five studies that included 10,998 subjects (probiotics 5548,
control 5450) reported data for all‐cause mortality for the effect of
probiotic supplementation on all‐cause mortality. Our meta‐analysis
found a reduction of 20% in all‐cause mortality in the probiotic group
compared to control (RR, 0.80; 95% CI, 0.66–0.96; heterogeneity:
τ2 = 0.00; (p = 0.55); I2 = 0%) (Figure 4). The number needed to treat
was 100. The GRADE rating for this outcome was “high.” Summary of
findings Table 3.
Publication bias. A funnel plot for publication bias looked symmetrical
(Figure 5).
Subgroup analyses. Table 1 gives the summary of data for subgroup
analyses. For the outcome of all‐cause mortality, data were
available to perform subgroup analyses based on settings
(hospital vs. community‐based studies), type of probiotics
(single strains vs. multiple strain vs. synbiotic), type of partici-
pants (term vs. preterm/low birth weight), type of feeding
(breastfeeding vs. formula feeding vs. mixed feeding), and
probiotic preparation (preparation containing Lactobacillus vs.
Bifidobacterium vs. both Lactobacillus and Bifidobacterium vs.
S. boulardii). No significant difference was noted among the
subgroups; however, the number of studies varied for each group
within the subgroup analysis.
TABLE 2 Vitamin A compared to placebo
for neonatal health
Vitamin A compared to placebo for neonatal health
Patient or population: neonates (0‐28 days)














126,548 (6 RCTs) ⊕⊕⊕⊕ HIGH




154,940 (12 RCTs) ⊕⊕⊕⊕ HIGH









100,562 (6 RCTs) ⊕⊕⊕⊕ HIGH
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in
the comparison group and the relative effect of the intervention (and its 95% CI).
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the
effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to
be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially
different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to
be substantially different from the estimate of effect
Abbreviations: CI, confidence interval; OR, odds ratio; RR, risk ratio.
IMDAD ET AL. | 19 of 88
Sensitivity analysis.
Random versus fixed effect models. Use of a fixed‐effect model did not
change the summary estimate for the effect of probiotics on all‐cause
mortality (RR, 0.80; 95% CI, 0.66–0.96; heterogeneity: χ2 = 22.55,
(p = 0.55); I2 = 0%) Analysis 2.7.
Risk of bias. Exclusion of three studies (Dongol Singh et al., 2017;
Fernández‐Carrocera et al., 2013; Kaban et al., 2019) that were at
high ROB for randomizations/allocation concealment did not change
the summary estimate to a great extent, and results remained
statistically significant Analysis 2.8.
Incidence of NEC
This outcome was reported by twenty‐nine studies that included a
total of 5574 (probiotics, 2843; control, 2731) participants.
The combined results showed that the probiotics group had a
relative reduction in NEC prevalence of 54% compared to control
group (RR, 0.46; 95% CI, 0.35–0.59; heterogeneity: τ2 = 0.11;
(p = 0.12); I2 = 24%) (Figure 6). The number needed to treat was
17. We have high certainty in this evidence. Summary of findings
Table 3.
Publication bias. A funnel plot for publication bias looked symmetrical.
Subgroup analyses. Table 1 shows the results of subgroup analyses.
For NEC, data were available to perform the following 3 subgroup
analyses: type of probiotics (single strain vs. multiple strain vs.
synbiotic), type of feeding (breastfeeding vs. formula feeding vs.
mixed feeding), and probiotic preparation (preparation containing
Lactobacillus vs. Bifidobacterium vs. both Lactobacillus and Bifido-
bacterium vs. S. boulardii). No significant difference was noted
among the subgroup analyses except the one based on probiotics
preparation (p value for subgroup difference 0.05). The probiotics
preparation that has Lactobacillus in it, either as a single strain
(RR, 0.39; 95% CI, 0.25–0.61; 13 studies) or in combination with
Bifidobacterium (RR, 0.44; 95% CI, 0.36–0.68; 13 studies), had a
significant effect compared to Bifidobacterim alone (RR, 0.20;
95% CI, 0.09, −0.47) or S. boulardii alone (RR, 0.94; 95% CI,
0.45–1.95; two studies). This subgroup analysis should be inter-
preted carefully, as the number of studies was not uniformly
distributed among all the subgroups, and the statistical difference
might be due to the small number of studies in two of the
subgroups.
Sensitivity analyses.
Random versus fixed effect models. The use of a fixed effect model did
not change the summary estimate for the effect of probiotics on NEC
(RR, 0.45; 95% CI, 0.37–0.56; heterogeneity: χ2 = 37.92, df = 29
(p = 0.12); I2 = 24%).
Risk of bias. The exclusion of three studies (Dongol Singh et al., 2017;
Fernández‐Carrocera et al., 2013; Kaban et al., 2019) with a high
F IGURE 4 (Analysis 2.1) Forest plot of comparison: 2 probiotics versus control, outcome: 2.1 all‐cause mortality
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TABLE 3 Probiotics supplementation during neonatal period
Probiotics supplementation compared to control during neonatal period
Patient or population: neonates (Mmost of the included studies had preterm and low birth weight neonates)















All‐cause mortality 10904 (25 RCTs) ⊕⊕⊕⊕ HIGHa,b,c,d RR, 0.80
(0.66–0.96)
Study population
47 per 1000 9 fewer per 1000 (15 fewer to
1 fewer)
Neonatal sepsis 8918 (21 RCTs) ⊕⊕⊕⊕ HIGHa,d,e RR, 0.78
(0.70–0.86)
Study population




55574 (29 RCTs) ⊕⊕⊕⊕ HIGHa,d,f RR, 0.46
(0.35–0.61)
Study population
101 per 1000 55 fewer per 1000 (66 fewer
to 41 fewer)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the
intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty:We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
aEven though three (Dongol Singh et al., 2017; Fernández‐Carrocera et al., 2013; Kaban et al., 2019) of the included studies in the analysis had high ROB
related to randomizations, the exclusion of these studies did not have much effect on the magnitude of the summary estimate or its statistical significance.
bI2 was 0%.
cAll‐cause mortality is an objective outcome and there were no concerns about the indirect measurement of the outcome.
dThe confidence interval of the summary estimate did not include 1.
eI2 was 23% and the p. value for heterogeneity was 0.16.
fThe I2 was 24%.
F IGURE 5 (Analysis 2.1) Funnel plot of
comparison: 2 probiotics versus Control,
outcome: 2.1 All‐cause mortality
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ROB due to randomization/allocation concealment did not change
the summary estimate significantly.
Incidence of neonatal sepsis
The effect of probiotics on the incidence of neonatal sepsis was re-
ported by 21 studies that included 9105 (probiotics, 4606; control,
4499) participants. The combined results showed a statistically sig-
nificant reduction in incidence of sepsis of 22% in the intervention
group compared to control (RR, 0.78; 95% CI, 0.70–0.86; hetero-
geneity: τ2 = 0.01; (p = 0.16); I2 = 23%). The number needed to treat
was 14. The grade rating for this outcome was “high.” Summary of
findings Table 3.
Publication bias. A funnel plot for publication bias looked symmetrical.
Subgroup analysis. Table 1 shows the results of subgroup analyses.
Subgroup analysis could be done for the incidence of neonatal
sepsis according to study setting, type of probiotic (single strain
vs. multiple strain vs. synbiotic), type of feeding (breastfeeding vs.
formula feeding vs. mixed feeding), and probiotic preparation
(preparation containing Lactobacillus vs. Bifidobacterium vs. both
Lactobacillus and Bifidobacterium vs. S. boulardii). Only the type of
feeding differed among subgroups, probiotic supplementation
seemed to have a significant effect for the prevention of neonatal
sepsis when the supplementation was given to babies who re-
ceived breastmilk only (RR, 0.76; 95% CI, 0.61–0.83; 8 studies) or
breastmilk in combination with formula milk (RR, 0.76; 95% CI,
0.64–0.90; seven studies), p value for subgroups difference
was 0.04.
Sensitivity analysis.
Random versus fixed effect models. Use of a fixed effect model had a
minimal effect on summary estimates for the effect of probiotics on
the incidence of neonatal sepsis (RR, 0.79; 95% CI, 0.73–0.85; het-
erogeneity: χ2 = 26.06, df = 20 (p = 0.16); I2 = 23%).
Risk of bias. No significant difference was noted when two studies
(Fernández‐Carrocera et al., 2013; Kaban et al., 2019) with a high
ROB were excluded from the analysis Analysis 2.21.
Sepsis specific mortality
Two studies reported the data for sepsis specific mortality. The
combined results showed a reduction of sepsis specific mortality
of 89% in the intervention group compared to control (RR, 0.21;
95% CI, 0.04–1.01; heterogeneity: τ2 = 0.00; χ2 = 0.91, df = 1
(p = 0.34); I2 = 0%). This is limited by a wide CI of the estimate
including 1.
F IGURE 6 (Analysis 2.9) Forest plot of comparison: 2 probiotics versus control, outcome: 2.9 necrotizing enterocolitis (any type)
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Adverse events
No adverse event was reported in any of the included studies.
Neurodevelopmental outcomes
Two studies assessed neurodevelopmental outcomes after
neonatal probiotic supplementation. We did not perform a
meta‐analysis for these outcomes, as these studies used different
scales.
Sari et al. (2011) reported the data for neurodevelopmental
outcomes at 18–22 months post neonatal probiotic supplementa-
tion for extremely low birth weight infants. Their results did not
show any difference in growth and neurodevelopmental outcomes
between the two groups. The growth outcomes were reported as
weight (probiotic group 10.5 ± 1.7 kg vs. control 10.5 ± 1.7 kg, p
value .92), length (probiotic group 79.4 ± 7.8 cm vs. control
81.0 ± 5.3 cm, p value .32), and head circumference (probiotic group
47.5 ± 6.5 cm vs. control 46.7 ± 1.8 cm, p value .53). The neurode-
velopmental outcomes were reported as mental development index
(probiotic group 90.7 ± 15.5 vs. control 90.4 ± 14.5, p value .88) and
Psychomotor Development Index (probiotic group 95.4 ± 17.2 vs.
control 93.2 ± 16.4, p value .39).
Oncel et al. (2014) also followed a cohort of extremely low
birth weight infants after neonatal supplementation with
probiotics or placebo. There was no significant difference in the
neurodevelopmental outcomes at 18–24 months of age post
supplementation, mental development index (probiotic 81 (median),
49 (min) to 124 (max) vs. placebo 82, 53–128; p value .48) or
Psychomotor Development Index (probiotic 80, 49–112 vs. placebo
79, 49–107; p value .67).
6 | DISCUSSION
6.1 | Summary of main results
This review evaluated three neonatal nutritional interventions.
Vitamin A supplementation during the neonatal period in the com-
munity setting did not have any significant effect on all‐cause mor-
tality at 1, 6, or 12 months. We did not identify any studies from
LMICs that assessed the use of dextrose gel for the treatment or
prevention of neonatal hypoglycaemia. Probiotic supplementation
during the neonatal period mainly given to low birth weight and
preterm babies was shown to reduce all‐cause mortality, NEC, and
neonatal sepsis.
6.2 | Overall completeness and applicability of
evidence
The evidence of neonatal vitamin A supplementation included 16
studies, and the number of participants in these studies exceeded
150,000. Overall, most of the included studies were at low ROB
across many of the ROB items assessed using the Cochrane ROB
scale. The statistical heterogeneity in the pooled data for mortality
outcomes at 6 and 12 months was noted for neonatal vitamin A
supplementation; however, the value of I2 was <50%. Subgroup
analyses done in a recent IPD analysis could potentially explain the
reasons for heterogeneity and are discussed in Section 6.5.
The results for the use of probiotics during the neonatal per-
iod seem very promising. Almost all the studies in this meta‐
analysis included preterm and/or low birth weight neonates. The
effect of probiotics on all‐cause mortality was reported in
25 studies, and the analysis included more than 10,000 participants.
The forest plot showed a homogenous effect in favor of the in-
tervention with I2 of 0%. We think that this effect is biologically
plausible, and the most likely pathway of reduction in neonatal
mortality from probiotic supplementation is via a reduction in
sepsis and NEC, as shown in Analysis 2.15 and Analysis 2.9, re-
spectively. We also think that these results are less likely due to
bias. The studies by Guney‐Varal et al. (2017), Kaban et al.
(2019), and Dongol Singh et al. (2017) were at high ROB due to
inadequate randomization methods. The exclusion of these three
studies from meta‐analysis for the effect of probiotics on all‐
cause mortality did not change the summary estimate sig-
nificantly (RR, 0.82; 95% CI, 0.68–0.99). A funnel plot for pub-
lication bias was symmetrical. The use of a fixed versus random
effect model also did not change the results significantly. In ad-
dition to these observations, the fact that the effect of probiotics
on the reduction of neonatal sepsis and NEC was mostly homo-
genous (I2 of 23% and 24%, respectively) indicates that the use of
probiotics could be beneficial for babies with low birth weight
and preterm birth. We notice, however, that there was significant
clinical heterogeneity in the dose, duration, and strains of pro-
biotics used; this indicates that more research is needed to de-
termine the appropriate dose and duration of probiotic
supplementation in neonates.
The use of probiotics for the prevention of NEC, sepsis, and
mortality in preterm and/or low birth weight babies has been
debated in the past. The use of probiotics was advocated after the
publication of a Cochrane review in 2011 (Alfaleh et al., 2011,
later updated in 2014, AlFaleh & Anabrees, 2014) that showed
that probiotics reduced NEC (stage II or more) (RR, 0.35; 95% CI,
0.24–0.52) and mortality (RR, 0.40; 95% CI, 0.27–0.60) in preterm/
low birth weight neonates (Ofek Shlomai et al., 2014; Robinson,
2014). Others challenged the appropriateness of the meta‐analysis
in the setting of clinical heterogeneity (Mihatsch et al., 2012;
Mihatsch, 2011) and called for large trials before this intervention
could be recommended in clinical practice (Mihatsch, 2011). This
led to two large clinical trials, the ProPrems trial conducted in
Australia and New Zealand (Jacob et al., 2013) and the PiPS trial
conducted in the United Kingdom (Costeloe et al., 2016). The
ProPrem trial used a mixture of probiotics (Bifidobacterium infantis,
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Streptococcus thermophilus, and Bifidobacterium lactis) and included
1099 preterm (<32 weeks) and very low birth weight (<1500 g)
neonates. The results of the ProPrems trial showed that the use of
probiotics did not reduce the incidence of sepsis and mortality, but
did reduce the incidence of NEC (RR, 0.46; 95% CI, 0.23–0.93)
(Jacob et al., 2013). The PiPS trial included 1315 neonates
between the gestational age of 23–30 weeks who were rando-
mised within 24–48 h to a single probiotic (Bifidobacterium breve
BBG‐001) or placebo. The results of the PiPS trial showed no
difference between the intervention and the control group for the
outcomes of NEC (RR, 0.93; 95% CI, 0.68–1.27), sepsis (RR, 0.97;
95% CI, 0.73–1.29), or death (RR, 0.93; 95% CI, 0.67–1.30)
(Costeloe et al., 2016). The results of these trials were surprising in
the setting of known evidence from meta‐analyses of the available
studies. A closer look at the results of the PiPS trial showed that
there was significant contamination of the control group, as about
49% of the neonates from the control group had the same type of
probiotic bacteria in their stool as those who were in the inter-
vention group. This decreased the power of the study, and it was
argued that a potential lack of effect might be explained by the
cross‐contamination of the control group (Deshpande et al., 2016;
McKinlay et al., 2016). The debate of appropriateness of probiotic
supplementation in the neonatal period has continued, and a re-
cent network meta‐analysis concluded that there is not enough
evidence in favor of either a single or a mixture of strains of
probiotics that could be suggested for routine clinical use for the
prevention of NEC, sepsis, and/or mortality in preterm/low birth
weight babies (van den Akker et al., 2018).
Our review focused on studies from LMIC. The effect of pro-
biotic supplementation on mortality, sepsis, and NEC was significant
when we pooled studies from these countries only. We noticed
clinical heterogeneity in the use of probiotics in terms of type of
probiotics, single versus multiple strains used, and baseline inter-
ventions such as the use of breastmilk. We think that the use of a
meta‐analysis is appropriate to pool these studies, as the primary
target of all the studies was the same, that is, correction of dysbiosis.
We further demonstrated that subgroup analysis based on certain
clinical factors reveals no significant difference in results. We notice,
however, the relative lack of studies from the community setting.
This is likely due to the increased rate of community over hospital‐
based births in LMIC. For this reason, we read the results of a
community‐based study by Panigrahi et al. (2017) with great interest.
This study was the largest study conducted on the use of probiotics
(synbiotics) and had a sample size of 4556; this is three times larger
than the sample size of the PiPS trial. Panigrahi et al. (2017) used a
synbiotic which was a mixture of the probiotic Lactobacillus plantarum
ATCC‐202195 and the prebiotic fructooligosaccharide. This study
recruited neonates who were at least 35 weeks of gestation and
weighed at least 2000 g from rural settings from India. The results of
the study showed a significant reduction in the primary outcome
(combination of sepsis and death) in the intervention group
compared to control (RR, 0.60; 95% CI, 0.48–0.74), culture‐positive
and culture‐negative sepsis, and lower respiratory tract infections
(Panigrahi et al., 2017). More such community‐based studies are
needed from other countries examining term, preterm, and low birth
weight infants.
Are probiotics safe for use during the neonatal period? We did
not find any substantial evidence of adverse events with the use of
probiotics in neonatal age group. It is important, however, to consider
the safety considerations of probiotic supplementation in this vul-
nerable population. Probiotics are not regulated as a medication and
are thus susceptible to variations in quality within and between
countries. If not carefully produced and handled, probiotics may also
contain pathogenic contaminants that may then lead to neonatal
sepsis. Probiotic supplementation has been linked to both bacterial
(Dani et al., 2016) as well as fungal sepsis (Vallabhaneni et al., 2014).
Despite their rare occurrence, neonates receiving probiotics should
be followed in a registry to ensure any reporting and observation of
the potential risk of sepsis in a large sample size in the real world
setting.
6.3 | Quality of the evidence
The GRADE quality of evidence was considered high for most of the
outcomes for neonatal vitamin A and probiotic supplementation. The
GRADE method of assessment of overall evidence considers the type
of study, ROB, statistical heterogeneity, indirectness, and imprecision
of the summary estimates as well as the risk of publication bias
(Guyatt et al., 2011).
All the included studies for neonatal vitamin A supplementation
were randomized and had minimal ROB. The statistical heterogeneity
for pooled studies for neonatal vitamin A supplementation was no-
ticeable but was not significant enough to decrease our confidence in
the summary estimate. Similarly, the CIs around the summary esti-
mate were narrow, and there was no increased risk of publication
bias for studies that assessed neonatal vitamin A supplementation.
All the included studies for neonatal probiotic supplementation
were also randomized. High ROB was noted for three of the included
studies (Dongol Singh et al., 2017; Fernández‐Carrocera et al., 2013;
Kaban et al., 2019), but exclusion of these studies did not change the
results of any of the outcomes, including all‐cause mortality, NEC,
and neonatal sepsis. The pooled results were mostly homogenous,
and the summary estimates were precise with narrow CIs. The funnel
plots for publication bias were symmetrical for the outcomes of all‐
cause mortality, NEC, and neonatal sepsis.
6.4 | Potential biases in the review process
We used standard methods of Campbell and Cochrane collabora-
tions to conduct the review. Two review authors screened the titles
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and abstracted the data from the included studies. Our inclusion/
exclusion criteria were decided a priori, and a peer reviewed pro-
tocol was published giving details of methods of conduct of this
review.
We performed two posthoc subgroup analyses for the effect of
probiotic supplementation during the neonatal period. This ana-
lysis was based on the type of feeding, as our team thought it was
essential to establish any differential effect of probiotics when the
intervention was delivered with breastmilk or formula or both. The
results for this analysis were similar among the subgroups for
outcomes of all‐cause mortality and NEC; however, there was
significant heterogeneity among subgroups for the outcome of
neonatal sepsis Analysis 2.18. A close examination of the data
showed that the difference among subgroups was due to the group
where the status of the feeding was “unclear.” Exclusion of this
subgroup showed a homogenous protective effect in the case of
breastmilk or formula milk‐fed babies against neonatal sepsis (data
not shown). So, we think that probiotics may have a significant
protective effect against neonatal sepsis, NEC, and mortality ir-
respective of the type of food offered. The second posthoc sub-
group analysis was based on study setting. We were interested in
knowing if the probiotics had a similar effect on infants born in the
hospital setting compared to those in the community setting. We
were interested in this analysis because a significant number of
births happen at home in LMIC. There were a limited number of
studies conducted in the community setting that addressed the
effect of probiotics; therefore, no solid conclusion could be drawn
at this time for any of the outcomes.
6.5 | Agreements and disagreements with other
studies or reviews
The effects of neonatal vitamin A supplementation have been
reviewed in two Cochrane reviews (Darlow et al., 2016; Haider
et al., 2017). The Cochrane review by Haider et al. (2017) focused
on randomized studies from the community setting only. We
considered studies from both community and hospital settings.
We updated the literature search and found one additional study
from the community setting (Ahmad et al., 2019) and added three
studies from the hospital setting (Basu et al., 2019; Giridhar
et al., 2019; Sun et al., 2019). The studies from hospital settings
were done in the neonatal intensive care setting for very low
birth weight babies. We did not pool the results of these studies
with those of the community‐based studies. The Cochrane review
on neonatal vitamin A supplementation for very low birth weight
infants included 11 trials and reported a reduction in risk of
death or oxygen requirement at 1 month of age (RR, 0.93; 95% CI,
0.88–0.99). Of the three studies we included in our review from
LMIC, only one study showed a reduction in composite outcome
of incidence of all‐cause mortality and oxygen requirement
for 28 days (RR, 0.44; 95% CI, 0.229–0.844)] from vitamin A
supplementation in very low birth weight infants (Basu et al.,
2019). The new study for neonatal vitamin A supplementation
from the community was small and included 306 participants. The
addition of this study did not change the results significantly
compared to those published in the 2017 Cochrane review
(Haider et al., 2017).
An individual participant meta‐analysis of neonatal vitamin A
studies conducted in the community setting was published during
the preparation of this review (West et al., 2019). This review ad-
dressed multiple subgroup analyses both at the study‐ and
individual‐level characteristics and used the original data from in-
dividual trials to pool the studies. The overall results were similar to
our results for all‐cause mortality at 6 and 12 months (West
et al., 2019). The subgroup analysis based on study‐level char-
acteristics showed that neonatal vitamin A supplementation sig-
nificantly reduced 6‐month mortality among the trials conducted in
South Asia (RR, 0.87; 95% CI, 0.77–0.98) but not in Africa; they also
showed a potential for increased risk of mortality in African coun-
tries (RR, 1.07; 95% CI, 1.00–1.15). Further subgroup analyses
showed that neonatal vitamin A supplementation reduced all‐cause
mortality in the context of moderate or severe maternal VAD (de-
fined as 10% or higher proportion of women with serum retinol
<0.7 μmol/L or 5% or more women with night blindness) (RR, 0.87;
95% CI, 0.80–0.94), in settings where baseline (control group) early
infant mortality was 30 or more per 1000 live births (RR, 0.91; 95%
CI, 0.85–0.98), and in the context of lack of maternal education
(>32% mothers had no schooling) (RR, 0.88; 95% CI, 0.80–0.96). The
subgroup analyses conducted based on individual‐level character-
istics such as sex, birth weight, gestational age and size, age at
dosing, parity, time of breastfeeding initiation, maternal education,
and maternal vitamin A supplementation did not show any sig-
nificant differential effect of neonatal vitamin A supplementation
compared to placebo for these groups. As most of the subgroup
analyses that we prespecified in our review were addressed in this
study (West et al., 2019), we did not repeat these analysis in our
current study.
Oral dextrose as a treatment of hypoglycaemia and prevention
of hypoglycaemia in high‐risk neonates has been evaluated in two
Cochrane reviews (Hegarty et al., 2017; Weston et al., 2016). The
review by Weston et al. (2016) addressed treatment of neonatal
hypoglycaemia and included two studies, one from New Zealand and
another from Ireland. They did not show any major difference in
episodes of hypoglycaemia between the two study groups. The re-
view by Hegarty et al. (2017) addressed the prevention of hypogly-
caemia in high‐risk neonates and included one study from New
Zealand. The included study showed a significant reduction in hy-
poglycaemia episodes in the intervention group compared to control
(RR, 0.76; 95% CI, 0.62–0.94). No randomized study was available
from LMIC in either of the two reviews mentioned above. We up-
dated the searches and did not find any study from LMIC.
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Other reviews have been published that assess the effect of
probiotic supplementation during the neonatal period. A Cochrane
review was published in 2011 (Alfaleh et al., 2011) with an update
in 2014 (AlFaleh & Anabrees, 2014). This has not since been
updated. The Cochrane review included studies from LMIC and
high‐income countries and concluded that probiotic supple-
mentation reduced NEC (stage II or more) (RR, 0.43; 95% CI,
0.33–0.56) and mortality (RR, 0.65; 95% CI, 0.52–0.81) but showed
no effect for nosocomial sepsis (RR, 0.91; 95% CI, 0.80–1.03).
More studies have been published since the publication of the
2014 Cochrane review update. Deshpande et al. (2017) reviewed
studies from LMIC that addressed probiotic supplementation
during the neonatal period. This review included twenty‐three
studies and concluded that probiotic supplementation reduced all‐
cause mortality (RR, 0.73; 95% CI, 0.59–0.90), NEC (RR, 0.46, 95%
CI, 0.34–0.61), and neonatal sepsis (RR, 0.80; 95% CI, 0.71–0.91).
We included thirty‐three studies and updated the meta‐analyses.
With this new data, the magnitude and the statistical significance
remained the same, but the summary estimates became more
precise for the outcomes of all‐cause mortality, NEC, and sepsis.
We also conducted additional subgroup analyses that were not
previously performed.
7 | AUTHORS' CONCLUSIONS
7.1 | Implications for practice
Neonatal vitamin A supplementation in the community setting does
not appear to reduce infant mortality at 1, 6, or 12 months of age.
Vitamin A supplementation during neonatal period increases the risk
of bulging fontanelle. No data were available for dextrose gel sup-
plementation for the prevention or treatment of neonatal hypogly-
caemia in LMIC.
Probiotic supplementation is a promising intervention and
can reduce all‐cause mortality, neonatal sepsis, and NEC in low
birth weight and/or preterm babies in LMIC in the hospital set-
ting. Though we observed no adverse effects, infants receiving
probiotics should be entered into a registry in order to observe
any concerns for safety in large sample sizes in the real world
setting.
7.2 | Implications for research
There was significant clinical heterogeneity in terms of strains and
dose of probiotics used in the included studies. More studies are
needed to decide upon the right strain and optimal dose and
duration of probiotics supplementation. Most of the included
studies for probiotics supplementation were conducted in
preterm/low birth weight babies in the neonatal intensive care
unit. It is not clear if the similar protective effects would be seen
when probiotics are given in the community setting or to term
babies. It is also unclear if the supplementation of prebiotics and
probiotics together (synbiotics) is more effective than probiotics
alone. More studies are needed to answer these questions and to
assess the effect of dextrose supplementation for the prevention
and treatment of neonatal hypoglycaemia in LMIC.
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
– The planned subgroup analyses for vitamin A were not conducted,
as the same analyses were available from a recent IPD analysis
(West et al., 2019).
– We did not use EPOC methodology for the ROB assessment, as all
the included studies were RCTs and the Cochrane ROB assess-
ment tool was used for the same.
– We did two posthoc subgroup analyses for probiotic supple-
mentation during the neonatal period. These included type of
feeding and study setting.
– We did the sensitivity analysis for ROB based on sequence gen-
eration and allocation concealment.
PUBLISHED NOTES
CHARACTERISTICS OF STUDIES
CHARACTERISTICS OF INCLUDED STUDIES
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Ahmad et al. (2019)
Methods A block‐randomized, double‐masked, placebo‐controlled intervention trial conducted in Bangladesh
Participants Inclusion criteria: "consent of the mother and willingness to have their infant participate; singleton birth at MCHTI clinic and
eligible for vaccination according to the national and MCHTI clinic policy".
Exclusion criteria: "planned at home delivery because of the low likelihood of vaccination at MCHTI within 48 h of birth, (2)
congenital disease or a serious infection showing that the infant was not healthy; infant with birth weight <1500 g and
inability to enrol within 48 h of birth due to lack of timely notification or other exceptional circumstances".
Interventions Intervention group: 50,000 IU vitamin A (retinyl palmitate)
Comparison: Placebo (unfortified soya based oil)
The intervention was delivered within 48 h of birth
Outcomes Neonatal mortality, adverse events, microbiome changes, thymus size
Notes
Data on mortality and bulging fontanelle were taken from publication (J Nutr 2019;00:1–8). Data on mortality was reported
at 15 weeks. We included the data with “all‐cause mortality at 6 months".
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The randomization lists of vitamin A and placebo within each group were
generated by WHO, using Stata, v11"
Allocation concealment
(selection bias)
Low risk Quote: "Preplanned statistical analyses using arbitrary group identifiers…"
Comment: Most likely done
Blinding of participants and
personnel (performance bias)
Low risk Quote: "dose of VA in oil or an identical placebo (PL) within 48…"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Preplanned statistical analyses using arbitrary group identifiers (group 1, group 2)
were completed on 4 April 2014 before unblinding…"
Incomplete outcome data
(attrition bias)
Low risk Attrition rate: 5.2%
Selective reporting (reporting bias) Low risk Author prespecified the outcomes. Trial was registered as ClinicalTrials.gov:
NCT01583972.
Other bias Low risk No other risk of bias was noted
Amini et al. (2017)
Methods Prospective randomized control trial conducted in Iran
Participants Inclusion Criteria: "All premature newborns (n = 115) weighting 750–1500 g or <32 weeks' gestation who received
antibiotics and total parenteral nutrition in NICU of Vali Asr Hospital were included"
Exclusion Criteria: "Premature babies <750 and more than 1500 g and neonates with congenital heart disease, congenital
malformations, and immune system deficiency, even in their family members, were excluded from the study."
Interventions
Intervention: Multistrain powder probiotic infant formula containing Streptococcus thermophilus, Lactobacillus rhamnosus,
Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium infantis, Lactobacillus casei. The dose was 0.8–1 g per day
in 8–10 doses given for 13 days
Comparison: Enteral feed without probiotic
Outcomes NEC
Notes Data were taken from table 3
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "In this double blind randomized clinical trial (RCT), block randomization
was used and 60 cases were randomly divided into 2 groups."
Allocation concealment (selection bias) Unclear risk No clear information was available about allocation concealment
Blinding of participants and personnel
(performance bias)
Unclear risk No clear information available
Blinding of outcome assessment
(detection bias)
Unclear risk No clear information available
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Basu et al. (2019)
Methods A randomized double‐blind placebo‐controlled trial India
Participants Inclusion Criteria: Inborn, VLBW (birth weight (BW) < 1500 g) neonates admitted in NICU and requiring respiratory support
in the form of oxygen inhalation through nasal prongs or head box, continuous positive airway pressure (CPAP), high flow
nasal cannula (HFNC), or mechanical ventilation (MV) at the age of 24 h, were included.
Exclusion Criteria: Neonates with major congenital malformation, any life‐threatening condition such as reversal of umbilical
artery end‐diastolic blood flow on antenatal Doppler, perinatal asphyxia with moderate to severe hypoxic ischemic
encephalopathy, shock with escalating doses of vasopressors, recurrent seizures, and suspected inborn errors of
metabolism
Interventions Intervention: 10,000 IU of retinol/dose, alternate days, 28 days or until discharge
Compairson: Placebo
Outcomes All‐cause mortality, sepsis, NEC
Notes Study conducted in very low birth weight babies
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomization into vitamin A or placebo group was done using random permuted
blocks of 4, 6, and 8, prepared by an independent statistician not involved in the study."
Allocation concealment
(selection bias)
Low risk Quote: "Allocation into vitamin A or placebo group was done using serially numbered opaque
and sealed envelopes by on‐duty residents who were appropriately trained for the
process beforehand. Allocation concealment was maintained throughout the study."
Blinding of participants and
personnel (performance bias)
Low risk Quote: "Vitamin A and placebo oral solutions were supplied in identical bottles of 20mL with
dropper marked at 1mL…."
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Treating physicians, nursing staffs, and the parents were unaware about the
composition of the bottles."
Incomplete outcome data
(attrition bias)




Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
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Benn et al. (2008)
Methods Randomized placebo controlled trial conducted in Guinea‐Bissau
Participants Inclusion Criteria: Weight at least 2500 g at presentation and no signs of overt illness or malformations
Exclusion Criteria: Weight <2500 g at presentation and/or signs of overt illness and/or malformations. Also, infants who died
in the maternity ward before the vaccination team could arrive
Total number randomized to the intervention group: 2145
Total number randomized to the control group: 2200
Interventions Intervention: 50,000 IU vitamin A intradermally
Control: 0.5 ml vegetable oil intradermally
Common intervention given to all groups: 10 IU vitamin E intradermally
Outcomes Primary outcomes: Overall mortality
Other outcomes: Bulging fontanelles, vomiting, irritability, infections, fever, skin problems, and healthcare contacts
Notes Vitamin A supplementation appeared to benefit boys but was harmful to girls
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The mother drew a lot from an envelope prepared by the study supervisor. Each
envelope contained 100 lots—50 marked “1” and 50 marked “2”—indicating from which
of two numbered bottles, “1” or “2,” the child should receive the supplement"
Comment: Most likely done
Allocation concealment
(selection bias)
Low risk Quote: "The lots were folded, making it impossible to tell what was written on them before
they were opened"
Comment: Most likely done
Blinding of participants and
personnel (performance bias)
Low risk Quote: "When asked, none of the three assistants who were responsible for the
randomisation procedures at the hospital and at the heath centres had any idea which
bottles contained vitamin A and which placebo. We concluded that the blinding of
mothers and assistants was successful"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "Accumulating evidence for sex differential effects of vitamin A supplementation
during the trial made us hypothesise before we started the analyses that
supplementation would be particularly beneficial for boys"
Comment: Most likely done
Incomplete outcome data
(attrition bias)
Low risk Total number of loss to follow up: 70 (1.6%)
The loss to follow up was not balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical significance
Other bias Low risk No other risk of bias was noted
Benn et al. (2010)
Methods Randomized placebo controlled two by two factorial trial conducted in Guinea‐Bissau
Participants Inclusion criteria: Weight <2500 g at presentation
Exclusion criteria: Weight >2500 g at presentation
Total number randomized to the intervention group: 864
Total number randomized to the control group: 872
Interventions Intervention: 25,000 IU vitamin A intradermally
Control: 0.5 ml vegetable oil intradermally
Common intervention given to all groups: 10 IU vitamin E intradermally
Outcomes Primary outcomes: Infant mortality
Other outcomes: Fever, septicaemia, malaria, malnutrition, and respiratory infections
Notes
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Once consent was provided, the mother drew an envelope from a bag. Each bag was
prepared by the study supervisor and contained 48 envelopes; each envelope contained a
lot name. Within each bag were 12 envelopes with lots marked “BCG 6,” 12 marked “BCG
7,” 12 marked “no BCG 6,” and 12 marked “no BCG 7.” The numbers “6” and “7” indicated
from which of two numbered bottles, “6” or “7,” the child should receive treatment (that is,
either 25,000 IU vitamin A or placebo)"
Comment: Most likely done
Allocation concealment
(selection bias)
Low risk Quote: "The envelopes were closed and non‐transparent, making it impossible to identify the
allocation before the envelopes were opened"




Unclear risk Quote: "Once consent was provided, the mother drew an envelope from a bag"
"Each bag was prepared by the study supervisor and contained 48 envelopes; each envelope
contained a lot name"




Low risk Quote: "Follow‐up was performed by assistants who were unaware of the allocated treatment"
Comment: Most likely done
Incomplete outcome data
(attrition bias)
Unclear risk Total number of loss to follow up: 145 (8.4%)
The loss to follow up was not balanced
Selective reporting
(reporting bias)
Low risk Authors seem to report all the outcomes irrespective of their statistical significance
Other bias Low risk No other risk of bias was noted
Benn et al. (2014)
Methods Double‐blind, placebo‐controlled randomized trial conducted in Guinea‐Bissau
Participants Inclusion criteria: Normal birth‐weight neonates who were healthy and due for BCG vaccination
Exclusion criteria: Birth weight <2500 g at presentation or overt illness and/or malformations
Total number randomized to the intervention group 1 (50,000 IU vitamin A): 2015
Total number randomized to the intervention group 25 (25,000 IU vitamin A): 2011
Total number randomized to the control group: 2022
Interventions Intervention: 50,000 IU vitamin A intradermally or 25,000 IU vitamin A intradermally
Control: 0.5 ml Vegetable oil intradermally
Common intervention given to all groups: 10 IU vitamin E intradermally
Outcomes Primary outcome: Infant mortality
Other outcomes: None measured
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote. "Each envelope was prepared by the data manager, who did not take part in
the enrolment procedures, and contained 48 folded lots indicating from which
of 3 numbered bottles—“3,” “4,” or “5”—the child should receive his or her
supplement"
Comment: Most likely done
Allocation concealment
(selection bias)
Low risk Quote. "…48 folded lots indicating from which of 3 numbered bottles—“3,” “4,” or
“5”—the child should receive his or her supplement"
Comment: Most likely done
Blinding of participants and personnel
(performance bias)
Low risk Quote. "At each inclusion site, the randomization procedure was carried out by 1
carefully trained assistant every day except during short vacations. After
providing consent, the mother drew a lot from an envelope. Each envelope was
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prepared by the data manager, who did not take part in the enrolment
procedures…"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Low risk Quote. "The registration system assistants and the special team were unaware of
the allocated treatment, because they were not present during enrolment, and
the information was not transferred to the children's vaccination card or
follow‐up forms"
Comment: Most likely done
Incomplete outcome data
(attrition bias)
Unclear risk Quote: “Of 6053 children invited to participate, 6048 were randomly allocated to
each of the 3 groups (50,000 IU vitamin A, 25,000 IU vitamin A, or placebo)
(Figure 1). The 3 randomly assigned groups were similar in terms of their
background characteristics (Table 1). A total of 176 deaths occurred; 2 of these
were due to accidents and were censored. Fourteen deaths occurred after the
child had been eligible for a national vitamin A campaign. Hence, censoring for
accidents and subsequent VAS, the cohort had 160 deaths during 4125 person‐
years of risk, corresponding to an MR of 39 per 1000 person‐years”
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Braga et al. (2011)
Methods Randomized, double blind control study conducted in Brazil
Participants Inclusion criteria: All infants included in this study were born locally and admitted to the Neonatal Intensive Care Unit
(NICU) with a birth weight from 750 to 1499 g, and had no major congenital malformations, life threatening
chromosomal alterations, or congenital infections
Interventions Intervention: Probiotic supplementation: Bifidobacterium breve and Lactobacillus casei: The intervention was started on
the second day of life and was maintained until 30 d of life, a diagnosis of NEC, discharge from the hospital, or death,
whichever occurred first. The dose was 3ml human milk from the bank milk to which L. casei and B. breve had been
added providing 3.5 × 107 to 3.5 × 109 CFU
Comparison: The control group received the same volume of human milk without probiotics
Outcomes Mortality, NEC and sepsis
Notes Authors did not do intention to treat analysis. We created the intention to treat analysis by taking the number
randomized as denominators. The data on outcomes was taken from table 2 of the main manuscript
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Randomization was carried out in blocks of 10, and the list of random numbers was
generated by the subprogram Epitable from Epi‐Info 6.04
Allocation concealment
(selection bias)
Low risk A sealed envelope with the identification number in ascending order, containing information
about which group they belonged to, was provided for each infant and sent to the
hospital's nutritional centre
Blinding of participants and
personnel (performance bias)
Low risk Neither the medical and nursing staff responsible for monitoring the infants nor the
researchers were aware of which group the infants were allocated to
Blinding of outcome assessment
(detection bias)
Low risk Neither the medical and nursing staff responsible for monitoring the infants nor the
researchers were aware of which group the infants were allocated to
Incomplete outcome data
(attrition bias)
Low risk Attrition in intervention group was 2% and 7% in the control group
Selective reporting (reporting bias) Low risk Most of the outcomes were reported
Other bias Low risk No other bias was noted
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Chowdhury et al. (2016)
Methods A randomized controlled trial conducted in Bangladesh
Participants Inclusion crietria: Preterm (<33 woks), VLBW (<1500 g) infants who are able to tolerate oral feeds and survive
beyond 48 h
Exclusion criteria: Babies with suspicion of clinical sepsis, presence of prenatal asphyxia, major congenital anomaly and
babies who expired due to other neonatal illness were excluded
Interventions Intervention: Probiotic supplementation: Bifidobacterium breve and Lactobacillus casei: The dose was 3ml once daily of
solution containing Bifidobacterium breve and Lactobacillus casei 106 CFU. The intervention was continued for at least
10 days
Comparison: No probiotics
Outcomes NEC, all‐cause mortality
Notes
Authors did not perform intention to treat analysis, however, we created the intention to treat analysis from Figure 1. The
data for mortality was taken from Figure 1 and the data for NEC was taken from table 2
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Coding to group 1 and 2 was done by a faculty of another department not related to this




Low risk Participants and investigators did not know group allocation
Blinding of participants and
personnel (performance bias)
Low risk Probiotics were added to breast milk by registrar or assistant registrar of the corresponding
unit before feeding
Blinding of outcome assessment
(detection bias)
Low risk Participants and investigators did not know group allocation
Incomplete outcome data
(attrition bias)
Low risk 15% attrition. Reasons for loss to follow up reported.
Selective reporting (reporting bias) Low risk All expected outcomes were reported
Other bias Low risk No concerns for other risk of bias
Cooper et al. (2017)
Methods A randomized double‐blind controlled trial conducted in South Africa in community settings
Participants Inclusion criteria: "healthy", full term (37–42 weeks), born to HIV + formula feeding mothers, ≤3 days old, 2500–4500 g,
singleton birth
Exclusion criteria: Congenital illness or malformation affecting growth; significant perinatal disease, antibiotics in 1st 3 days
of life, caregivers could not comply, or in another trial
Interventions Intervention: Probiotics: Formula containing prebiotic (bovine milk‐derived oligosaccharides) and probiotic ((B. lactis strain
CNCM‐I‐3446 with 1 × 107 cfu/g. of powder formula). The duration of intervention was 6 months
Comparison: Formula without prebiotic and probiotic
Outcomes All‐cause mortality
Notes
The data was taken from the last paragraph of the result section. We note that the intervention group received both
prebiotics and probiotics and the control group did not receive any prebiotics or probiotics. Some of the study participants
were HIV positive
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The randomization was performed using the in‐house TrialSys
software".
Allocation concealment (selection bias) Low risk Formulas labelled similarly
Blinding of participants and personnel
(performance bias)
Low risk Parents (caregivers), investigators, study support staff, and the clinical
project managers were blinded to the identity of the products.
Blinding of outcome assessment
(detection bias)
Low risk Likely same care‐team
Incomplete outcome data (attrition bias) Low risk Total loss to follow up was 1%
Selective reporting (reporting bias) Low risk Authors do not seem to selectively report outcomes
Other bias Low risk No other risk of bias was noted.
Cui et al. (2019)
Methods A prospective, double‐blinded randomized study conducted in China
Participants Inclusion criteria: Formula‐fed preterm infants, gestational age ≥30 and <37 weeks; birthweight ≥1500 g and ≤ 2000 g with
vital sign and hemodynamic parameters stable
Exclusion criteria: Congenital diseases, expected hospitalisations <2 weeks and maternal or neonatal antibiotics or other
probiotics before admission
Interventions Intervention: Lactobacillus reuteri DSM 17938, five drops daily for minim of 7 days. Each drop had 1×108 colony‐forming units
Comparison: Placebo
Outcomes Sepsis, NEC, growth
Notes Data were taken from table 2
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomization was conducted according to a random computer‐
determined allocation order considering gestational age"
Comment: Most likely done
Allocation concealment (selection bias) Unclear risk No clear information available for allocation concealment
Blinding of participants and personnel
(performance bias)
Low risk Quote: "Blinding was possible because the nurses who administered L.
reuteri to the infants were not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"
Blinding of outcome assessment
(detection bias)
Unclear risk It was not clear if the families of the participating neonates were aware of
the treatment assignments
Incomplete outcome data (attrition bias) Low risk About 18% attrition reported that was balanced in two groups
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
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Dashti et al. (2014)
Methods Prospective triple‐blinded, interventional, randomized clinical trial
Participants Inclusion criteria: Birth weight of 700‐1800 g, stable hemodynamic, be able to have enteral feeding, and written parental
consent.
Exclusion criteria: Evidence or suspicion of congenital intestinal obstruction or perforation, prenatal or postnatal diagnosis of
gastroschisis, large omphalocele, or congenital diaphragmatic hernia, and major congenital anomalies."
Interventions Intervention: Protexin (probiotics). Protexin (Restore): 1 × 109 CFU (colony forming unit), 1 g (one sachet) contains:
Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus bulgaricus, Lactobacillus casei,
Streptococcus thermophilus, Bifidobacterium breve, and Bifidobacterium
The dose was as follows
– Neonates weighing <1000 g were fed with a half of sachet once daily (5×108 CFU of probiotics),
– Neonates weighing 1001–1500 g were fed with 3/4 of a sachet once daily (7.5×108 CFU of probiotics)
– Neonates weighing more than 1500 g were fed with a full sachet once daily (1×109 CFU of probiotics).
Control: "placebo that was physically indistinguishable from the probiotic powder"
Outcomes NEC, mortality and sepsis
Notes The data for NEC, mortality and sepsis was taken from table 2. We assumed that group A was the intervention group and
group B was the control. Authors did not mention clearly in the paper which group is the intervention group and which one
is the control group.The duration of intervention was not clearly stated
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk No clear data is available to support the assessment however the two groups were
comparable after randomizations and allocation seems to be concealed. So less likely that
randomizations was not done properly
Allocation concealment
(selection bias)
Low risk Quote: "To blind the trial the probiotic and placebo sachets were set in similar
indistinguishable packages"
Blinding of participants and
personnel (performance bias)
Low risk Quote: "The control group was fed with milk and a placebo that was physically
indistinguishable from the probiotic powder"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "After starting the feeding, infants were observed continuously by a chart containing
basic information like daily weight, feeding volume, abdominal girth, appearance of
erythema of abdominal wall, loose stools with blood, vomiting, and orogastric tube




Low risk Quote: "Feeding was discontinued if there was any sign of feeding intolerance (defined as the
presence of gastric aspirate in the amount that was more than a half of the previous
feeding or abdominal distension)"
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Demirel et al. (2013)
Methods Prospective, blinded, randomized control trial conducted in Turkey
Participants Inclusion criteria: Neonates born ≤32 weeks and birthweight ≤1500 g who survived to start enteral feedings.
Exclusion criteria: Major congenital anomalies, lack of parental consent, death in first seven days after study start
Interventions Intervention: Probiotic supplementation: S. boulardii: Dose was 250mg (5 billion cfu), added to breastmilk or formula,
frequency was once daily and supplementation continued till discharge
Comparison: Placebo
Outcomes NEC, sepsis, mortality
Notes Data was not analysed as intention to treat analysis. We created the intention to treat analysis by using the number
randomized and the outcome numbers given in table 3
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote, "Randomisation was simple and unadjusted and was performed using
sequential numbers generated at the computer centre of the NICU"
Allocation concealment
(selection bias)
Low risk Quote, "The allocations were sealed in opaque, sequentially numbered envelopes"
Blinding of participants and
personnel
(performance bias)
Low risk Quote, "The supplements were prepared by personnel on the breast milk team
following the instructions in the sealed envelope. These individuals were the only
personnel who were aware of the group assignments, and they were not involved
in the care of the infants"
Blinding of outcome assessment
(detection bias)
Low risk Quote, "The supplements were prepared by personnel on the breast milk team
following the instructions in the sealed envelope. These individuals were the only
personnel who were aware of the group assignments, and they were not involved
in the care of the infants"
Incomplete outcome data
(attrition bias)
Low risk 7/278 dropped out. The intervention and the control group were fairly similar
Selective reporting
(reporting bias)
Low risk Authors seems to report all the outcomes mentioned in the analysis plan
Other bias Low risk No other bias was noted
Dilli et al. (2015)
Methods Prospective, randomized, controlled trial conducted in TurkeyQuote
Participants Inclsuin criteria:: "VLBW infants with a gestational age of <32 weeks and a birth weight of <1500 g, born at or transferred to
the NICU within the 1st week of life and fed enterally before inclusion, were eligible
Exclusion criteria: Infants with any disease other than those linked to prematurity or congenital anomalies of the intestinal
tract, not fed enterally or who died before the seventh day after birth, whose mothers had taken nondietary probiotic
supplements, and whose parents refused to participate were excluded"
Interventions Intervention: Probitics/Prebiotics
Multiple Arm trial
1) Probiotic (Bifiidobacterium lactis, 5×109 colony‐forming units)
2) Prebiotic (inulin, 900mg)
3) Synbiotic (Bifidobacterium lactis, 5×109 colony‐forming units, 30mg plus inulin, 900mg
4) The control group: maltodextrin powder as a placebo
The dose was 1 sachet per day of pre/probiotics with breast milk or formula until discharge or death, for a maximum of 8
weeks, whichever comes first
Outcomes NEC, sepsis and mortality
Notes The data were taken from table 3. We included data as probiotics+synbiotics vs. prebiotics+placebo
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Infants were randomized by balanced blocks using sealed
envelopes"
Allocation concealment (selection bias) Low risk Quote: "Infants were randomized by balanced blocks using sealed
envelopes"
Blinding of participants and personnel
(performance bias)
Low risk Quote: " In feeding units, sachets were opened and mixed with 1ml of
sterile water or breastmilk immediately before administration to infants
who were receiving enteral feeding on the day of the supplementation.
The feeding team was not involved in the care of the infant and
followed directions on the sealed envelopes"
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Blinding of outcome assessment
(detection bias)
Low risk Quote: "The only personnel who knew of the infants group assignments
were the investigators". As the outcomes were mostly objective, it is
less likely that study had significant detection bias
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up reasons reported
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other sources of bias were noted
Dutta et al. (2015)
Methods A randomized, placebo‐controlled trial conducted in India
Participants Inclusion criteria:
(1) Neonates born at 27–33 weeks gestation in our hospital
(2) aged <96 h of life
(3) who were likely to either remain admitted in hospital or reside within 30 km of the hospital for the next 28 days
(4) who were tolerating at least 15ml/kg/day of milk feeds
Exclusion criteria:
(1) a gastro‐intestinal malformation
(2) prior NEC or sepsis
(3) any life‐threatening malformation that limited estimated life expectancy to less than a month
Interventions Intervention group: Probiotic Lactobacillus acidophilus (662.5 million), Lactobacillus rhamnosus (362.5 million), Bifidobacterium
longum (87.5 million), and Saccharomyces boulardii (137.5 million)
Four groups
A. High‐dose long course 1010 cells 12 hourly for 21 days
B. High‐dose short course 1010 cells 12 hourly for days 1–14; followed by placebo from days 15–21
C. Low‐dose long course 109 cells 12 hourly for 21 days
D. Control group: Placebo for 21 days
Outcomes NEC, mortality and sepsis
Notes We combined all the probiotics groups (group A + B + C) to avoid the double counting of the placebo.
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "A block randomized sequence was generated online by an investigator who was
not involved in the recruitment of subjects"
Allocation concealment
(selection bias)
Low risk Quote: "A block randomized sequence was generated online by an investigator who was
not involved in the recruitment of subjects"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The external appearance and the contents of the sachets of high dose, low dose,
and placebo were identical looking.
Blinding of outcome assessment
(detection bias)
Low risk As the intervention was concealed properly, less likely that outcomes assessors were
aware of the allocation
Incomplete outcome data
(attrition bias)
Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seems to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Edmond et al. (2015)
Methods Randomized, double‐blind, placebo‐controlled trial conducted in Ghana
Participants Recruited from the community, at least 2 h old, able to tolerate oral feeds and the family was likely to stay in the area.
Parental consent was needed for inclusion to study.
Interventions Intervention: Vitamin A: single dose: each dose was 50,000 IU
Control: Placebo
Common intervention given to all groups: Vitamin E
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Outcomes Primary outcome: All‐cause mortality
Other outcomes: Diarrhea, vomiting, bulging fontanelle, irritability, fever
Notes Some of the participants were HIV positive
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: “The computerised block randomisation scheme was done with a block size of 20, so
that in each block ten infants received vitamin A and ten received placebo”
Comment: Most likely done
Allocation concealment
(selection bias)
Low risk Quote: “An independent statistician who was not part of the trial prepared the
randomisation code at the WHO offices in Geneva, Switzerland. The code was available
only to the Data Safety and Monitoring Board (DSMB) and their statistician”
Comment: Most likely done
Blinding of participants and
personnel (performance bias)
Low risk Quote: “The research team and parents were fully unaware of the content of the capsules,
which were only labelled with the infant number. Amanufacturer (StridesArcolab
Limited, Bangalore, India) supplied the capsules. Separate staff, who were not part of the
trial, labelled all capsules”
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "…"
Comment: Most likely done
Incomplete outcome data
(attrition bias)
Low risk Quote: “Our loss to follow‐up was only 1.1% at the time of ascertainment of our primary
outcome at 6 months and only 2.9% at 12 months”
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Fernández‐Carrocera et al. (2013)
Methods Propsective, double‐blind, randomized clinical trial conducted in Mexico
Participants Inclusion criteria: Preterm newborns who weighed <1500 g admitted at the intensive and intermediate care units
Exclusion criteria: Preterm newborns weighing <1500 g with a low Apgar score (<6 at 5 min), gastrointestinal malformations,
genetic syndromes, asphyxia and IA–IB NEC stages according to Bell's
Interventions Intervention: Probiotic supplementation: "Lacidophilus 1.0×109 colony forming units (CFU) CFU/g, Lactobacillus rhamnosus
4.4×108 CFU/g, Lactobacillus casei 1.0×109 CFU/g, Lactobacillus plantarum 1.76×108 CFU/g, Bifidobacteruim infantis
2.76×107 CFU/g, Streptococcus theremophillus 6.6×105 CFU/g, each pack (Laboratorio Italmex SA)"
Control: "The control group received their regular feeds from their mother's own milk when available with nothing added, or
a premature infant formula"
Outcomes All‐cause mortality, NEC
Notes Data were taken from table 3
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)




Low risk "which was handled by the Human Milk Bank staff that was not involved in the care of the
patients and adhered to proper trial procedures."
Blinding of participants and
personnel (performance bias)
Low risk "As allocation concealment measure, the study group received a suspension that matched
the physical appearance of milk and the bottles were labelled only with the patient's
name and identification number as usual."
Blinding of outcome assessment
(detection bias)
Low risk Attending physicians and nurses caring for the infants were blinded to the group
assignments.
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Incomplete outcome data
(attrition bias)
Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Giridhar et al. (2019)
Methods Randomized, parallel group, placebo controlled trial
Participants Inclusion criteria: All infants admitted to the neonatal intensive care unit with birth weight between 750 and 1250 g and
between 24 to 96 h of life
Exclusion criteria: Lethal congenital malformations, terminal illness characterized by shock or bradycardia for more than 2 h,
refusal of consent
Interventions Intervention 1: Vitamin A: 5000 IU (0.125ml) IM on alternate days till establishment of adequate enteral feeds followed by
oral vitamin A 10,000 IU (1ml) once daily for a total duration of 28 days
Control intervention 1: Placebo: 0.125ml 0.9% normal saline IM alternate days till establishment of adequate enteral feeds
followed by 1ml oral dose of inert pharmacy made substance once daily for a total duration of 28 days
Outcomes Proportion of infants with vitamin A deficiency (plasma retinol <200mcg/L), mortality, sepsis
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The random sequence was generated online from the web site www.
randomizer. org"
Allocation concealment (selection bias) Low risk Quote: "Each stratum had permuted, even‐numbered, randomly varying block sizes"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The investigators, supervisors, caregivers, laboratory personnel, and
statistician were blinded to the intervention"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The investigators, supervisors, caregivers, laboratory personnel, and
statistician were blinded to the intervention"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Guney‐Varal et al. (2017)
Methods Prospective, randomized controlled trial conducted in Turkey
Participants Inclusion Criteria: preterm infants with a gestational age ≤32 week and a birth weight ≤ 1500 g
Exclusion Crietria: "detected chromosomal abnormalities, previous gastrointestinal system surgery, a diagnosis of metabolic
disease, babies lost in the first postnatal week and babies with severe sepsis episode were excluded from the study"
Interventions Intervention: Probiotic supplementation: Lactobacillus rhamnosus (4.1×108 cfu) + Lactobacillus casei (8.2×108 cfu) +
Lactobacillus plantorum (4.1×108 cfu) + Bifidobacterium animalis (4.1×108 cfu)
Comparison: No probiotics
Outcomes Mortality, NEC, sepsis
Notes Data were taken from table 2
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) High risk "Alternate randomization was used to enrol the infants to the
study arms"
This method of randomization is not adequate
Allocation concealment (selection bias) High risk Less likely to be done as the sequence generation was done on
alternate basis
Blinding of participants and personnel
(performance bias)
Unclear risk No details are provided about blinding
Blinding of outcome assessment (detection bias) Unclear risk No details are provided about blinding
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Hariharan et al. (2016)
Methods Prospective, randomized control trial conducted in India
Participants Inclusion criteria: "Infants with birth weight <1250 g, gestation <32 weeks"
Interventions Intervention: Lactobacillus acidophilus, Bifidobacterium bifidum, Saccharomyces boulardii 2.5 ×109 UFC of each twice a day, from the
3rd day of life, for 6 week courses
Comparison: No probiotic
Outcomes Mortality, NEC, sepsis
Notes Only abstract available
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) Unclear risk No details were available as only the abstract was available
Allocation concealment (selection bias) Unclear risk No details were available as only the abstract was available
Blinding of participants and personnel (performance bias) Unclear risk No details were available as only the abstract was available
Blinding of outcome assessment (detection bias) Unclear risk No details were available as only the abstract was available
Incomplete outcome data (attrition bias) Unclear risk No details were available as only the abstract was available
Selective reporting (reporting bias) Low risk Minimal loss to follow up
Other bias Unclear risk No details were available as only the abstract was available
Hernández‐Enríquez et al. (2016)
Methods Prospective randomized controlled trial conducted in Mexico
Participants Inclusion criteria: Infants with very low birth weight
Interventions Intervention: Lactobacillus reuteri 5 drops, equivalent to 100 million colony forming units (1 × 108 CFU) daily, whether they
were newborns with weight >1000 to 1500 g. In the case of newborns with weight <1000 g them 3 drops were
administered Lactobacillus reuteri (60 million CFU) daily
The duration of supplementation was 20 days
Compasrion: Group B (control group) received no probiotic.
Outcomes NEC, sepsis
Notes Study published in Spanish. Data extracted from the abstract
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Study published in Spanish. Details not available
Allocation concealment (selection bias) Unclear risk Study published in Spanish. Details not available
Blinding of participants and personnel (performance bias) Unclear risk Study published in Spanish. Details not available
Blinding of outcome assessment (detection bias) Unclear risk Study published in Spanish. Details not available
Incomplete outcome data (attrition bias) Unclear risk Study published in Spanish. Details not available
Selective reporting (reporting bias) Unclear risk Study published in Spanish. Details not available
Other bias Unclear risk Study published in Spanish. Details not available
Huaxian, 2013
Methods Randomized controlled trial conducted in China
Participants Inclusuion criteria: Preterm babies admitted to NICU
Interventions Intervention: Probiotics and early minimal feeding
Control: Early minimal feedings
Outcomes NEC
Notes Only abstract was available
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) Unclear risk No details were available as only the abstract was available
Allocation concealment (selection bias) Unclear risk No details were available as only the abstract was available
Blinding of participants and personnel (performance bias) Unclear risk No details were available as only the abstract was available
Blinding of outcome assessment (detection bias) Unclear risk No details were available as only the abstract was available
Incomplete outcome data (attrition bias) Unclear risk No details were available as only the abstract was available
Selective reporting (reporting bias) Low risk Minimal loss to follow up
Other bias Unclear risk No details were available as only the abstract was available
Humphrey et al. (1996)
Methods A placebo‐controlled trial conducted in Indonesia
Participants Inclusion criteria: All infants born at Hasan Sadikin Hospital in Bandung, Indonesia from June 18, 1992, to June 3, 1993
Exclusion criteria: Infants that were considered very low birthweight (<1500 g) and infants with life‐threatening conditions
Total number randomized in the intervention group: 1034
Total number randomized in the control group: 1033
Interventions Intervention: 1 dose of 52 μmol of vitamin A (as retinyl palmitate) orally
Control: Placebo (<0.10 μmol of vitamin A) orally
Common intervention given to all groups: 23 μmol vitamin E (as dl‐α‐tocopherol) orally
Outcomes Primary outcome: Infant Morbidity & Mortality
Other outcomes: Diarrhea, fever, cough, rapid breathing, wheezing, otitis media, pneumonia, sepsis
Notes
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The randomization scheme and coded supplement packets were prepared by a
team in Baltimore, none of whom was involved in recruitment or follow‐up of infants in
Indonesia"
Comment: Most likely done
Allocation concealment
(selection bias)
Low risk Quote: "Supplements were individually coded, odorless, and identical in appearance"
Comment: Most likely done
Blinding of participants and
personnel (performance bias)
Low risk Quote: "The randomization scheme and coded supplement packets were prepared by a
team in Baltimore, none of whom was involved in recruitment or follow‐up of infants in
Indonesia
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Low risk Quote:: "Two study pediatricians, masked to the treatment group of the case, independently
reviewed each verbal autopsy and assigned as a probable cause of death all diagnoses
for which the criteria of the algorithm were met"
Comment: Most likely done
Incomplete outcome data
(attrition bias)
Unclear risk Total number of loss to follow up: n (%)
The loss to follow up was balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Hussain et al. (2016)
Methods Propsective, randomized controlled trial conducted in Pakistan
Participants Inclusion criteria:
1. Pre‐term neonates <36 weeks gestation
2. Low birth weight neonates <2.5 Kg
3. Both genders
4. Both NG feed and bottle feed neonates
5. All neonates that were admitted at day 1 of life
Exclusion criteria:
1. Neonates <30 weeks low birth weight neonates, <1.5 Kg
2. Neonate on mechanical ventilatory support
3. IUGR (gestational age>36 weeks and weight <2.5 kg
4. Patients with congenital cyanotic heart diseases or has birth asphyxia and persistent cyanosis and need of oxygen
inhalation.
Interventions Intervention: Probiotic supplementation: Bifidobacteria.
Comparison: No probiotics
Outcomes NEC
Notes The strain of the probiotic was not clearly stated. The dose and duration of the intervention was not given
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote: "neonates were divided in two groups by using random
number tables"
Allocation concealment (selection bias) Unclear risk Seems unlikely, but no clear statement is made regarding this
matter
Blinding of participants and personnel (performance bias) Unclear risk No supporting statement is age in this regard
Blinding of outcome assessment (detection bias) Unclear risk No clear statement is made in this regard
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Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report the relevant outcomes
Other bias Low risk No other source of bias was noted
Kaban et al. (2019)
Methods A double‐blind randomized controlled clinical trial conducted in Indonesia
Participants Inclusion criteria: Gestational age of 28–34 weeks, birth weight of 1000–1800 g in a stable condition
Exclusion criteria: Lower gastrointestinal tract obstruction, massive gastrointestinal tract bleeding, NEC, sepsis and shock,
and refusal of the infants' parents to participate in the study
Interventions Intervention: Lactobacillus reuteri DSM 17938, duration of at least 7 days or until the subject was discharged, experienced
NEC, or died, five drops per day, 108 colony‐forming units/day
Comparison: Placebo: The placebo contains a mixture of pharmaceutical‐grade medium‐chain triglycerides and sunflower oil
together with pharmaceutical‐grade silicon
Outcomes Mortality, sepsis and death
Notes Data were taken from table 4
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
High risk Quote: "Subjects were allocated to the groups by a third party using a simple
alternating randomization technique"
Comment: Alternation allocation of patients is not random
Allocation concealment (selection bias) Unclear risk Quote: "Subjects were allocated to the groups by a third party using a simple
alternating randomization technique"
Comment: It is not clear if the allocation was revealed before the patient were
allocated to intervention or placebo
Blinding of participants and personnel
(performance bias)
Unclear risk Authors mentioned that it was a double blind trial but no details were provided on
how the blinding was done
Blinding of outcome assessment
(detection bias)
Unclear risk Authors mentioned that it was a double blind trial but no details were provided on
how the blinding was done
Incomplete outcome data (attrition bias) Low risk No attrition was reported
Selective reporting (reporting bias) Unclear risk Authors seem to report all the relevant outcomes
Other bias Unclear risk No other risk of bias was noted
Klemm et al. (2008)
Methods Community‐based, double‐masked, cluster‐randomized, and placebo‐controlled trial conducted in Bangladesh
Participants Inclusion criteria: Infants born to consenting mothers who were participating in the parent trial
Exclusion criteria: Infants of consenting mothers who had died before they could be supplemented by staff, infants born
outside of the study area, and infants who could not be reached to receive a supplement during the first 30 days after
birth
Total number randomized in the intervention group: 8525
Total number randomized in the control group: 8591
Interventions Intervention: 50,000 IU vitamin A
Control: Placebo
Common intervention given to all groups:
Outcomes Primary outcome: All‐Cause infant mortality
Other outcomes: Bulging fontanel
Notes – "Follow‐up of the trial cohort at 3 years of age revealed no evidence of adverse effects associated with having had a
perinatal bulging fontanel in terms of cognitive, motor, and behavioral test outcomes"
– This study was concluded early by direction of the Data Safety and Monitoring Board
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Sectors were listed in geographically contiguous order and were
randomized in blocks of 4 within each of 3 previously randomized
maternal supplementation trial treatment arms…"
Comment: Most likely done
Allocation concealment (selection bias) Unclear risk Quote: "Community maps of the area were developed, homes were issued
numeric addresses, and married women of reproductive age were
enumerated and issued unique study identification numbers"
Comment: Most likely done
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The supplements for both groups were opaque gelatinous capsules
identical in shape, size, and color containing edible oil"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "Infant vital status was assessed weekly at home for the first 12
weeks of life by field staff and then again at 24 weeks of age"
Comment: Most likely done
Incomplete outcome data (attrition bias) Low risk Total number of loss to follow up: 11 (0.07%)
The loss to follow up was not balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Malaba et al. (2005)
Methods Randomized, placebo‐controlled, 2‐by‐2 factorial design trial was conducted in Zimbabwe
Participants Inclusion criteria: Neither the mother nor the infant had an acutely life‐threatening condition, the infant was a singleton with
a birth weight of >1500 g, and the mother planned to stay in the region after delivery
Exclusion criteria: Either the mother and/or the infant had an acutely life‐threatening condition, the infant was not a
singleton or had a birth weight of <1500 g, and the mother did not plan to stay in the region after delivery




Total number randomized in the control group: Pp: 3522
Interventions Intervention:
– Mothers received 400,000 IU vitamin A (as retinyl palmitate) and infants received 50,000 IU vitamin A (Aa group)
– Mothers received 400,000 IU vitamin A and infants received placebo (Ap group)
– Mothers received placebo and infants received 50,000 IU vitamin A (Pa group)
Control: Both mothers and infants received placebo (Pp group)
Common intervention given to all groups: Soy oil base with vitamin E as a preservative (50 IU per maternal capsule; 10 IU per
infant capsule)
Outcomes Primary outcome: Infant mortality
Other outcomes: None
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote: "A separate team at Johns Hopkins University prepared the
study capsule packets. Study identification numbers were
randomly allocated to the treatment groups by computer in
blocks of 12"
Comment: Most likely done
Allocation concealment (selection bias) Low risk Quote: "Lists linking the study number to the treatment were kept
in sealed envelopes and encrypted computer files"
"Treatment and placebo capsules appeared identical…"
Comment: Most likely done
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Blinding of participants and personnel (performance bias) Unclear
risk
Quote: "Treatment and placebo capsules appeared identical…"
Comment: Most likely done
Blinding of outcome assessment (detection bias) Low risk Quote: "Cause of death was determined from medical records for
infants who died in a hospital or from a review of verbal autopsy
information by a study pediatrician, who was masked to
treatment group, for infants dying at home"
Comment: Most likely done
Incomplete outcome data (attrition bias) Unclear
risk
Total number of loss to follow up: n (%)
The loss to follow up was not balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Masanja et al. (2015)
Methods A randomized, double‐blind, placebo‐controlled trial conducted in Tanzania
Participants Inclusion criteria: Able to feed orally, parents planned to stay in the study area for at least 6 months, and informed written
consent was provided
Exclusion criteria: Infants enrolled in another trial
Total number randomized in the intervention group: 15,995
Total number randomized in the control group: 16,004
Interventions Intervention: 50,000 IU of vitamin A (as retinol palmitate) orally
Control: Placebo (minute amounts of vitamin E (9.5–12.6 IU) in soybean oil) orally
Common intervention given to all groups: Minute amounts of vitamin E (9.5–12.6 IU) in soybean oil
Outcomes Primary outcome: Mortality between supplementation and 6 months of age
Other outcomes: Mortality between supplementation and 28 days of age, Mortality between supplementation and 365 days
of age, and hospital admission in the first 6 months of life
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "We randomly assigned infants to receive either vitamin A or a placebo. The unit of
randomisation was the individual infant. Block randomisation was done at WHO (Geneva,
Switzerland) in block sizes of 20 (ten infants received vitamin A and ten received placebo)"
Comment: Most likely done
Allocation concealment
(selection bias)
Low risk Quote: "The vitamin A and placebo capsules were identical in taste and appearance. Capsules
were individually packed in blister packs of two capsules each; one for the dose and the
second for the backup dose. Labels for the capsules were printed at WHO with country
and infant study number in sequential order"
Comment: Most likely done
Blinding of participants and
personnel (performance bias)
Low risk Quote: "Codes for the experimental regimens were kept with the data and safety monitoring
board and broken during the analysis after a cleaned and locked database for the study
was submitted to WHO"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Low risk Quote: "All reported deaths of children were investigated and trained field staff visited the
family at least 6 weeks after the date of death to do a verbal autopsy interview"
"Trained field interviewers visited enrolled infants at home (or in health facilities for cases in
which the mother and child were not discharged after delivery) 1 day and 3 days after
dosing to monitor possible adverse events after supplementation"
Comment: Most likely done
Incomplete outcome data
(attrition bias)
Unclear risk Total number of loss to follow up: n (%)
The loss to follow up was not balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
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Mazumder et al. (2015)
Methods Randomized, double‐blind, placebo‐controlled trial conducted in India
Participants Inclusion criteria: Livebirths born in the study area
Exclusion criteria: Died before screening, serious illness, and/or were admitted into the intensive care unit
Total number randomized in the intervention group: 22,493
Total number randomized in the control group: 22,491
Interventions Intervention: 50,000 IU vitamin A plus vitamin E 9.5–12.6 IU
Control: Placebo (vitamin E 9.5–12.6 IU)
Common intervention given to all groups: Vitamin E 9.5–12.6 IU
Outcomes Primary outcome: Infant mortality from supplementation to 6 months
Other outcomes: Neonatal mortality, mortality between supplementation and 12 months of age, infant hospital
admission one or more times due to any illness between supplementation and 6 months of age, potential adverse
events in the 3‐day period following supplementation, and vitamin A status in a sub‐sample of infants at 2 weeks
and 3 months of age
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The unit of randomisation was the individual infant. We randomly
assigned infants using a block randomisation scheme with a block size
of 20, so that in each block ten infants received vitamin A and ten
received placebo. The randomisation list was prepared offsite at WHO
(Geneva, Switzerland) by a statistician not otherwise involved with the
trial"
Comment: Most likely done
Allocation concealment (selection bias) Low risk Quote: "The vitamin A and placebo capsules were identical in colour, shape,
and size. Capsules were individually packaged in identical blister packs
with two capsules, one for the dose and the other as a backup"
Comment: Most likely done
Blinding of participants and personnel
(performance bias)
Low risk Quote: "Investigators, participants' families, and the data analysis team
were masked to treatment allocation"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Research staff were trained to do surveillance, interview families,
obtain informed consent, give capsules, collect baseline and follow‐up
information, and data capture"
Comment: Most likely done
Incomplete outcome data (attrition bias) Low risk Total number of loss to follow up: 40 (0.09%)
The loss to follow up was not balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Nandhini et al. (2016)
Methods A prospective, double blind. controlled trail conducted in India
Participants Inclusion criteria: Preterm infants, enterally fed, 28–34 weeks, birthweight >1000 g, admitted to the NICU
Exclusion crietria: major congenital anomalies, surgical problems of the GI tract, severe birth asphyxia, early onset sepsis
Interventions Intervention: Synbiotic supplementation: probiotics (Lactobacillus acidophilus (700 million CFU), Bifidobacterium longum (400
million CFU), Lactobacillus rhamnosus (400 million CFU), Lactobacillus plantaris (300 million CFU), Lactobacillus casei (300
million CFU), Lactobacillus bulgaricus (300 million CFU), Bifidobacterium infantis (300 million CFU) and Bifidobacterium breve
(300 million CFU) + Prebiotic (fructo‐oligosaccharide)
The dose was given two times daily for 7 days. The Probitiotics were mixed with breastmilk
Comparison: Standard of care without synbiotics
Outcomes Mortality, neonatal sepsis, NEC
Notes Data were included from table 2. We created the intervention to treat analysis
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk After obtaining informed consent from the parents, neonates satisfying the inclusion
criteria were randomized prior to starting enteral feeds into two groups using
computer generated random numbers kept in opaque sealed envelopes
Allocation concealment (selection bias) Low risk After obtaining informed consent from the parents, neonates satisfying the inclusion
criteria were randomized prior to starting enteral feeds into two groups using
computer generated random numbers kept in opaque sealed envelopes
Blinding of participants and personnel
(performance bias)
Unclear risk No details are provided in the study
Blinding of outcome assessment
(detection bias)
Unclear risk No details are provided in the study
Incomplete outcome data (attrition bias) Low risk Miminal loss to follow up
Selective reporting (reporting bias) Low risk Author seem to report all the outcomes
Other bias Low risk No other bias was noted
Niekerk et al. (2015) (HIV exposed)
Methods A randomized, double blind, placebo‐controlled clinical trial conducted in South Africa
Participants Inclsuion criteria: "(i) HIV‐positive or HIV‐negative mothers who gave birth to a premature and VLBW baby at TBCH and
consented to participate in the study; (ii) only breastfeeding mothers, regardless of their HIV status; and (iii) HIV‐positive
mothers that were on the prevention of mother to child transmission treatment schedule. Babies were included if they (i)
had a birth weight of 500 g and 1250 g; (ii) were either HIV‐exposed or HIV‐unexposed; and (iii) received breast milk
(either from their mothers or donor breast milk)"
Exclusion criteria: abnormalities such as gastroschisis, a large omphalocele or congenital diaphragmatic hernia
Interventions Intervention: Probiotics: L. rhamnosus GG [0.35 ×10^9 colony‐forming units (CFU)] and B. infantis (0.35 ×109 CFU), 5 drops
daily for 28 days
Control: Placebo
Outcomes Mortality and NEC
Notes Data were taken from table 3. This was a multiple arm trial and we included the data for HIV exposed and HIV nonexposed
separately
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Participants were randomized into either the study or control groups
(probiotic vs. placebo supplementation) with a random‐number sequence
allocated to each participant number"
Allocation concealment (selection bias) Low risk Quote: "No differences in the colour and appearance of the probiotic and placebo
were noted. The probiotic and placebo were blinded with the use of a colour‐
coded label (orange or purple)"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other bias was noted
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Niekerk et al. (2015) (HIV nonexposed)





Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Participants were randomized into either the study or control groups
(probiotic vs. placebo supplementation) with a random‐number sequence
allocated to each participant number"
Allocation concealment (selection bias) Low risk Quote: "No differences in the colour and appearance of the probiotic and placebo
were noted. The probiotic and placebo were blinded with the use of a colour‐
coded label (orange or purple)"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The attending physician, nurses, researcher, research assistant and study
participants were blinded to the group assignment"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other bias was noted
Oncel et al. (2014)
Methods A prospective, double‐blinded, randomized, placebo controlled trial conducted in Turkey
Participants Inclusion criteria: Preterm infants with a gestational age ≤32 weeks and birth weight ≤1500 g, which survived to feed
enterally, were eligible for the study.
Exclusion crietria: Major congenital malformations and lack of parental consent.
Interventions Intervention group: Probiotic supplementation:Infants in the probiotic group received 5 drops of oil‐based suspension
containing 1×108 colony‐forming units of Lactobacillus reuteri DSM 17938". The probiotic was given once a day, until
death or discharge from the hospital
Comparison: Placebo
Outcomes Mortality, NEC
Notes We created the intention to treat analysis by using the numbers from fig. 1 and the table 2. We included all the patients who
were randomized to intervention or control group
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Study infants were randomly assigned to probiotic or placebo by using sequential numbers
generated at the computer centre of the NICU by 1:1 allocation ratio
Allocation concealment
(selection bias)
Low risk The allocations were contained in opaque, sequentially numbered sealed envelopes
Blinding of participants and
personnel (performance bias)
Low risk Identical vial containing only oil base were administered following the same protocol as the
probiotic group.
Blinding of outcome assessment
(detection bias)
Low risk Seems less likely
IMDAD ET AL. | 47 of 88
Incomplete outcome data
(attrition bias)
Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other bias was noted
Panigrahi et al. (2017)
Methods A community‐based, double‐blind, placebo controlled randomized trial conducted in India
Participants Inclusion criteria: Neonate >24 h and <96 h old, ≥2000 g at birth, breastfeeding begun by 24 h of life, ability to tolerate oral
feeds, informed consent by parent or guardian
Exclusion criteria: Evidence or suspicion of clinical sepsis before the infant was randomized, gestational age reported voluntarily by
the mother to be <35 weeks, infant >96h old, infant did not cry immediately after birth, mother had fever (>38°C) within 2 days
of delivery, mother had foul‐smelling amniotic discharge within 2 days of delivery, mother had abdominal tenderness within 2
days of delivery, amniotic fluid was meconium‐stained, infant was on antibiotics, mother unlikely to stay in the village for 60 days,
difficulty in carrying out study (maternal sickness etc.), or presence of major congenital anomalies (defined as any malformation
that was felt to be life‐threatening or that required surgical intervention)"
Interventions Intervention: Synbiotic supplementation: The synbiotic preparation consisted of a capsule containing ~109 Lactobacillus
plantarum ATCC strain 202195 and 150mg of fructooligosaccharide with 100mg maltodextrin as excipient
The synbiotic was administered orally to the newborns for 7 days beginning on day 2–4 of life
Comparison: Placebo capsules contained only 250mg of maltodextrin
Outcomes Mortality, sepsis
Notes This was a community based study. Data were taken from table 2
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Each assignment was the product of a random permutation scheme
that assigned 2 intervention and 2 placebo slots to each of 38
consecutive blocks of 4 assignments for each village. This numbered list
and corresponding bar codes were created by the GCRC (General
Clinical Research Center) at the University of Maryland with assistance
from the Department of Bioinformatics"
Allocation concealment (selection bias) Low risk Quote: "This numbered list and corresponding bar codes were created by
the GCRC (General Clinical Research Center) at the University of
Maryland with assistance from the Department of Bioinformatics and
given to the clinical trial supplier (Laxai USA, South Plainfield, New
Jersey, USA) for labelling of the synbiotics and to prepare packages for
each village to be assigned consecutively to enrolled subjects"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "physicians had no access to randomization, distribution, or
administration of the intervention making them completely blinded to
the intervention"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "physicians had no access to randomization, distribution, or
administration of the intervention making them completely blinded to
the intervention"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Rahmathullah et al. (2003)
Methods Community based, randomized, double‐blind, placebo controlled trial conducted in southern India
Participants Inclusion criteria: Liveborn infants from all pregnancies in the participating villages
Exclusion criteria: Stillbirths, Miscarriages, Any delivery more than 20 km outside the study area, and infants who died
before the study team arrived
Total number randomized in the intervention group: 6624
Total number randomized in the control group: 6570
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Interventions Intervention: 24,000 IU vitamin A
Control: Placebo
Common intervention given to all groups: Edible oil solution
Outcomes Primary outcome: Infant mortality at 6 months
Other outcomes: None
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomisation was at the individual level, stratified by
geographical area in blocks of four. Because births were likely in a
variety of locations, randomisation was conducted at the time of
recruitment"
Comment: Most likely done
Allocation concealment (selection bias) Low risk Quote: "Treatment codes were kept in a sealed envelope in a locked filing
cabinet in Baltimore"
Comment: Most likely done
Blinding of participants and personnel
(performance bias)
Low risk Quote: "Investigators, study staff, and mothers were masked to the
assigned treatment"
Comment: Most likely done
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "Project staff visited the household every 2 weeks to assess the
vital status of the child and any morbidity.
"Investigators, study staff, and mothers were masked to the assigned
treatment"
Comment: Most likely done
Incomplete outcome data (attrition bias) Unclear risk Total number of loss to follow up: 143 (1.1%)
The loss to follow up was not balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Rehman et al. (2018)
Methods A randomized control conducted in Pakistan
Participants Inclsuion criteria:"preterm infants having gestation of 27 to 36 + 7 weeks; they were VLBW (<1500 g) and they survived to
feed enterally"
Exclusion criteria: None available as only abstract was available for data extraction
Interventions Authors mentioned that they supplemented the neonates with Probiotic mixtures. Exact strain was not clear
Outcomes NEC
Notes Study only available as abstract
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Study available as abstract
Allocation concealment (selection bias) Unclear risk Study available as abstract
Blinding of participants and personnel (performance bias) Unclear risk Study available as abstract
Blinding of outcome assessment (detection bias) Unclear risk Study available as abstract
Incomplete outcome data (attrition bias) Unclear risk Study available as abstract
Selective reporting (reporting bias) Unclear risk Study available as abstract
Other bias Unclear risk Study available as abstract
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Rojas et al. (2012)
Methods A multicenter, double‐blinded, randomized, placebo‐controlled trial conducted in Colombia
Participants Inclusion Cciteria: "Preterm infants admitted to NICU, birth weight ≤ 2000 g, haemodynamically stable (blood pressure not
requiring boluses or pressors), and ≤ 48 h of age"
Exclusion criteria: "Infants with evidence or suspicion of congenital intestinal obstruction or perforation, gastroschisis, large
omphalocele, congenital diaphragmatic hernia, major congenital heart defects, or anticipated transfer to a NICU not
participating in the study were excluded"
Interventions Intervention: Probiotic administration:"Infants in the probiotic group received 5 drops of an oil‐based suspension containing
108 colony‐forming units of L reuteri DSM 17938"
Comparison: Oil based placebo
Outcomes Mortality, NEC
Notes Data were taken from table 2. The duration of the intervention was not clearly stated
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: " Study participants were randomly assigned to probiotic or placebo by the use of a
computer‐generated balanced block randomization scheme"
Allocation concealment
(selection bias)
Low risk Quote: "Treatment assignment was performed by using sealed, sequentially numbered,
opaque envelopes, color‐coded for strata, available in each NICU pharmacy"
Blinding of participants and
personnel (performance bias)
Low risk Quote: "Infants were administered probiotic or placebo regardless of whether enteric feeds
were started"
Blinding of outcome assessment
(detection bias)
Low risk The authors do not report clearly if the outcome assessment was blinded, however in the
setting of adequate allocation concealment and blinding of interventions it is less likely
the outcome assessors knew the intervention vs placebo group
Incomplete outcome data
(attrition bias)
Low risk Quote: "The study was terminated before the completion of the targeted sample because of
a substantial drop in patient recruitment among participating institutions as well as
funding restrictions that limited our ability to recruit the required additional subjects"
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Roy et al. (2014)
Methods A prospective, randomized, double blind, placebo‐controlled trial in India
Participants Inclusion criteria: "Admission to the NICU, a stable oral feeding within 72 h of birth and an informed parental consent;
gestational age (GA) < 37 weeks; birth weight <2500 g; adequate renal and liver function; a postnatal age <2 week; did
not have baseline fungal colonization at enrolment (with colonization defined by isolation of fungi from a culture
specimen obtained from any site during the first 3 days of life); did not receive any form of antifungal prophylaxis other
than the probiotic used"
Exclusion criteria: "presence of major congenital malformation; antenatal and perinatal risk factors for sepsis, major
congenital malformation; stigma of congenital infection; severe lesions diagnosed by cranial ultrasound (e.g.
intraventricular haemorrhage (IVH) grade 3 and 4 and major ischemic lesions); altered liver and renal function; likely to
die within 72 h of birth; and babies of mothers taking supplemental probiotics by capsule/powder"
Interventions Intervention: "6×109 CFU Lactobacillus: half a sachet of Lactobacillus acidophilus 1.25 billion, B. longum 0.125billion, B.
bifidum 0.125billion, and B. lactis 1 billion/1 g sachet, daily for 6 weeks or NICU discharge
Control:sterile water in breastmilk
Outcomes NEC, mortality and sepsis
Notes Data were taken from table 2
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The newborns were randomized into two groups by a random‐generated
(computer‐generated), predetermined number table"
Allocation concealment
(selection bias)
Low risk Quote: "All doctors, nurses, laboratory staff, and parents are blind to the randomized
allocation"
Less likely that allocation was revealed
Blinding of participants and
personnel (performance bias)
Low risk Quote: "All doctors, nurses, laboratory staff, and parents are blind to the randomized
allocation"
Blinding of outcome assessment
(detection bias)




Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Saengtawesin et al. (2014)
Methods A prospective, randomized control trial conducted in Thailand
Participants Inclusion criteria: "all preterm infants with gestational age ≤34 weeks and birth weight ≤1500 g"
Exclusion criteria: "Very low birth weight preterm infants who had severe birth asphyxia, chromosome anomalies, cyanotic
congenital heart disease, congenital intestinal obstruction, gastroschisis, omphalocele, nil per oral >3 weeks and parents
who declined consent"
Interventions Intervention: Probiotics: "Infloran(1×10^9 Lactobacillus acidophilus and 1×109 Bifidobacterium bifida): 125mg/kg/dose two
times daily for 6 weeks
Control: "unsupplemented breast milk or preterm formula"
Outcomes Neonatal Sepsis, NEC
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "randomized by blocks of four into two groups, study and control group"
Comment: Most likely done
Allocation concealment
(selection bias)
Low risk Quote: "Infants in the control group were fed either breast milk or premature formula alone.
Infloran® was stored in a refrigerator at 4°C to 8°C, at the hospital pharmacy and sent
then to the neonatal unit according to prescription"
Comment: The sequence was kept at a central location
Blinding of participants and
personnel (performance bias)
Low risk Seems less likely that participants were aware of the intervention
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Whenever an infant was suspected to have NEC, he/she was evaluated by two
attending neonatologist"
Seems less likely that outcome assessment was biased
Incomplete outcome data
(attrition bias)
Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
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Samanta et al. (2009)
Methods A prospective randomized double‐blind control trial conducted in India
Participants Inclusion criteria: "preterm (<32 weeks) VLBW (<1500 g) born between October 2007 and March 2008, started feed
enterally, survived beyond 48 h of life"
Exclusion criteria: "babies with major congenital and GI anomalies and babies who expired due to other neonatal illnesses"
Interventions Intervention: Probitotics containing Bifidobacteria infantis, Bifidobacteria bifidum, Bifidobacteria longum, Lactobacillus
acidophilus: Dose 2.5 billion cfu each of 4 strains twice daily until NICU discharge
Control: Breastmilk without probiotics
Outcomes Mortality, sepsis
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "the infants were randomly assigned to two groups by random
number table sequence"
Allocation concealment (selection bias) Unclear risk No details are provided
Blinding of participants and personnel
(performance bias)
Unclear risk No details are provided
Blinding of outcome assessment
(detection bias)
Unclear risk No details are provided
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Sari et al. (2011)
Methods Prospective, randomized, controlled trial Turkey
Participants Inclusion criteria: Infants with gestational age of <33 weeks or birth weight of 1500 g
Exclusion criteria: Major congenital malformations and lack of parental consent
Interventions Intervention: "Lactobacillus sporogenes with a dose of 350 000 000 c.f.u. once a day until discharge"
Control: "The control group was fed with breast milk or formula without the probiotics
Outcomes NEC, mortality, sepsis
Notes Data were taken from table 2 of the study. We created the intention to treat analysis
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "using sequential numbers generated at the computer center of…"
Allocation concealment (selection bias) Low risk Quote: "The allocations were contained in opaque, sequentially numbered
sealed envelopes"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "Thus, the only personnel who knew of the infants’ group
assignments were the investigators and those in the breast‐milk team
who were not involved in the care of the study infants"
Blinding of outcome assessment
(detection bias)
Low risk
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Quote: "Whenever an infant was suspected to have NEC, the infant was
evaluated by two senior‐attending neonatologists who did not know the
group assignment of the infant"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Serce et al. (2013)
Methods A prospective, double blind, placebo controlled trial conducted in Turkey
Participants Inclusion criteria: "VLBW infants (gestational age ≤32 weeks; birth weight ≤1500 g) who survived to feed enterally were
eligible for the trial"
Exclusion criteria: "Infants who had severe asphyxia (stage III), major congenital anomalies, those who had been fasted for
more than 3 weeks, died in the first postnatal 14 days and infants who used antifungal therapy were excluded"
Interventions Intervention: "The study group received Saccharomyces boulardii (50 mg/kg equal to 0.5×109 cell/kg per dose twice daily until
discharge
Comparison: placebo (distilled water; 1 ml per dose twice daily)
Outcomes Mortality, NEC, sepsis
Notes Data were taken from table 3
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomization was performed by using sequential numbers
generated at the computer…"
Allocation concealment (selection bias) Low risk Quote: "The allocations were contained in opaque, sequentially numbered
sealed envelopes"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The allocations were contained in opaque, sequentially numbered
sealed envelopes"
Comment less likely that participants were aware
Blinding of outcome assessment
(detection bias)
Unclear risk No information was provided on who made the assessment
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Shadkam et al. (2015)
Methods A prospective, triple blind, placebo controlled trial conducted in Iran
Participants Inclusion criteria: "premature infants admitted at the neonatal intensive care unit (NICU) during October 2012‐March 2013.
Gestational age of infants was estimated at 28–34 weeks using the Dubowitz method, and birth weight of infants was
calculated to be 1000–1800 g"
Exclusion criteria: "presence of disorders such as digestive obstruction, GI bleeding, gastroschisis, omphalocele, withdrawal
syndrome, neonatal proven or clinical sepsis, congenital heart defect and asphyxia (degree II or III)"
Interventions Intervention: "5 ml of a mixture containing Lactobacillus reuteri DSM 17938. One drop of this product holds a minimum of 20
million live Lactobacillus reuteri protectis." The intervention was given two times daily. The intervention was given until
the child achieved full enteral feedings
Control: "placebo group received 0.5 ml of distilled water every 12 hours"
Outcomes Mortality, sepsis, NEC
Notes Data were taken from table 2
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Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "using the random allocation software"
Allocation concealment (selection bias) Unclear risk No details were provided on where the allocation was placed
Blinding of participants and personnel
(performance bias)
Low risk Quote: "the intervention was implemented by nurses, and the physician was
not aware of the condition of neonates in detail"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "the intervention was implemented by nurses, and the physician was
not aware of the condition of neonates in detail"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Shashidhar et al. (2017)
Methods A double blind randomized controlled trial in India
Participants Inclusion criteria: "All neonates with a birth weight between 750 and 1499 g admitted to the NICU"
Exclusion criteria: "Neonates with gastrointestinal anomalies, severe congenital malformation, and those not started on
enteral feeds by day 14 of life were excluded"
Interventions Intervention: "Multicomponent probiotic formulation of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium
longum, and Saccharomyces boulardii in the form of powdered sachets of 1 g each. The intervention was administered once
a day at a dose of 1.25×109 CFU starting within 24 h of initiation of feeds. The probiotic supplementation was continued
till discharge given once a day if the volume of feeds was 2ml or more, and in two divided doses if the baby received
<2ml/feed
Control: "The no probiotic group received only breast milk and served as the control"
Outcomes Mortality, NEC
Notes Data were taken from table 2
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "The subjects were randomly allocated into two groups using
computer generated random numbers by an investigator not directly
involved in the study"
Allocation concealment (selection bias) Low risk Quote: "Sequentially numbered opaque sealed envelopes were used for
allocation concealment"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The two groups were coded as A and B and the group code was kept
off site in an opaque sealed envelope and opened only after the final
analysis was done"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The two groups were coded as A and B and the group code was kept
off site in an opaque sealed envelope and opened only after the final
analysis was done"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
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Dongol Singh et al. (2017)
Methods A randomized, double blind, placebo controlled conducted in Nepal
Participants Inclusion criteria: Preterm babies admitted to the NICU
Exclusion criteria: "Sick infants (neonates with clinical or proven sepsis), those with congenital malformation especially
(central nervous system) malformation and other such as gastrointestinal obstruction, gastrointestinal bleeding,
gastroschisis, omphalocoele, congenital heart defect and birth asphyxia (grade III). Out born babies were also excluded in
this study"
Interventions Intervention: "probiotics Lactobacillus casei var. rhamnosis (LCR 35) 0.8 mg (half packet) dissolved in 2ml of EBM in infant
more than 1500 g and 0.4mg probiotics (1/4th packet) dissolved in 1ml of EBM in infants <1500 g was given twice a day
until they reached full feeding"
Control: "placebo as expressed breast milk only"
Outcomes NEC and mortality
Notes Data were taken from the last two paragraphs of the result section
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote: "using random selection by lottery"
Allocation concealment (selection bias) High risk Quote: "Intervention was instructed by the researcher and conducted by
nursing staff of NICU"
Blinding of participants and personnel
(performance bias)
Low risk Less likely that neonates were aware of the intervention
Blinding of outcome assessment
(detection bias)
Unclear risk No clear information was provided on who made the assessment for clinical
outcomes
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Sinha et al. (2015)
Methods Randomized, double‐blind, placebo‐controlled trial conducted in India in community settings
Participants Inclusion criteria: infants aged 3 days, born in the hospitals weighing 1500–2500 g"
Exclusion criteria: "extremely premature infants (<34 weeks), sick infants, those with congenital malformations incompatible
with life, and those with guardians not giving consent and belonging to out of study areas"
Interventions Intervention: "VSL#3 (a mix of eight strains: Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum,
Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus
delbrueckii spp bulgaricus, at a dose of 10 billion cfu for 30 days, starting on the third day of life and continued for
30 days"
Control: "A similar‐looking maltodextrin preparation in the same outer packing was administered to the control group"
Outcomes Mortality, sepsis
Notes Data were taken from table 2 and table 4. For sepsis, we included the numbers for suspected sepsi
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "A team of scientists at INCLEN Trust, New Delhi, used a computer‐
generated table for subject allocation"
Allocation concealment (selection bias) Low risk Quote: "Allocation concealment was ensured by sequentially numbering
the sachet packets containing VSL#3 or placebo after block
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randomisation. Identical packaging of VSL#3 and a placebo with similar
consistency and colour was provided"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "Parents of enrolled infants, investigators and field workers were
masked to treatment allocation. Data analysis was performed in a
blinded manner"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Parents of enrolled infants, investigators and field workers were
masked to treatment allocation. Data analysis was performed in a
blinded manner"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Soofi et al. (2017)
Methods A cluster randomized, placebo controlled trial conducted in Pakistan
Participants Inclusion criteria: All infants born in the study village were eligible for inclusion.
Exclusion criteria: Infants with congenital anomalies were excluded
Interventions Intervention: The intervention group received a single dose of vitamin A 50,000 IU
Comparison: the comparison group received placebo.
Both the groups received vitamin E.
Outcomes All‐cause mortality, febrile illness, diarrhoea or pneumonia
Notes
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: “This was a cluster randomized, placebo‐controlled trial”; and “an
external consultant generated the computerized allocation sequence of
clusters to each study intervention to either group using Epi Info 3.5.3
with restricted randomization based on population size, expected births
and LHW presence”
Allocation concealment (selection bias) Low risk Quote: “An external consultant generated the computerized allocation
sequence of clusters to each study intervention to either group using Epi
Info 3.5.3 with restricted randomization based on population size,
expected births and LHW presence”
Blinding of participants and personnel
(performance bias)
Low risk Quote: “The capsules were identical in appearance (Banner Pharmacaps,
Canada) and supplied through the courtesy of the Micronutrient
Initiative (Ottawa, Canada). The capsules were packaged in containers
labelled as A & B. The content of the capsules were masked from field
staff and supervisors, and the codes were only known to the external
consultant responsible for cluster randomizations and the chair of the
DSMB. The masking was maintained until the completion of the study”
Blinding of outcome assessment
(detection bias)
Low risk Quote: “The capsules were identical in appearance (Banner Pharmacaps,
Canada) and supplied through the courtesy of the Micronutrient
Initiative (Ottawa, Canada). The capsules were packaged in containers
labelled as A & B. The content of the capsules were masked from field
staff and supervisors, and the codes were only known to the external
consultant responsible for cluster randomization and the chair of the
DSMB. The masking was maintained until the completion of the study”
Incomplete outcome data (attrition bias) Low risk Quote: “We were able to follow 10,286 (93%) infants until death or 6
months of age”
Selective reporting (reporting bias) Low risk Author seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
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Sun et al. (2019)
Methods A prospective, randomized study conducted in China
Participants Inclusion criteria: Admitted to the neonatal intensive care unit at a gestational age of 28 weeks, 96 h of age
Exclusion criteria: Genetic metabolic diseases; congenital major abnormalities; congenital TORCH infections with overt signs
at birth; terminal stage of illness (pH 7.0 or hypoxia with bradycardia 2 h); or the lack of parental consent




Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "A blocked randomization method stratified by the neonatal
intensive care unit size was used to assign infants to either the control
or oral VA group"
Allocation concealment (selection bias) Low risk Quote: "solutions, which were only labelled with the study site and infant
number"
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The medical and nursing teams caring for the infants were thus
completely unaware of the content of the solutions"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "The medical and nursing teams caring for the infants were thus
completely unaware of the content of the solutions, which were only
labelled with the study site and infant number"
Incomplete outcome data (attrition bias) Low risk No loss to follow up was noted
Selective reporting (reporting bias) Low risk Authors seem to report all the relevant outcomes
Other bias Low risk No other risk of bias was noted
Tewari et al. (2015)
Methods A double‐blinded, placebo‐controlled, randomized trial conducted in India
Participants Inclusion criteria: "Preterm neonates <34 weeks admitted to the NICU"
Exclusion criteria:
"i. Extramural preterm neonates >10 day age with clinical or lab marker of sepsis
ii. Preterm babies with necrotizing enterocolitis (NEC) or an intestinal surgical anomaly
iii. Preterm babies with a lethal congenital anomaly, dysmorphism or aneuploidy"
Interventions Intervention: "Bacillus clausii containing 2×109 spores in 5 ml minibottle in a dose of 2 ml per‐oral every 8 h mixed with the
enteral feeds through orogastric tube or oral feeds, giving them 2.4×109 spores per day. Probiotic supplementation was
continued till postnatal age of 6 weeks, or till discharge or death or occurrence of LOS, whichever was earlier for babies
in both"
Control: "Babies in the placebo group received sterile water, 2 ml per‐oral every 8 h mixed with feeds"
Outcomes Mortality, sepsis, NEC
Notes Data were taken from table 3 and 4. We combined the numbers for very preterm and extreme preterm babies
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomization was done using an online service (www.
randomization.com)"
Allocation concealment (selection bias) Low risk Quote: "Serially numbered opaque sealed envelopes with the allocation
were available with the in‐charge nurse of the NICU, who dispensed the
intervention in a syringe for oral administration"
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Blinding of participants and personnel
(performance bias)
Low risk Quote: "All probiotic and sterile water mini bottles were coded and labels
concealed"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "All the investigators were blinded to the intervention"
Incomplete outcome data (attrition bias) Low risk Minimal loss to follow up
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
West et al. (1995)
Methods A randomized, double‐masked trial conducted in Nepal
Participants Inclusion criteria: Infants 5 months of age or younger
Exclusion criteria: Infants >5 months of age
Total number randomized in the intervention group: 5832
Total number randomized in the control group: 6086
Interventions Intervention:
– 15,000 RE (50,000 IU) vitamin A administered orally in approximately 3 drops of oil for neonates (<1 month old)
– 30,000 RE (100,000 IU) vitamin A administered orally in approximately 6 drops of oil for infants ages 1–5 months old
Control:
– 75 RE (250 IU) administered orally for neonates (<1 month old)
– 150 RE (500 IU) administered orally for infants ages 1–5 months old
Common intervention given to all groups: Approximately 3.3 IU vitamin E per drop of oil
Outcomes Primary outcome: Infant mortality, all‐cause mortality
Other outcomes: Malnutrition, ALRI, diarrhea or dysentery, whooping cough, meningitis, sudden death
Notes All analyses were completed on an intent‐to‐treat basis
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "After a random start, wards were systematically assigned, blocked
on VDAs, for infants to receive…"
Comment: Most likely done
Allocation concealment (selection bias) Low risk Quote: "…from gelatinous capsules of identical appearance"
Comment: Most likely done
Blinding of participants and personnel
(performance bias)
Low risk Quote: "The protocol and procedures for the trial were reviewed and
approved by the Nepal Medical Research Council, Kathmandu, and the
Joint Committee on Clinical Investigation at the Johns Hopkins
University School of Medicine, Baltimore"
Comment: Most likely done.
Blinding of outcome assessment
(detection bias)
Unclear risk Quote: "Verbal autopsy reports were independently reviewed by two
physicians (SKK and RA) who standardized their reviews for ‘S0 pre‐
study death reports"
Comment: Most likely done
Incomplete outcome data (attrition bias) Unclear risk Total number of loss to follow up: n (%)
The loss to follow up was not balanced
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Unclear risk No other risk of bias was noted
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Xu et al. (2016)
Methods A prospective, randomized, case‐controlled trial conducted in China
Participants Inclusion criteria: "hospital‐born formula‐fed infants with a gestational age of 30–37 weeks and a birth weight between
1500 and 2500 g"
Exclusion criteria: "severe neonatal pathologies, such as severe birth complications, GI malformations, chromosomal
abnormalities, known immunodeficiency, hydrops fetalis, central venous catheter, antifungal drugs, and probiotics"
Interventions Intervention: "The intervention group received Saccharomyces boulardii CNCM I‐745, administered two times per day as
separate medication, not mixed with formula, at a dosage of 50mg/kg. The study period ended at the 28th day after birth
or when the infant was discharged from the hospital. Minimum duration of intervention was 7 days"
Control: "Nothing was administered to the control group"
Outcomes Neonatal sepsis
Notes Data were taken from table 2
Risk of bias table
Bias
Authors'
judgement Support for judgement
Random sequence generation
(selection bias)
Low risk Quote: "Randomization was conducted according to a random computer‐
determined allocation order considering birth weight"
Allocation concealment (selection bias) Low risk Quote: "Blinding was possible because the nursing staff who administered
S. boulardii to the infants was not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"
Comment: Less likely that randomization sequence was revealed
Blinding of participants and personnel
(performance bias)
Low risk Quote: "Blinding was possible because the nursing staff who administered
S. boulardii to the infants was not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"
Blinding of outcome assessment
(detection bias)
Low risk Quote: "Blinding was possible because the nursing staff who administered
S. boulardii to the infants was not involved in the daily care and the
attending neonatal team was unaware of the randomization
assignments"
Incomplete outcome data (attrition bias) High risk Quote: "25 (20%) patients were considered dropouts"
Selective reporting (reporting bias) Low risk Authors seem to report all the outcomes irrespective of their statistical
significance
Other bias Low risk No other risk of bias was noted
Characteristics of excluded studies
Abdulkadir et al. (2016)
Reason for exclusion Study conducted in a high income country (UK)
Abrahamse‐Berkeveld et al. (2016)
Reason for exclusion Study conducted in a high income country (Germany and Italy)
Abrahamsson et al. (2005)
Reason for exclusion No relevant outcomes were found
ADAPTS trial (2019)
Reason for exclusion Wrong settings: Ongoing study in Australia
Agarwal et al. (2003)
Reason for exclusion No relevant clinical outcomes were reported
Agarwal (2018)
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Reason for exclusion Study conducted in a high income country (Australia)
Ahmadipour et al. (2019)
Reason for exclusion Study conducted to treat neonatal Jaundice.
Ahmadpour Kacho et al. (2005)
Reason for exclusion No relevant outcomes were reported
Al‐Hosni et al. (2012)
Reason for exclusion Study conducted in a high income country (USA)
Ala‐Houhala et al.(1988)
Reason for exclusion Study conducted in a high income country (Finland)
Allen et al. (2010)
Reason for exclusion Study conducted in high income country (UK)
Armanian et al. (2014)
Reason for exclusion Study participants were given only Prebiotics and no probiotics
Arthur et al. (1992)
Reason for exclusion Study population did not include Neonates
Aryayev et al. (2018)
Reason for exclusion Study conducted in high income country
Athalye‐Jape et al. (2018)
Reason for exclusion Study conducted in high income country
Awad et al. (2010)
Reason for exclusion Study was retracted
Ayah et al. (2007)
Reason for exclusion Vitamin A was given at 14 weeks
Aydin et al. (2012)
Reason for exclusion Population included children with Congential Heart disease only
Baglatzi et al. (2016)
Reason for exclusion Study conducted in a high income country
Bakker (2005)
Reason for exclusion Study continued supplementation of probiotics for 4 months
Bakker Zierikzee (2005)
Reason for exclusion Study conducted in a high income country (Netherland)
Bin‐Nun et al. (2005)
Reason for exclusion Study conducted in Israel
Bocquet et al. (2013)
Reason for exclusion Study conducted in a high income country (France)
Bonati (1993a)
Reason for exclusion Study conducted in a high income country (Italy)
Bonati (1996b)
Reason for exclusion Study conducted in a high income country (Italy)
Bora & Deori (2019)
Reason for exclusion Study compared two forms of the same intervention
Cekola et al. (2015)
Reason for exclusion Study conducted in a high income country (USA)
Chabra et al. (2013)
Reason for exclusion Study conducted in a high income country (USA)
Chandel et al. (2017)
Reason for exclusion No relevant clinical outcomes were available
Chi (2019)
Reason for exclusion No clinical outcomes were available
Chouraqui et al. (2008)
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Reason for exclusion Study conducted in a high income country (France)
Chrzanowska‐Liszewska (2011)
Reason for exclusion Study conducted in a high income country (Poland)
Chua et al. (2017)
Reason for exclusion Study conducted in a high income country (Netherland)
Corkins & Kovacevich (2001)
Reason for exclusion Study conducted UK
Costalos et al. (2003)
Reason for exclusion Study conducted in a high income country (Greece)
Costeloe (2016)
Reason for exclusion Study conducted in a high income country (UK)
Coutsoudis et al. (1996)
Reason for exclusion No clinical outcomes were available
Dani et al. (2002)
Reason for exclusion Study conducted in high income country (
Darboe et al. (2007)
Reason for exclusion Study conducted on wrong study population (infants)
Delimont et al. (2019)
Reason for exclusion Study conducted on older children and used Sorghum‐Based and
Corn‐Based Fortified Blended Foods
Delvin et al. (2000)
Reason for exclusion Study conducted in a high income country (US)
Deng & Chen (2010)
Reason for exclusion No abstract or full text available and no relevant outcomes were
available.
Denkel et al. (2017)
Reason for exclusion Study conducted in a high income country (Germany)
Deshpande 2016
Reason for exclusion Study conducted in high income country
Diaby et al. (2018)
Reason for exclusion Observational study assessing the coverage of vitamin A
supplementation
Dilli et al. (2013)
Reason for exclusion Study conducted on wrong patient population (infants with
congenital heart diseases)
Elom et al. (2019)
Reason for exclusion Wrong study population
Escribano et al. (2018)
Reason for exclusion Study conducted in a high income country (Spain)
Galderisi et al. (2016)
Reason for exclusion The study investigated glucose monitoring and not the dextrose gel
Garg et al. (2017)
Reason for exclusion Wrong study design (retrospective cohort study)
Garland et al. (2011)
Reason for exclusion Study conducted in a high income country (Australia)
Garofoli et al. (2018)
Reason for exclusion Wrong setting
Gomber (1996)
Reason for exclusion Wrong study design
Gomez‐Rodriguez et al. (2019)
Reason for exclusion
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Compared two different regimens of probiotics. No placebo group
was included.
Gonchar et al. (2016)
Reason for exclusion No relevant outcomes were available. Study only available in the
form of abstract. Authors were contacted for full text but no
response
Guo‐Qiang et al. (2016)
Reason for exclusion Wrong study design
Hammerman & Bin‐nun (2007)
Reason for exclusion Wrong intervention
Harris et al. (2016)
Reason for exclusion Study conducted in New Zealand
Hays (2015)
Reason for exclusion Study conducted in a high income country
Hoy‐Schulz et al. (2016)
Reason for exclusion Study conducted on wrong patient population
Hoyos (1999)
Reason for exclusion Wrong study design
Hua et al. (2014)
Reason for exclusion
Only abstract available and no relevant clinical outcomes were
available
Huang et al. (2016)
Reason for exclusion No relevant outcomes were available
Hunter et al. (2012)
Reason for exclusion Wrong study design
Härtel (2019)
Reason for exclusion The study is being conducted in a high income country (Germany)
Idindili et al. (2007)
Reason for exclusion Study conducted on wrong patient population
Indrio et al. (2008)
Reason for exclusion Study conducted in a high income country
IRCT (2015)
Reason for exclusion Wrong comparison
Jacobs (2017)
Reason for exclusion Study conducted in a high income country
Janvier et al. (2014)
Reason for exclusion Study conducted in a high income country
Kahbazi et al. (2019)
Reason for exclusion Wrong study population
Kanic et al. (2015)
Reason for exclusion Study conducted in a high income country
Karthikeyan & Bhat (2017)
Reason for exclusion Study conducted in a high income country
Kiatchoosakun (2014)
Reason for exclusion No relevant outcomes were available
Kirkwood et al. (2010)
Reason for exclusion Wrong study design
Kliegman (2005)
Reason for exclusion Wrong study design
Koksal et al. (2015)
Reason for exclusion Only abstract was available and no analyzable data were reported
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Kukkonen et al. (2008)
Reason for exclusion Wrong study design
Leele et al. (2015)
Reason for exclusion Study conducted in a high income country (Singapore)
Li (2019)
Reason for exclusion The intervention continued for 4 months
Lin (2009)
Reason for exclusion Study conducted in a high income country (Taiwan)
Long & Dempsey (2018)
Reason for exclusion Study conducted in a developed country
Lozano (2008)
Reason for exclusion Study conducted in a high income country
Lund et al. (2014)
Reason for exclusion
The control group did not receive the placebo but polio vaccine. It is
difficult to tease out the effect of vitamin A supplementation vs.
No vitamin A supplementation.
Lundelin et al. (2017)
Reason for exclusion Study conducted in a high income country
Mactier et al. (2012)
Reason for exclusion Study conducted in a high income country
Maldonado‐Lobon (2015)
Reason for exclusion Study conducted in a high income country
Manzano et al. (2017)
Reason for exclusion Study conducted in a high income country (Spain)
Manzoni et al. (2006)
Reason for exclusion Study conducted in a high income country (Italy)
Manzoni et al. (2009)
Reason for exclusion Study conducted in a high income country (italy)
Marissen et al. (2019)
Reason for exclusion This is an ongoing study in Germany which is a high income country.
Martins et al. (2009)
Reason for exclusion Wrong study population
Materna (2010)
Reason for exclusion Study conducted in a high income country
McCulloch et al. (2012)
Reason for exclusion Study conducted in a high income country (UK)
McKinlay (2016)
Reason for exclusion Study conducted in a high income country
Meyer & Gortner (2014)
Reason for exclusion Study conducted in a high income country (Germany)
Mg (2011)
Reason for exclusion Study conducted in a high income country (Italy)
Mihatsch et al. (2010)
Reason for exclusion Study conducted in a high income country (Germany)
Millar (2017)
Reason for exclusion Study conducted in a high income country
Moles et al. (2015)
Reason for exclusion Study conducted in high income country
Nadella et al. (2019)
Reason for exclusion Wrong intervention
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Nct (2006)
Reason for exclusion Study conducted in high income country
Nct (2016)
Reason for exclusion Wrong settings
Papagaroufalis et al. (1991)
Reason for exclusion Study conducted in high income country (Greece)
Papagaroufalis et al. (2014)
Reason for exclusion Study conducted in high income country (Greece)
Patole et al. (2016)
Reason for exclusion Study conducted in a high income country (Australia)
Pearson et al. (1992)
Reason for exclusion Study conducted in a high income country (USA)
Plummer et al. (2018)
Reason for exclusion Study conducted in a high income country (Australia)
Puccio et al. (2007)
Reason for exclusion Study conducted in a high income country (Italy)
Qiao et al. (2017)
Reason for exclusion No relevant outcomes were available
Radke et al. (2017)
Reason for exclusion Study conducted in a high income country (Germany)
Raguž et al. (2016)
Reason for exclusion Wrong study design
Rakshasbhuvankar et al. (2017)
Reason for exclusion Study conducted in a high income country (Australia)
Rawat et al. (2016)
Reason for exclusion Study conducted in the USA
Repa et al. (2015)
Reason for exclusion Study conducted in a high income country (Austria)
Robbins & Fletcher (1993)
Reason for exclusion wrong comparator
Rodriguez‐Herrera et al. (2019)
Reason for exclusion Study conducted in a high income country
Rodríguez (2015)
Reason for exclusion Study compared two forms of Probiotics and no comparison with
placebo was available
Rohan (2016)
Reason for exclusion Study conducted in a high income country (UK)
Ross et al. (1993)
Reason for exclusion Study included children 6 months and older
Rouge et al. (2009)
Reason for exclusion Study conducted in a high income country (France)
Rubaltelli et al. (2000)
Reason for exclusion Study conducted in a high income country (Italy)
Sadowska‐Krawczenko et al. (2012)
Reason for exclusion Study conducted in a high income country (Germany)
Samuels et al. (2016)
Reason for exclusion Study conducted in a high income country (Netherland)
Shenai et al. (1987)
Reason for exclusion Study conducted in a high income country (USA)
Smilowitz et al. (2017)
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Reason for exclusion Study conducted in a high income country (USA)
Storm et al. (2019)
Reason for exclusion Study conducted in a high income country USA
Stratiki et al. (2007)
Reason for exclusion Study conducted in a high income country (Greece)
Strus et al. (2018)
Reason for exclusion Study conducted in a high income country (Poland)
Ter (2017)
Reason for exclusion Study conducted in Australia
Thanhaeuser et al. (2014)
Reason for exclusion Study conducted in a high income country (Austria)
Totsu et al. (2014)
Reason for exclusion Study conducted in a high income country (Japan)
Tyson et al. (1999)
Reason for exclusion Study conducted in a high income country (USA)
Venkatarao et al. (1996)
Reason for exclusion Infant received vitamin A at 6 months
Vlieger et al. (2009)
Reason for exclusion Study conducted in high income country (Netherland)
Wardle et al. (2001)
Reason for exclusion Study conducted in high income country (UK)
West et al. (1991)
Reason for exclusion Study included children 6‐59 months of age
Yang et al. (2011)
Reason for exclusion Full text not available and no abstract was available either so no
relevant outcomes were available.
Characteristics of studies awaiting classification
Barclay et al. (2003)
Methods Randomized controlled trial
Participants Term infants
Interventions Formula with pre‐pro and synbiotics
Outcomes Growth
Notes Study available only in the abstract form
Chubarova and Sharyafetdinova (2017)
Methods Randomized Controlled trial
Participants Preterm neonates
Interventions A combination of freeze‐dried strains of lactobacilli and bifidobacteria: Lactobacillus rhamnosus, Bifidobacterium infantis,
Bifidobacterium longum, Lactobacillus acidophilus (at time of manufacture 2 billion CFUs per 3 g of the preparation), also
containing the additional component maltodextrin. The comparison group received placebo
Outcomes NEC and stay in NICU and others
Notes Only abstract available. It is not clear on where the study was done
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Characteristics of ongoing studies
DelPiano (2016)
Study name Our open‐label, randomized controlled study has the primary endpoint of reducing diarrhea and infectious diseases
(number of episodes/severity) and the secondary endpoint of decreasing infant mortality
Methods Randomized control trial
Participants The trial is currently conducted in Luzira, a suburb of Kampala, the capital of Uganda, and in Gulu and Lira, in the north
of Uganda.The study is projected to enrol 4000 babies (control = 2000 and treatment=2000) who will be followed
till 1 year of life. As controls, 2000 babies of the same community are planned to be considered
Interventions The probiotic product selected for the trial is composed of 3 designated microorganisms, namely Bifidobacterium breve
BR03 (DSM 16604), B. breve B632 (DSM 24706), and Lactobacillus delbrueckii subsp. delbrueckii LDD01 (DSM
22106)
Outcomes Incidence of diarrhea and mortality
Starting date
Contact information Gastroenterology Department, Santa Rita Hospital‐Policlinico di Monza †Department of Gynecology and Obstetrics,
Santa Rita Hospital‐Policlinico di Monza, Vercelli ‡Biolab Research Ltd, Novara, Italy
Notes
Goodman (2015)
Study name Prevention of vitamin A deficiency by supplementation alongside routine vaccinations: a randomised controlled
trial in Ghana infants
Methods Randomised controlled trial
Participants Participant inclusion criteria
1. Mothers normally resident in the study area
2. Informed consent obtained from the mother
Participant exclusion criteria
1. Mothers unable to give informed consent
2. Mothers considered to be at high risk of adverse outcome in puerperal period
3. Multiple deliveries
4. Severe adverse reaction to vitamin A supplementation
Interventions 1st Group:
1. Mothers 200,000 IU vitamin A shortly after delivery
2. Infants: 25,000 IU vitamin A with each Diphtheria, Pertussis, Tetanus (DPT) vaccine 1, 2 and 3
2nd Group:
1. Mothers 200,000 IU vitamin A at infant's Bacillus Calmette‐Guerin (BCG) vaccine and another 200,000 IU
vitamin A at infant's 1st DPT
2. Infants: 50,000 IU vitamin A with each DPT 1, 2 and 3
Outcomes Primary outcome measure
1. Serum retinol levels, assessed by carrying out mRDR testing of infants at 6 weeks, 6 and 9 months
2. Modified Retinol Dose Response (mRDR) tests
3. Incidence of side effects such as bulging of the anterior fontanel and vomiting
4. Incidence of severe morbidity
Secondary outcome measures
1. Breast milk retinol concentrations, assessed at 6 weeks, 6 and 9 months for an assessment of the impact of
the different supplementation regimes
2. mRDR testing of infants at 9 months of age
Starting date 01/01/2004




Notes No results are available
Heydarabad (2018)
Study name Evaluation of the effect of probiotics on late‐onset sepsis in very preterm newborns
Methods A randomized, triple blinded, placebo controlled clinical trial with two parallel groups
Participants Inclusion criteria include: 1. Preterm infants weighting 1000‐1500 g and <32 weeks’ gestational age at birth 2.
Enrolled within 48 h of birth
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Exclusion criteria: (a) Major congenital anomalies (Esophageal atresia,omphalocele, imperforate anus). (2) Major
congenital heart malformations. (3) Genetic anomalies(e.g. Trisomy 21 or other trisomies). (4) Considered
likely to die within 72 h of birth. (5) Death before minimal entral feeding (10‐20cc/kg/day). (6) Parents from
whom informed consent cannot be obtained. (7) Sepsis in admission (CRP > 10mg/dl in 1th day of
admission). (8) Asphyxia (grade II, III). (9) Maternal chorioamnionitis
Interventions Very low‐birth‐weight preterm infants with a gestational age of <32 weeks and a weight of 1000‐1500 gr who
are admitted to the NICU of Shahid Motahari Hospital in Urmia during the first 48 h of their birth. Patients
are randomly divided into two groups; the intervention group receive probiotic and the control group
receive Dish water as placebo
Outcomes Late onset sepsis
Starting date 2018‐03‐05
Contact information Kamran Dehghan




Study name Effect of probiotic supplementation on feed tolerance and weight gain in low birth weight infants on tube feeds
Methods Randomized, parallel group trial
Participants Inclusion criteria: All neonates with a birth weight between 1000 and 1800 gm admitted to the NICU in whom
enteral feeds can be started.
Exclusion criteria:
Neonates with weight <1000 gm
Neonates with gastrointestinal anomalies
Neonates with major congenital malformations
Neonates in whom the feed could not be started by day 14 of life
Interventions Intervention 1: Probiotic: Probiotic containing Lactibacillus acidophilus, Lactibacillus rhamnosus, Bifidobacterium
longum, Saccharomyces boulardi in form of powdered sachet of 1 g each
Control Intervention 1: Nil: Nil
Outcomes To compare the time taken (in days) to reach full enteral feeds (150ml/kg/day) in low birth weight infants on
orogastric feeds between the probiotic and no probiotic group
To compare episodes of feed intolerance and weight gain in both the groups.Timepoint: Time taken to reach full
enteral feeds
Starting date 31‐07‐2018








Study name Use of zinc and pre‐probiotics as a therapeutic adjunct in neonatal sepsis in preterms‐ An Open label
randomized controlled trial
Methods Randomized, parallel group, multiple arm trial
Participants All intramural preterm neonates from 28 week 1day to 36 week 6 days admitted to NICU at GMCH
Aurangabad with proven sepsis during the study period, whose parents consented to be part of the study
were included
Diagnostic criteria for sepsis was
(a) Positive “sepsis screen,” that is, presence of at least two of the following three parameters, namely, Total
leucocyte count <5000/mm3, Low absolute neutrophil count (as per standard charts), C‐reactive
protein>1mg/dl,
(b) Radiological evidence of pneumonia
(c) Culture positive sepsis
(d) Meningitis
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Interventions Zinc and prebiotics: zinc and pre‐probiotic group was given both zinc 10mg per day and pre‐probiotics as syrup
5ml per day containing L. acidophilus (1.25 billion), B. longum (0.125 billion), B. bifidum (0.125 billion), B.
lactis (1 billion) and Inulin (25mg) till discharge
Zinc: Zinc group was given oral zinc 10mg once a day irrespective of age of newborn till discharge.
Pre‐biotic group: Pre‐probiotics group was given as Syrup 5ml per day containing L. acidophilus (1.25 billion), B.
longum (0.125 billion), B. bifidum (0.125 billion), B. lactis (1 billion) and Inulin (25mg) till discharge
Control: Not receiving any of the above
Outcomes Reduction in mortality
Starting date Date Completed: 31/08/2016





Notes Description results are available at the web site where the clinical trial was registered. We wrote to authors to
obtain the results
Mirmohammdi (2018)
Study name Determination of the effect of probiotics on prevention of necrotizing enterocolitis in preterm infants
Methods This randomized clinical trial will be conducted on preterm infants with low birth weight and very low birth
weight.
Participants Inclusion criteria: VLBW infants (gestational age ≤34 weeks and birth weight ≤1500 g) survive until the onset of
oral nutrition
Exclusion criteria: (1) Severe asphyxia (stage III) (2) Congenital major anomalies (3) Babies who have not started
oral feeding for 3 weeks after birth. (4) Infants receiving antifungal treatment
Interventions The intervention group consisted of newborn infants with probiotic podilakat made by Iran Fertilizer Company
in a quantity of 1 drops per kg of weight every 12 h with breast milk or milk powder
The control group is a neonate who will receive 0.5 cc normal saline every 12 h with breastfeeding or
breastfeeding
Outcomes Baby weight at the end of the 3rd month
Starting date 2019‐07‐29
Contact information mir farhad mirmohammdi




Study name Role of prophylactic microbial supplements in prevention of blood stream infection and intestinal tract injury in
premature neonates
Methods Randomized, parallel group trial
Participants All infants admitted to our NICU with birth weight <2 kg or gestational age <35 weeks as assessed by EDD and
further confirmed by Ballards score who survive the first 24 hrs of life will be enrolled in the study
Interventions Mixture of Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, and Streptomyces boulardii in
a dose of 1.25 billion CFU twice daily started with the first feed which can be in the form of expressed
breast milk or preterm formula feed and continued till discharge
The control group will receive expressed breast milk or preterm formula feed with no supplements added
Outcomes 1. Necrotising colitis
2. Nosocomial sepsis
In preterm low birth weight babies
Starting date 01/12/2012







Notes Study started in 2012 but no results have been published yet
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Nandhini 2012
Study name A clinical study to analyse the effectiveness of administration of harmless bacteria in preventing infection of
intestine in preterm babies
Methods Randomized, parallel group trial
Participants Inclusion criteria:








Interventions Intervention 1: probiotics: Bifidobacterium and Lactobacilli species‐ capsule(available as pre pro HS capsules
marketed by fourrts limited) one capsule, administered twice a day orally mixed with breast milk for 7 days
Control Intervention 1: none
Outcomes Incidence and severity of NEC. Timepoint: during period of hospital stay
Starting date 15‐02‐2011





Notes The web site said that the study is completed. We wrote to authors to ask for the results
Punnahitananda, 2011
Study name Effect of oral probiotic supplementation on the rate of hospital acquired infection and necrotizing enterocolitis
in preterm very low birth weight infants
Methods Randomized controlled study
Participants Participant inclusion criteria
1. VLBW preterm infants (gestational age (GA) < 35 weeks, body weight (BW) < 1.5 kg)
2. Admitted to the neonatal intensive care unit (NICU) who survived the first 3 days of life
Participant exclusion criteria
1. Infants with chromosome abnormality
2. Infants with severe congenital defects
3. Infants with gastrointestinal anomalies (e.g., omphalocele, gastroschisis, intestinal obstruction)
4. Infants with unstable hemodynamic status
Interventions Daily enteral probiotic supplementation of live Lactobacillus acidophilus and Bifidobacterium infantis at a dose of
2.5 ×108 CFU of each strain once a day for at least 28 days versus placebo
Outcomes Primary outcome measure
Nosocomial Infections
Secondary outcome measures
1. Necrotizing enterocolitis (NEC)
2. Feeding tolerance
3. Time to reach full enteral feeding
Starting date 28/04/2011








Study name Probiotics for prevention of necrotising enterocoilitis in preterm neonates
Methods Randomized, parallel group, placebo controlled trial
Participants 1. gestational age 28–34 weeks
2. Birth weight of <2 kg
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Exclusion criteria: Preterm newborn
1. Birth weight >2 kg
2. Lethal Congenital malformation
3. Newborn on ventilator
Interventions Intervention 1: giving probiotics: 50% of preterm newborn are given probiotics while rest 50% are not given
probiotics
Intervention 2: giving probiotics: 50% of preterm newborn are given probiotics while rest 50% are not given
probiotics
Control Intervention 1: not applicable
Outcomes Occurrence of necrotising enterocolitis
Starting date 28/09/2017
Contact information Mahendra Rathod





Notes It is not clear if the study is completed.
Razavi, 2014
Study name Effect of probiotic in prevention of necroziting entrocolitis in preterm infants in Hafez hospital
Methods Randomized, blinding: double blinded, placebo
Participants Inclusion criteria: premature neonates with 1500 gr and below that are stable and tolerate (10cc/kg/day)
formula or breast milk.Exclusion criteria: decline to participate; severe congenital anomaly; death
Interventions Intervention group: add probiotics (Probiotic drops Pedilact Manufacturing zist takhmir) milk at the rate of 0/
1cc/kg/day until hospital
Control group: The control group was used as control and did not receive drug
Outcomes Sign and symptom of NEC
Starting date 2014‐05‐22
Contact information Dr.Seyed Mostajab Razavi





Study name A study of the effect of probiotic organism administration on feeding tolerance in very low birth weight
newborn babies
Methods Randomized, parallel group, active controlled trial
Participants Inclusion criteria: All neonates (infants in the first 28 days of life) with a birth weight <1.5 kg, admitted to NICU
SJMCH Bangalore. Postnatal age <2 wks and started enteral feeds.
Exclusion criteria: Neonates GI tract anomalies, severe congenital malformations.
Interventions Intervention 1: probiotic sachets: Lactobacillus Spp, Bifidobacter Spp, Saccharomyces boulardi
oral 1 sachet once a day orally mixed in breast milk till discharge
Control Intervention 1: breast milk: breast milk only
Outcomes Incidence of feed intolerance
Incidence of NEC stage 2 or more
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Sinha, 2019
Study name Phase III, multicentre, randomized, double‐blind, placebo‐controlled study to evaluate efficacy of probiotic
supplementation for prevention of neonatal sepsis in 0–2 months old low birth weight infants in India
Methods Randomized, parallel group, placebo controlled trial
Participants Inclusion criteria:
1. Birth weight: 1500 g to 500 g
2. Age of the new‐born Day 3‐7 on recruitment, that is, not later than 7th day
3. Stable clinical condition as assessed by physician and accepting feeds orally (where stable is defined as,
does not require intravenous fluids and vasopressor medication to maintain circulation and accepts oral
feeding or breastfeeding).
4. The mother (with the new‐born) is planning to stay in study area for a period of at least 2 months
Exclusion criteria:
1. New born with extreme prematurity, that is, <34 weeks
2. New born with illness requiring prolonged hospitalisation and interference with oral feeding
3. Presence of a gross congenital malformation incompatible with life
4. Parent or Legally authorized representative (LAR) not providing written consent
Interventions Intervention 1: Vivomixx Drops, that is, Lactic acid bacteria and Bifidobacteria drop with medium chain
triglyderide oil.
1. Each bottle cap contains at least 50 Billion Lactic acid bacteria and Bifidobacteria
a. Streptococcus thermophilus DSM 24731
b. Bifidobacterium longum DSM 24736, B. breve DSM 24732 and B. infantis DSM 24737)
c. Lactobacillus acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, and L. delbrueckii
subs. bulgaricus DSM 24734
2. Each bottle contains MCT, that is, Medium chain triglyceride oil 5 ml.
The contents of the cap should be mixed with MCT oil and shaken well prior to administration. Store in
refrigerator at 2–8°C: 1 ml per day for 30 days (corresponding to NLT 10 billion CFU per day)
Control Intervention 1: Placebo Drops
1. Each Bottle cap contains Maltodextrin
2. Each bottle contains MCT, that is, Medium chain triglyceride oil 5 ml
The contents of the cap should be mixed with MCT oil and shaken well prior to administration. Store in
refrigerator at 2‐ 8 degrees centigrade.: 1 ml per day for 30 days
Outcomes 1. Sepsis
2. Possible serious bacterial infections (PSBIs). Timepoint: 60 days
Starting date Date of first enrolment: 01‐12‐2019
Contact information Division of Reproductive, Maternal and Child Health





Notes Study started in Jan 2019
Summary of findings tables
Additional tables
DATA AND ANALYSES
1. Vitamin A versus control
Outcome or subgroup Studies Participants Statistical method Effect estimate
11. All‐cause neonatal mortality 6 126548 Risk ratio (IV, Random, 95% CI) 0.99 [0.90, 1.08]
12. All‐cause infant mortality at 6
months 12 154940 Risk ratio (IV, Random, 95% CI) 0.98 [0.89, 1.07]
13. All‐cause infant mortality at 12
months 8 118376 Risk ratio (IV, Random, 95% CI) 1.04 [0.94, 1.14]
14. Adverse events: bulging
fontanelle 6 100256 Risk ratio (IV, Random, 95% CI) 1.53 [1.12, 2.09]
15. Adverse events: vomiting 5 99582 Risk ratio (IV, Random, 95% CI) 1.00 [0.93, 1.07]
16. All‐cause neonatal mortality:
sensitivity analysis: fixed effect
model 5 126242 Risk ratio (IV, Fixed, 95% CI) 0.99 [0.90, 1.08]
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17. All‐cause infant mortality at 6
months: sensitivity analysis: fixed
effect model 12 154940 Risk ratio (IV, Fixed, 95% CI) 0.97 [0.91, 1.03]
18. All‐cause infant mortality at 12
months: sensitivity analysis: fixed
effect model 8 118376 Risk ratio (IV, Fixed, 95% CI) 1.02 [0.96, 1.08]
2. Probiotics versus control
Outcome or subgroup Studies Participants Statistical method Effect estimate
21. All‐cause mortality 26 10998 Risk ratio (IV, Random, 95% CI) 0.80 [0.66, 0.96]
22. All‐cause mortality: subgroup
analysis: settings 26 10998 Risk ratio (IV, Random, 95% CI) 0.80 [0.66, 0.96]
221. Hospital based 23 4691 Risk ratio (IV, Random, 95% CI) 0.78 [0.65, 0.94]
222. Community based 3 6307 Risk ratio (IV, Random, 95% CI) 1.25 [0.51, 3.05]
23. All‐cause mortality: subgroup
analysis: type of probiotics 26 10998 Risk ratio (IV, Random, 95% CI) 0.80 [0.66, 0.96]
231. Preparation contain a single
strain of probiotics 9 2242 Risk ratio (IV, Random, 95% CI) 0.80 [0.61, 1.05]
232. Preparation contained multiple
strains of probiotics 12 3050 Risk ratio (IV, Random, 95% CI) 0.80 [0.58, 1.09]
233. Preparation contained synbiotics
(prebiotics + probiotics) 5 5706 Risk ratio (IV, Random, 95% CI) 0.69 [0.29, 1.61]
24. All‐cause mortality: subgroup
analysis: type of participants 26 10998 Risk ratio (IV, Random, 95% CI) 0.80 [0.66, 0.96]
241. Study include preterm/low birth
weight babies 25 10587 Risk ratio (IV, Random, 95% CI) 0.79 [0.65, 0.95]
242. Study included term infants only 1 411 Risk ratio (IV, Random, 95% CI) 1.38 [0.31, 6.08]
25. All‐cause mortality: subgroup
analysis: type of feedings 26 10998 Risk ratio (IV, Random, 95% CI) 0.80 [0.66, 0.96]
251. Baby received breastmilk only 14 7721 Risk ratio (IV, Random, 95% CI) 0.81 [0.62, 1.05]
252. Baby received formula milk only 1 411 Risk ratio (IV, Random, 95% CI) 1.38 [0.31, 6.08]
253. Baby recieved both both
breastmilk and formula milk 8 2385 Risk ratio (IV, Random, 95% CI) 0.69 [0.48, 0.99]
254. Type of feeding was unclear 3 481 Risk ratio (IV, Random, 95% CI) 1.33 [0.63, 2.81]
26. All‐cause mortality: subgroup
analysis: probiotics preparation 26 10998 Risk ratio (IV, Random, 95% CI) 0.80 [0.66, 0.96]
261. Preparation contained
Lactobacillus 10 7002 Risk ratio (IV, Random, 95% CI) 0.82 [0.63, 1.05]
262. Preparation contained
Bifidobacterium 1 400 Risk ratio (IV, Random, 95% CI) 0.43 [0.17, 1.09]
263. Preparation contained both
Lactobacillus and Bifidobacterium 13 3110 Risk ratio (IV, Random, 95% CI) 0.71 [0.47, 1.08]
264. Preparation contained
Saccharomyces boulardii only 2 486 Risk ratio (IV, Random, 95% CI) 1.12 [0.46, 2.71]
27. All‐cause mortality: sensitivity
analysis: fixed effect models 26 10998 Risk ratio (IV, Fixed, 95% CI) 0.80 [0.66, 0.96]
28. All‐cause mortality: sensitivity
analysis: risk of bias 26 10998 Risk ratio (IV, Random, 95% CI) 0.80 [0.66, 0.96]
281. High Risk of bias for
randomisation/allocation
concealment 3 285 Risk ratio (IV, Random, 95% CI) 0.27 [0.05, 1.40]
282. Low or Unclear Risk of bias for
randomisation/allocation
concealment 23 10713 Risk ratio (IV, Random, 95% CI) 0.82 [0.68, 0.99]
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29. Necrotizing enterocolitis
(any type) 30 5574 Risk ratio (IV, Random, 95% CI) 0.46 [0.35, 0.59]
210. Necrotizing enterocolitis:
subgroup analysis: probiotic
preparation 30 5574 Risk ratio (IV, Random, 95% CI) 0.46 [0.35, 0.59]
2101. Preparation contained
Lactobacillus 13 2738 Risk ratio (IV, Random, 95% CI) 0.39 [0.25, 0.61]
2102. Preparation contained
Bifidobacterium 1 400 Risk ratio (IV, Random, 95% CI) 0.20 [0.09, 0.47]
2103. Preparation contained both
Lactobacillus and
Bifidobacterium 14 1950 Risk ratio (IV, Random, 95% CI) 0.49 [0.36, 0.68]
2104. Preparation contained
Saccharomyces boulardii only 2 486 Risk ratio (IV, Random, 95% CI) 0.94 [0.45, 1.95]
211. Necrotizing enterocolitis:
subgroup analysis: type of
feeding 30 5574 Risk ratio (IV, Random, 95% CI) 0.46 [0.35, 0.59]
2111. Baby receieved breastmilk only 13 1945 Risk ratio (IV, Random, 95% CI) 0.43 [0.31, 0.59]
2112. Baby receieved formula
milk only 1 93 Risk ratio (IV, Random, 95% CI) 0.21 [0.03, 1.76]
2113. Baby received both breastmilk
and formula milk 9 2445 Risk ratio (IV, Random, 95% CI) 0.55 [0.33, 0.92]
2114. Type of feeding was unclear 7 1091 Risk ratio (IV, Random, 95% CI) 0.41 [0.17, 1.00]
212. Necrotizing enterocolitis:
subgroup analysis: type of
probiotics 30 5574 Risk ratio (IV, Random, 95% CI) 0.46 [0.35, 0.59]
2121. Preparation contained a single
strain of probiotics 12 2679 Risk ratio (IV, Random, 95% CI) 0.48 [0.30, 0.76]
2122. Preparation contained multiple
strains of probiotics 15 2156 Risk ratio (IV, Random, 95% CI) 0.48 [0.35, 0.67]
2123. Preparation contained
synbiotics
(prebiotics + probiotics) 3 739 Risk ratio (IV, Random, 95% CI) 0.28 [0.12, 0.67]
213. Necrotizing enterocolitis:
sensitivity analysis: fixed effect
models 30 5574 Risk ratio (IV, Fixed, 95% CI) 0.45 [0.37, 0.56]
214. Necrotizing enterocolitis:
sensitivity analysis: risk of bias 30 5574 Risk ratio (IV, Random, 95% CI) 0.46 [0.35, 0.59]
2141. Low or unclear risk of bias for
randomisation/allocation
concealment 27 5289 Risk ratio (IV, Random, 95% CI) 0.46 [0.35, 0.61]
2142. High risk of bias for
randomisation/allocation
concealment 3 285 Risk ratio (IV, Random, 95% CI) 0.33 [0.09, 1.13]
215. Neonatal sepsis 21 9105 Risk ratio (IV, Random, 95% CI) 0.78 [0.70, 0.86]
216. Neonatal sepsis: subgroup
analysis: settings 21 9105 Risk ratio (IV, Random, 95% CI) 0.78 [0.70, 0.86]
2161. Hospital based 19 3209 Risk ratio (IV, Random, 95% CI) 0.83 [0.76, 0.91]
2162. Community based 2 5896 Risk ratio (IV, Random, 95% CI) 0.67 [0.49, 0.91]
217. Neonatal sepsis: type of
probiotics 21 9105 Risk ratio (IV, Random, 95% CI) 0.78 [0.70, 0.86]
2171. Preparation contained single
strain of probiotics 8 1328 Risk ratio (IV, Random, 95% CI) 0.84 [0.74, 0.96]
2172. Preparation contained multiple
strains of probiotics 9 2482 Risk ratio (IV, Random, 95% CI) 0.81 [0.68, 0.97]
2173. Preparation contained
synbiotics
(prebiotics + probiotics) 4 5295 Risk ratio (IV, Random, 95% CI) 0.67 [0.54, 0.83]
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218. Neonatal sepsis: subgroup
analysis: type of feeding 21 9105 Risk ratio (IV, Random, 95% CI) 0.78 [0.70, 0.86]
2181. Baby received breastmilk only 8 6961 Risk ratio (IV, Random, 95% CI) 0.71 [0.61, 0.83]
2182. Baby received formula milk
o nly 2 218 Risk ratio (IV, Random, 95% CI) 0.59 [0.22, 1.56]
2183. Baby received both formula
and breastmilk only 7 1401 Risk ratio (IV, Random, 95% CI) 0.76 [0.64, 0.90]
2184. Type of feeding was unclear 4 525 Risk ratio (IV, Random, 95% CI) 0.95 [0.82, 1.09]
219. Neonatal sepsis: subgroup
analysis: probiotic preparation 21 9105 Risk ratio (IV, Random, 95% CI) 0.78 [0.70, 0.86]
2191. Preparation contained
Lactobacillus 11 7068 Risk ratio (IV, Random, 95% CI) 0.74 [0.62, 0.87]
2192. Preparation contained
Bifidobacterium 1 400 Risk ratio (IV, Random, 95% CI) 0.81 [0.60, 1.09]
2193. Preparation contained both
Bifidobacterium and
Lactobacillus 6 1026 Risk ratio (IV, Random, 95% CI) 0.83 [0.68, 1.02]
2194. Preparation contained
Saccharomyces boulardii only 3 611 Risk ratio (IV, Random, 95% CI) 0.73 [0.57, 0.94]
220. Neonatal Sepsis: Sensitivity
analysis: Fixed Effect Model 21 9105 Risk ratio (IV, Fixed, 95% CI) 0.79 [0.73, 0.85]
221. Neonatal sepsis: sensitivity
analysis: risk of bias 21 9105 Risk ratio (IV, Random, 95% CI) 0.78 [0.70, 0.86]
2211. Low or unclear risk of bias for
randomization/allocation
concealment 19 8892 Risk ratio (IV, Random, 95% CI) 0.79 [0.71, 0.87]
2212. High risk of bias due to
randomization/allocation
concealment 2 213 Risk ratio (IV, Random, 95% CI) 0.47 [0.25, 0.90]
222. Sepsis specifc mortality 2 4672 Risk ratio (IV, Random, 95% CI) 0.21 [0.04, 1.01]
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APPENDIX A
Literature Search Strategy
Medline Strategy using PubMed
Vitamin A
((((("Vitamin A"[Mesh]) OR (Vitamin A[tiab] OR Aquasol A[tiab]
OR Retinol[tiab] OR All Trans Retinol[tiab] OR All‐Trans‐Retinol[tiab]
OR Vitamin A1[tiab] OR Vitamin A 1[tiab] OR 11‐cis‐Retinol[tiab] OR
11 cis Retinol[tiab] OR Tretinoin[tiab]) AND Supplement*[tiab])) AND
(("Infant"[Mesh] OR "Premature Birth"[Mesh]) OR (Neonat*[tiab] OR
neo nat*[tiab]) OR (newborn* OR new Born*[tiab] OR newly born*
[tiab]) OR (preterm[tiab] OR preterms[tiab] OR pre term[tiab] OR pre
terms[tiab]) OR (premature*[tiab] AND (birth*[tiab] OR born[tiab]
OR deliver*[tiab])) OR (low[tiab] AND (birthweight*[tiab] OR birth
weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR elbw[tiab]) OR infant*
[tiab] OR (baby[tiab] OR babies[tiab])))) NOT ("Animals"[Mesh] NOT
("Animals"[Mesh] AND "Humans"[Mesh]))
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Glucose
(((((("Glucose"[Mesh]) OR (Dextrose OR Glucose[tiab]) AND
supplement*)))) AND (("Infant"[Mesh] OR "Premature Birth"[Mesh])
OR (Neonat*[tiab] OR neo nat*[tiab]) OR (newborn* OR new Born*
[tiab] OR newly born*[tiab]) OR (preterm[tiab] OR preterms[tiab] OR
pre term[tiab] OR pre terms[tiab]) OR (premature*[tiab] AND (birth*
[tiab] OR born[tiab] OR deliver*[tiab])) OR (low[tiab] AND (birth-
weight*[tiab] OR birth weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR
elbw[tiab]) OR infant*[tiab] OR (baby[tiab] OR babies[tiab])))) NOT
("Animals"[Mesh] NOT ("Animals"[Mesh] AND "Humans"[Mesh]))
Probiotics
((((("Probiotics"[Mesh] OR "Prebiotics"[Mesh] OR "Synbio-
tics"[Mesh]) OR (Probiotic*[tiab] OR prebiotic*[tiab] OR synbiotic*
[tiab]))) AND (("Infant"[Mesh]OR "Premature Birth"[Mesh]) OR
(Neonat*[tiab] OR neo nat*[tiab]) OR (newborn* OR new Born*[tiab]
OR newly born*[tiab]) OR (preterm[tiab] OR preterms[tiab] OR pre
term[tiab] OR pre terms[tiab]) OR (premature*[tiab] AND (birth*
[tiab] OR born[tiab] OR deliver*[tiab])) OR (low[tiab] AND (birth-
weight*[tiab] OR birth weight*[tiab])) OR (lbw[tiab] OR vlbw[tiab] OR
elbw[tiab]) OR infant*[tiab] OR (baby[tiab] OR babies[tiab])))) NOT
("Animals"[Mesh] NOT ("Animals"[Mesh] AND "Humans"[Mesh]))
CINAHL Strategies
Vitamin A
(MH”Vitamin A") OR TI ("Vitamin A" OR "Aquasol A" OR Retinol
OR "All Trans Retinol" OR "All‐Trans‐Retinol" OR "Vitamin A1" OR
"Vitamin A 1" OR "11‐cis‐Retinol" OR "11 cis Retinol" OR Tretinoin)
OR AB ("Vitamin A" OR "Aquasol A" OR Retinol OR "All Trans Re-
tinol" OR "All‐Trans‐Retinol" OR "Vitamin A1" OR "Vitamin A 1" OR
"11‐cis‐Retinol" OR "11 cis retinol" OR Tretinoin)
AND
TI (Supplement*) OR AB (Supplement*) OR MH "Dietary Sup-
plementation" OR MH "Dietary Supplements"
AND
(MH "Infant" OR MH "Infant, Premature" OR MH "Infant,
Newborn") OR TI ((Neonat* OR neo nat*) OR (newborn* OR new
Born* OR newly born*) OR (preterm OR preterms OR pre term OR
pre terms) OR (premature* AND (birth* OR born OR deliver*)) OR
(low AND (birthweight* OR birth weight*)) OR (lbw OR vlbw OR
elbw) OR infant* OR (baby OR babies)) OR AB ((Neonat* OR neo
nat*) OR (newborn* OR new Born* OR newly born*) OR (preterm OR
preterms OR pre term OR pre terms) OR (premature* AND (birth*
OR born OR deliver*)) OR (low AND (birthweight* OR birth weight*))
OR (lbw OR vlbw OR elbw) OR infant* OR (baby OR babies))
NOT
(MH "Animals" NOT (MH "Animals" AND MH "Humans"))
Limiter: Exclude MEDLINE records
Glucose
(MH "Glucose") OR TI (Dextrose OR Glucose) OR AB (Dextrose
OR Glucose)
AND
TI (Supplement*) OR AB (Supplement*) OR MH "Dietary Sup-
plementation" OR MH "Dietary Supplements"
AND
(MH "Infant" OR MH "Infant, Premature" OR MH "Infant,
Newborn") OR TI ((Neonat* OR neo nat*) OR (newborn* OR new
Born* OR newly born*) OR (preterm OR preterms OR pre term OR
pre terms) OR (premature* AND (birth* OR born OR deliver*)) OR
(low AND (birthweight* OR birth weight*)) OR (lbw OR vlbw OR
elbw) OR infant* OR (baby OR babies)) OR AB ((Neonat* OR neo
nat*) OR (newborn* OR new Born* OR newly born*) OR (preterm OR
preterms OR pre term OR pre terms) OR (premature* AND (birth*
OR born OR deliver*)) OR (low AND (birthweight* OR birth weight*))
OR (lbw OR vlbw OR elbw) OR infant* OR (baby OR babies))
NOT
(MH "Animals" NOT (MH "Animals" AND MH "Humans"))
Limiter: Exclude MEDLINE records
Probiotics
`(MH "Probiotics") OR (MH "Prebiotics") OR TI (probiotic* OR pre-
biotic* OR synbiotic*) OR AB (probiotic* OR prebiotic* OR synbiotic*)
AND
(MH "Infant" OR MH "Infant, Premature" OR MH "Infant,
Newborn") OR TI ((Neonat* OR neo nat*) OR (newborn* OR new
Born* OR newly born*) OR (preterm OR preterms OR pre term OR
pre terms) OR (premature* AND (birth* OR born OR deliver*)) OR
(low AND (birthweight* OR birth weight*)) OR (lbw OR vlbw OR
elbw) OR infant* OR (baby OR babies)) OR AB ((Neonat* OR neo
nat*) OR (newborn* OR new Born* OR newly born*) OR (preterm OR
preterms OR pre term OR pre terms) OR (premature* AND (birth*
OR born OR deliver*)) OR (low AND (birthweight* OR birth weight*))
OR (lbw OR vlbw OR elbw) OR infant* OR (baby OR babies))
NOT
(MH "Animals" NOT (MH "Animals" AND MH "Humans"))
Limiter: Exclude MEDLINE records
Scopus Strategies
Vitamin A
(TITLE‐ABS("Vitamin A" OR "Aquasol A" OR retinol OR "All
Trans Retinol" OR "Vitamin A1" OR "11‐cis‐Retinol" OR tretinoin))
AND (TITLE‐ABS(Supplement*)) AND (TITLE‐ABS ((neonat* OR "neo
nat*") OR (newborn* OR "new born*" OR "newly born*") OR (preterm
OR preterms OR "pre term" OR "pre terms") OR (premature*) AND
(birth* OR born OR deliver*) OR (low AND (birthweight* OR "birth
weight*")) OR (lbw OR vlbw OR elbow) OR infant* OR (baby OR
babies))) AND NOT INDEX(medline)
Glucose
TITLE‐ABS (Glucose OR Dextrose) AND TITLE‐ABS (supple-
ment*) AND TITLE‐ABS ((neonat* OR "neo nat*") OR (newborn* OR
"new born*" OR "newly born*") OR (preterm OR preterms OR "pre
term" OR "pre terms") OR (premature*) AND (birth* OR born OR
deliver*) OR (low AND (birthweight* OR "birth weight*")) OR (lbw
OR vlbw OR elbow) OR infant* OR (baby OR babies)) AND NOT
INDEX (medline)
Probiotics
TITLE‐ABS (Probiotic* OR Prebiotic* OR Synbiotic*) AND TITLE‐
ABS ((neonat* OR "neo nat*") OR (newborn* OR "new born*" OR
"newly born*") OR (preterm OR preterms OR "pre term" OR "pre
terms") OR (premature*) AND (birth* OR born OR deliver*) OR (low
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AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbow)
OR infant* OR (baby OR babies)) AND NOT INDEX (medline)
CENTRAL
Vitamin A
1. 1 MeSH descriptor: [infant] explode all trees
2. MeSH descriptor: [Premature Birth] explode all trees
3. (Neonat*:ti,ab OR neo nat*:ti,ab OR (newborn*:ti,ab OR new
Born*:ti,ab OR newly born*:ti,ab) OR (preterm:ti,ab OR pre-
terms:ti,ab OR pre term:ti,ab OR pre terms:ti,ab) OR (prema-
ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR
(low:ti,ab AND (birthweight*:ti,ab OR birth weight*:ti,ab)) OR
(lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab) OR infant*:ti,ab OR (ba-
by:ti,ab OR babies:ti,ab)
4. #1 OR #2 OR #3
5. MeSH descriptor: [Animals] explode all trees
6. MeSH descriptor: [Humans] explode all trees
7. (#5 NOT (#5 AND #6))
8. supplement*:ti,ab
9. MeSH descriptor: [Vitamin A] explode all trees
10. "Vitamin A":ti,ab OR "Aquasol A":ti,ab OR Retinol:ti,ab OR "All
Trans Retinol":ti,ab OR "All‐Trans‐Retinol":ti,ab OR "Vitamin
A1":ti,ab OR "Vitamin A 1":ti,ab OR "11 cis Retinol":ti,ab OR
"11‐cis‐Retinol":ti,ab OR Tretinoin:ti,ab
11. #9 OR #10
12. #11 AND #8
13. #12 AND #4 NOT #7
14. "accession number" near pubmed
15. #13 NOT #14
Glucose
1. 1 MeSH descriptor: [infant] explode all trees
2. MeSH descriptor: [Premature Birth] explode all trees
3. (Neonat*:ti,ab OR neo nat*:ti,ab) OR (newborn*:ti,ab OR new
Born*:ti,ab OR newly born*:ti,ab) OR (preterm:ti,ab OR pre-
terms:ti,ab OR pre term:ti,ab OR pre terms:ti,ab) OR (prema-
ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR
(low:ti,ab AND (birthweight*:ti,ab OR birth weight*:ti,ab)) OR
(lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab) OR infant*:ti,ab OR (ba-
by:ti,ab OR babies:ti,ab)
4. #1 OR #2 OR #3
5. MeSH descriptor: [Animals] explode all trees
6. MeSH descriptor: [Humans] explode all trees
7. (#5 NOT (#5 AND #6))
8. supplement*:ti,ab
9. MeSH descriptor: [Glucose] explode all trees
10. Dextrose:ti,ab OR Glucose:ti,ab
11. #9 OR #10
12. #11 AND #8
13. #12 AND #4 NOT #7
14. "accession number" near pubmed
15. #13 NOT #14
Probiotics
1. 1 MeSH descriptor: [infant] explode all trees
2. MeSH descriptor: [Premature Birth] explode all trees
3. (Neonat*:ti,ab OR neo nat*:ti,ab) OR (newborn*:ti,ab OR new
Born*:ti,ab OR newly born*:ti,ab) OR (preterm:ti,ab OR pre-
terms:ti,ab OR pre term:ti,ab OR pre terms:ti,ab) OR (prema-
ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR
(low:ti,ab AND (birthweight*:ti,ab OR birth weight*:ti,ab)) OR
(lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab) OR infant*:ti,ab OR (ba-
by:ti,ab OR babies:ti,ab)
4. #1 OR #2 OR #3
5. MeSH descriptor: [Animals] explode all trees
6. MeSH descriptor: [Humans] explode all trees
7. (#5 NOT (#5 AND #6))
8. MeSH descriptor: [Probiotics] explode all trees
9. MeSH descriptor: [Prebiotics] explode all trees
10. MeSH descriptor: [Synbiotics] explode all trees
11. #8 OR #9 OR #10
12. Probiotic*:ti,ab OR prebiotic*:ti,ab OR synbiotic*:ti,ab
13. #11 or #12
14. #13 AND #4 NOT #7
15. "accession number" near pubmed
16. #14 NOT #15
LILACS
Vitamin A
(tw:(("Vitamin A"))) OR (ti:(("Aquasol A" OR retinol OR "All Trans
Retinol" OR "Vitamin A1" OR "11‐cis‐Retinol" OR tretinoin))) OR
(ab:(("Aquasol A" OR retinol OR "All Trans Retinol" OR "Vitamin A1"
OR "11‐cis‐Retinol" OR tretinoin))) AND (ti:(supplement*)) OR (ab:(-
supplement*)) AND (tw:(Infant)) OR (tw:("Premature Birth")) OR
(ti:(((neonat* OR "neo nat*") OR (newborn* OR "new born*" OR
"newly born*") OR (preterm OR preterms OR "pre term" OR "pre
terms") OR (premature*) AND (born OR deliver*) OR (low AND
(birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR
(baby OR babies)))) OR (ab:(((neonat* OR "neo nat*") OR (newborn*
OR "new born*" OR "newly born*") OR (preterm OR preterms OR
"pre term" OR "pre terms") OR (premature*) AND (born OR deliver*)
OR (low AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw
OR elbw) OR (baby OR babies)))) AND db:("LILACS")
Glucose
((tw:(glucose)) OR (ti:(dextrose)) OR (ab:(dextrose)) AND (ti:(supple-
ment*)) OR (ab:(supplement*))) AND ((tw:(infant)) OR (tw:(“premature
birth”)) OR (ti:((neonat* OR "neo nat*") OR (newborn* OR "new born*"
OR "newly born*") OR (preterm OR preterms OR "pre term" OR "pre
terms") OR (premature*))) AND (ti:((born OR deliver*) OR (low AND
(birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR (baby
OR babies))) OR (ab:((neonat* OR "neo nat*") OR (newborn* OR "new
born*" OR "newly born*") OR (preterm OR preterms OR "pre term" OR
"pre terms") OR (premature*))) AND (ab:((born OR deliver*) OR (low
AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR
(baby OR babies)))) AND (instance:"regional") AND (db:("LILACS"))
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Probiotics
((tw:(probiotics OR prebiotics OR synbiotics)) OR (ti:(probiotic*
OR prebiotic* OR synbiotic*)) OR (ab:(probiotic* OR prebiotic* OR
synbiotic*))) AND ((tw:(infant)) OR (tw:(“premature birth”)) OR (ti:((-
neonat* OR "neo nat*") OR (newborn* OR "new born*" OR "newly
born*") OR (preterm OR preterms OR "pre term" OR "pre terms") OR
(premature*))) AND (ti:((born OR deliver*) OR (low AND (birth-
weight* OR "birth weight*")) OR (lbw OR vlbw OR elbw) OR (baby
OR babies))) OR (ab:((neonat* OR "neo nat*") OR (newborn* OR "new
born*" OR "newly born*") OR (preterm OR preterms OR "pre term"
OR "pre terms") OR (premature*))) AND (ab:((born OR deliver*) OR
(low AND (birthweight* OR "birth weight*")) OR (lbw OR vlbw OR




1. 1 'retinol'/exp OR 'retinol palmitate'/exp OR '11 cis retinol'/exp
OR 'retinoic acid'/exp
2. 'vitamin a':ti,ab OR 'aquasol a':ti,ab OR retinol:ti,ab OR 'all trans
retinol':ti,ab OR 'all‐trans‐retinol':ti,ab OR 'vitamin a1':ti,ab OR




5. #1 OR #2
6. #3 OR #4
7. #5 AND #6
8. 'infant'/exp OR 'prematurity'/exp OR 'newborn'/exp
OR 'low birth weight'/exp OR 'very low birth weight'/exp OR
'extremely low birth weight'/exp OR 'premature labor'/exp
9. neonat*:ti,ab OR 'neo nat*':ti,ab OR newborn*:ti,ab OR 'new
born*':ti,ab OR 'newly born*':ti,ab OR preterm:ti,ab OR pre-
terms:ti,ab OR 'pre term':ti,ab OR 'pre terms':ti,ab OR (prema-
ture*:ti,ab AND (birth*:ti,ab OR born:ti,ab OR deliver*:ti,ab)) OR
(low:ti,ab AND (birthweight*:ti,ab OR 'birth weight*':ti,ab)) OR
lbw:ti,ab OR vlbw:ti,ab OR elbw:ti,ab OR infant*:ti,ab OR ba-
by:ti,ab OR babies:ti,ab
10. #8 OR #9
11. #7 AND #10
12. #11 NOT ([animals]/lim NOT [humans]/lim)
13. #12 NOT [medline]/lim
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